aim
audit
prescrib
practic
busi
gener
icu
develop
standardis
practic
tool
improv
safeti
prescrib
error
occur
commonli
uk
hospit
admiss
cost
extra
bed
day
per
admiss
cost
nation
health
servic
estim
billion
per
annum
major
mistak
avoid
method
audit
daili
infus
chart
patient
three
separ
spot
check
week
assess
aspect
prescript
make
legal
valid
accord
nation
guidanc
new
procedur
introduc
includ
standardis
prescript
sticker
common
preprint
infus
prescript
noradrenalin
propofol
forth
educ
use
new
prescript
sticker
month
later
audit
process
repeat
assess
prescript
fi
rst
round
intervent
demonstr
improv
safe
prescrib
prescript
initi
fulfi
lled
best
practic
criteria
improv
afterward
also
reduc
number
infus
run
without
prescript
versu
see
figur
conclus
audit
support
need
standardis
prescrib
practic
within
critic
care
especi
deal
potenti
harm
vasoactivesed
drug
small
costeff
ectiv
intervent
sticker
improv
prescrib
accuraci
thu
patient
safeti
intens
care
result
mock
theft
success
accomplish
six
occas
period
occas
limpet
photograph
thief
record
date
time
access
therefor
event
real
theft
would
possibl
quickli
easili
indentifi
culprit
conclus
cd
miss
extrem
stress
staff
involv
access
cd
may
feel
unfairli
scrutinis
potenti
fals
accus
exist
investig
theft
cd
costli
usual
involv
pharmacist
manag
polic
issu
resolv
potenti
suspect
usual
suspend
work
lead
disrupt
patient
care
util
limpet
modifi
staff
behaviour
reduc
number
occas
durat
time
open
drug
cupboard
left
unattend
previous
demonstr
provid
facil
determin
exactli
access
cd
cupboard
time
initi
studi
shown
benefi
ts
limpet
tool
detect
theft
therefor
instal
limpet
mitig
diffi
culti
investig
cd
theft
like
prove
eff
ectiv
deterr
refer
limpet
drug
cabinet
alarm
technolog
safer
drug
stewardship
abstract
poster
present
theft
tamper
control
drug
cd
remain
preval
patient
safeti
issu
sadli
numer
report
critic
care
staff
steal
cd
person
use
fi
nancial
gain
notabl
case
cd
substitut
medic
order
delay
detect
theft
creat
hazard
medic
error
potenti
expos
patient
opioid
intox
healthcar
worker
critic
care
staff
access
cd
drug
found
miss
diffi
cult
identifi
perpetr
therefor
implement
deterr
also
improv
method
detect
warrant
method
limpet
devic
incorpor
proxim
sensor
camera
unit
instal
within
cd
cupboard
critic
care
unit
whenev
cupboard
access
date
time
record
photograph
taken
identifi
staff
member
mock
theft
subsequ
undertaken
design
staff
member
random
time
allow
test
product
determin
number
time
thief
correctli
identifi
ed
introduct
purpos
studi
assess
practic
identifi
manag
inadvert
hypothermia
whether
could
improv
educ
introduct
protocol
hypothermia
associ
multipl
physiolog
abnorm
includ
reduc
myocardi
contractil
peripher
vasoconstrict
increas
infect
risk
impair
coagul
inadvert
hypothermia
may
therefor
avoid
risk
factor
critic
ill
uk
nation
institut
clinic
excel
issu
guidanc
avoid
inadvert
hypothermia
temperatur
periop
period
audit
practic
three
standard
guidelin
patient
least
temperatur
observ
patient
becom
inadvert
hypotherm
inadvert
hypotherm
patient
rewarm
method
data
collect
prospect
bodi
temperatur
record
routin
nurs
staff
use
tympan
thermomet
note
occas
bodi
temperatur
drop
along
associ
intervent
use
addit
bed
sheet
forc
air
warm
devic
fi
rst
audit
period
simpl
educ
programm
deliv
also
introduc
department
protocol
prevent
manag
inadvert
hypothermia
six
month
later
reaudit
practic
result
data
collect
patient
patienthour
fi
rst
audit
period
patient
patienthour
second
audit
period
fi
rst
period
patient
least
temperatur
measur
compar
second
period
p
averag
number
overdu
temperatur
observ
per
day
fi
rst
period
second
p
twentyfour
per
cent
patient
becam
hypotherm
fi
rst
period
compar
second
p
howev
time
patient
remain
hypotherm
reduc
averag
hour
hour
p
intervent
made
document
case
fi
rst
period
second
p
conclus
saw
improv
follow
educ
programm
introduct
clinic
protocol
although
remain
room
improv
refer
introduct
ventilatorassoci
pneumonia
vap
lead
caus
death
amongst
hospitalacquir
infect
also
link
increas
length
stay
cost
care
institut
healthcar
improv
ventil
bundl
compris
seri
intervent
implement
togeth
shown
decreas
incid
vap
aim
studi
determin
complianc
bundl
devis
strategi
improv
complianc
method
retrospect
review
complianc
exist
vap
bundl
conduct
adult
patient
ventil
icu
larg
district
gener
hospit
bundl
compris
four
element
head
peptic
ulcer
prophylaxi
deep
vein
thrombosi
dvt
prophylaxi
sedat
hold
bundl
consid
compliant
four
perform
fi
nding
audit
present
depart
subsequ
discuss
barrier
noncompli
identifi
ed
follow
period
educ
revis
updat
bundl
implement
repeat
audit
cover
month
subsequ
conduct
result
preintervent
overal
complianc
bundl
stood
subsequ
increas
post
intervent
p
complianc
level
individu
element
vari
head
ulcer
prophylaxi
dvt
prophylaxi
sedat
hold
post
intervent
statist
signifi
cant
increas
complianc
regard
sedat
hold
observ
p
individu
element
show
statist
chang
howev
new
element
introduc
demonstr
high
level
complianc
cuff
pressur
cm
h
oral
hygien
chlorhexidin
conclus
post
intervent
statist
signifi
cant
improv
overal
bundl
complianc
found
therebi
highlight
engag
member
multidisciplinari
team
identifi
barrier
noncompli
deliv
educ
possibl
improv
complianc
total
complianc
suboptim
target
bundl
redesign
given
tool
record
complianc
greater
clariti
due
presenc
clearli
defi
ned
exclus
criteria
also
signifi
cant
step
right
direct
improv
reliabl
care
deliv
patient
reinforc
concept
qualiti
improv
continu
cycl
refer
introduct
demand
intens
care
reach
new
height
medic
advanc
age
popul
increas
proport
patient
multi
comorbid
ideal
bed
occup
icu
around
wherea
beyond
associ
increas
mortal
william
harvey
hospit
district
gener
hospit
nine
icu
bed
icnarc
nation
databas
suggest
consist
high
occup
purpos
studi
assess
bed
occup
impact
servic
deliveri
method
data
collect
analys
trend
icu
bed
occup
overnight
discharg
surgic
cancel
nonclin
transfer
data
gather
april
march
use
qualiti
indic
intens
care
societi
readmiss
prematur
discharg
discharg
night
cancel
plan
surgeri
nonclin
transfer
regress
analysi
conduct
assess
correl
mortal
eff
ect
excess
occup
causal
increas
demand
icu
bed
result
bed
occup
remain
high
increas
associ
increas
overnight
discharg
surgic
cancel
nonclin
transfer
calcul
demand
bed
icu
hospit
bed
icu
bed
per
popul
drop
signifi
cantli
includ
region
specialti
servic
persist
gap
icu
bed
suppli
demand
associ
increas
unfavour
outcom
qualiti
indic
conclus
steadi
increas
occup
last
year
due
multipl
factor
includ
increas
clinic
servic
coronari
care
centr
head
neck
unit
trauma
centr
present
result
manageri
level
facilit
increas
bed
capac
refer
introduct
physician
intens
irregular
workday
life
thu
need
use
time
continu
educ
effi
cient
way
present
major
challeng
supplier
continu
studi
program
onlin
master
program
physicotechn
medicin
ptm
address
work
physician
want
acquir
knowledg
fi
eld
biomed
engin
medic
physic
attach
great
import
special
need
particip
therefor
investig
gener
condit
import
work
physician
regard
qualifi
continu
educ
method
gener
condit
continu
educ
program
ptm
examin
basi
evalu
questionnair
addit
student
ask
interview
demand
could
give
anonym
feedback
feedback
card
result
flexibl
student
appreci
fl
exibl
regard
time
environ
learn
activ
fl
exibl
enabl
student
use
even
small
time
frame
travel
time
learn
student
choos
prefer
time
place
learn
activ
secur
plan
student
organ
time
frame
learn
besid
daili
work
famili
life
possibl
academ
career
especi
phase
attend
plan
commun
earli
possibl
transpar
structur
particip
ask
transpar
term
expect
workload
expenditur
time
plan
studi
get
focus
relat
previou
knowledg
learn
success
support
relat
new
content
previou
knowledg
student
fi
rst
medic
degre
mainli
clinic
exampl
illustr
abstract
topic
also
help
student
recogn
relev
content
individu
support
student
need
contact
person
term
learn
organ
technic
support
question
regard
cours
materi
conclus
could
show
extraoccup
continu
studi
program
physician
adjust
special
situat
therefor
compli
particular
requir
could
identifi
fi
main
requir
continu
fulfi
lled
onlin
master
program
ptm
regularli
survey
evalu
refer
introduct
collabor
approach
patient
manag
shown
improv
patient
outcom
resourcelimit
nh
critic
care
bed
premium
therefor
prevent
unnecessari
admiss
optimis
wardbas
manag
essenti
object
servic
qualiti
improv
project
improv
collabor
critic
care
director
neurosurg
high
care
unit
tertiari
univers
teach
hospit
propos
use
simpl
ward
round
tool
collabor
round
would
facilit
systemat
patient
review
prompt
earli
recognit
critic
unwel
improv
patient
outcom
method
initi
observ
period
behaviour
practic
neurosurg
unit
conduct
qualit
quantit
data
collect
follow
analysi
outcom
measur
simpl
ward
round
tool
construct
mnemon
nt
forget
devis
programm
collabor
ward
round
take
place
three
time
per
week
period
introduct
daili
blood
test
essenti
diagnost
tool
routin
practic
manag
icu
patient
associ
cost
risk
anaemia
evid
frequenc
breadth
blood
test
evid
rationalis
blood
test
signifi
cant
cost
save
made
without
neg
eff
ect
mortal
length
icu
stay
blood
test
icu
request
nurs
uniqu
practic
icu
compar
hospit
depart
method
previous
carri
survey
assess
blood
request
practis
uk
icu
demonstr
routin
test
icu
nurs
led
major
staff
underestim
cost
test
use
result
survey
literatur
review
develop
routin
blood
test
guidelin
gener
mix
icuhdu
follow
period
staff
educ
audit
blood
request
practic
day
result
blood
test
compli
guidelin
period
spent
blood
test
accord
guidelin
spent
inappropri
test
per
year
tabl
cost
spent
coagul
screen
conclus
icu
unnecessari
blood
test
signifi
cant
cost
burden
approxim
per
year
limit
unnecessari
cost
consult
lead
request
complet
blood
test
pro
forma
even
icu
ward
round
indic
blood
test
clinic
need
follow
day
refer
introduct
icu
visit
gener
limit
hour
per
day
select
time
hour
institut
abid
intern
regul
recent
modifi
ed
allow
famili
member
signifi
cant
other
present
throughout
day
accompani
icuadmit
rel
particip
uninterrupt
time
fashion
time
limit
daili
activ
method
januari
april
questionnair
fi
lled
famili
icuadmit
patient
questionnair
includ
question
concern
overal
degre
satisfact
unit
evalu
qualiti
accommod
space
ere
famili
icu
patient
ere
state
freedom
within
icu
premis
surround
belov
sick
rel
addit
constantli
advis
design
secretari
share
experi
possibl
insight
improv
overal
politi
servic
result
two
hundr
patient
includ
studi
averag
age
patient
year
averag
length
icu
stay
day
famili
desir
presenc
accompani
relat
patient
within
icu
premis
meal
serv
famili
express
satisfact
ere
psycholog
support
belov
ill
one
fifteen
per
cent
famili
argu
permit
number
visitor
one
person
per
visit
address
lack
commun
medic
staff
patient
famili
conclus
compar
limit
visit
statu
within
icu
ward
past
major
famili
express
gener
accept
satisfact
toward
newli
adopt
polici
addit
new
polici
patient
display
mark
improv
psycholog
level
cooper
experienc
less
episod
agit
even
medic
team
elabor
interest
toward
polici
profound
comprehens
way
support
icu
patient
investig
current
employ
strengthen
outcom
studi
introduct
aim
studi
prospect
assess
famili
satisfact
intens
care
set
identifi
fi
eld
possibl
improv
method
studi
perform
period
icu
properli
translat
valid
famili
satisfact
icu
fsicu
questionnair
use
total
questionnair
hand
famili
member
upon
patient
discharg
number
questionnair
return
evalu
particip
fivepoint
likert
scale
respons
transform
percentag
score
higher
valu
repres
better
satisfact
result
overal
satisfact
care
report
good
excel
famili
member
respect
icu
staff
concern
care
well
symptom
manag
favor
score
also
note
term
decisionmak
rel
report
good
excel
rate
regard
inform
need
hand
famili
member
felt
neither
includ
exclud
decisionmak
process
moreov
small
number
answer
receiv
poor
emot
support
final
frequenc
commun
icu
nurs
atmospher
wait
room
note
fair
subject
respect
conclus
famili
member
highli
satisfi
ed
icu
care
patient
receiv
nevertheless
studi
show
fi
eld
commun
nurs
well
wait
room
atmospher
defi
nite
need
improv
concern
emot
support
decisionmak
studi
reveal
current
use
measur
icu
still
appli
famili
probabl
requir
chang
introduct
signifi
cant
improv
chemotherapi
haematopoiet
stem
cell
transplant
gener
intens
care
mean
patient
live
longer
often
present
icu
variou
stage
diseas
encourag
patient
haematolog
malign
hm
express
wish
valu
end
life
eol
prior
icu
admiss
would
ensur
autonomi
respect
aim
studi
determin
whether
patient
hm
admit
die
icu
form
advanc
care
plan
acp
document
prior
admiss
method
data
collect
adult
patient
hm
admit
die
icu
tertiari
haematolog
referr
centr
london
period
year
result
inform
collect
patient
characterist
shown
tabl
patient
eol
decis
made
donotattemptresuscit
document
found
case
document
inform
exchang
particip
deliber
decisionmak
process
found
patient
even
though
haematolog
physician
estim
prognosi
patient
moder
poor
vast
major
case
death
occur
withhold
withdraw
treatment
icu
conclus
small
number
patient
hm
die
icu
document
acp
prior
admiss
sinc
major
icu
patient
lack
person
decisionmak
capac
acp
would
ensur
care
consist
patient
wish
eol
action
congruent
valu
burden
famili
healthcar
provid
allevi
cost
decreas
refer
introduct
perceiv
futil
care
may
jeopard
patient
qualiti
care
increas
icu
staff
turnov
relat
workload
interdisciplinari
collabor
aim
evalu
concept
team
scienc
name
inclus
leadership
style
invit
appreci
other
contribut
psycholog
safeti
key
anteced
speak
learn
behavior
determin
eff
ect
perceiv
futil
intent
quit
method
staff
survey
four
interdisciplinari
icu
two
intermedi
care
unit
two
tertiari
care
hospit
questionnair
contain
valid
scale
assess
inclus
leadership
head
nurs
attend
physician
nursephysician
collabor
collabor
introduct
decis
withhold
therapeut
intervent
patient
complex
decis
wrap
profound
ethic
debat
role
physician
cure
treat
allevi
suff
ere
fi
rst
two
goal
possibl
medic
role
dedic
endoflif
treatment
adjust
patient
benefi
method
retrospect
cohort
studi
includ
adult
patient
sepsi
admit
emerg
room
er
tertiari
care
univers
hospit
juli
june
result
studi
period
patient
sepsi
admit
er
withheld
therapeut
decis
compar
group
group
without
therapeut
limit
patient
fi
rst
group
older
vs
p
comorbid
vs
p
higher
proport
need
help
daili
activ
karnofski
perform
statu
kp
vs
p
hospit
mortal
patient
decis
limit
therapeut
intervent
signifi
cantli
higher
vs
p
variabl
independ
associ
withhold
therapi
decis
age
adjust
per
year
p
presenc
comorbid
adjust
p
chronic
wound
adjust
p
patient
need
help
daili
activ
kp
adjust
p
fi
rst
group
lower
proport
receiv
antibiot
vs
p
consid
inadequ
agent
respons
sepsi
episod
less
frequent
chang
vs
p
howev
diff
erenc
found
regard
elaps
time
admiss
er
fi
rst
medic
contact
time
sinc
recognit
sepsi
antibiot
administr
although
group
withhold
decis
less
specimen
collect
microbiolog
blood
cultur
vs
p
specimen
vs
p
conclus
studi
decis
withhold
therapi
independ
associ
increas
age
presenc
comorbid
loss
function
autonomi
level
intervent
antibiot
administr
decis
withhold
therapi
infl
uenc
effi
caci
therapeut
attitud
refer
conclus
despit
declin
rate
worldwid
autopsi
remain
import
tool
qualiti
safeti
assur
retrospect
studi
autopsi
show
knowledg
correct
premortem
diagnosi
would
alter
therapi
critic
ill
cirrhot
patient
introduct
wellvalid
risk
score
patient
oncolog
hematolog
malign
present
emerg
depart
ed
previou
research
found
prognost
blood
biomark
proadrenomedullin
proadm
associ
infectionrel
complic
mortal
thu
may
help
manag
febril
patient
malign
yet
prognost
valu
proadm
gener
oncolog
patient
present
ed
remain
unclear
herein
object
studi
evalu
prognost
potenti
proadm
clinic
paramet
consecut
cohort
patient
oncolog
hematolog
malign
regard
icu
admiss
mortal
method
enrol
consecut
patient
oncolog
hematolog
malign
seek
ed
care
tertiari
care
hospit
februari
octob
prospect
collect
variou
clinic
featur
measur
blood
paramet
includ
proadm
upon
admiss
assess
outcom
data
electron
medic
record
icu
admiss
length
stay
lo
postacut
care
locat
use
contact
patient
day
hospit
admiss
logist
regress
model
area
receiv
oper
curv
auc
use
assess
associ
baselin
paramet
outcom
includ
total
patient
oncolog
hematolog
malign
n
admit
icu
n
surviv
followup
strong
associ
initi
proadm
level
mortal
risk
odd
ratio
per
increas
ci
auc
ci
associ
remain
signifi
cant
multivari
adjust
initi
vital
sign
blood
pressur
puls
temperatur
comorbid
chronic
heart
failur
chronic
obstruct
pulmonari
diseas
diabet
coronari
heart
diseas
adjust
ci
also
signifi
cant
associ
proadm
lo
adjust
regress
coeffi
cient
per
increas
ci
conclus
studi
includ
consecut
patient
oncolog
hematolog
malign
found
moder
associ
proadm
mortal
lo
proadm
combin
clinic
paramet
may
help
improv
siteofcar
decis
patient
futur
introduct
prospect
multicentr
observ
studi
carri
assess
extent
critic
care
team
manag
patient
hospit
care
outsid
critic
care
unit
health
servic
execut
hse
ireland
process
implement
nation
earli
warn
score
ew
ew
referr
critic
care
recommend
studi
record
ew
patient
refer
critic
care
team
describ
subsequ
intervent
made
critic
care
team
patient
outcom
method
six
critic
care
depart
universityaffi
liat
hospit
across
ireland
collect
data
referr
critic
care
team
period
data
anonymis
code
analys
central
result
cumul
total
call
made
critic
care
team
six
hospit
common
reason
referr
request
critic
care
review
patient
n
reason
referr
includ
cardiac
arrest
request
transfer
patient
hospit
request
vascular
access
averag
durat
spent
critic
care
team
review
patient
ward
minut
increas
minut
cardiac
arrest
call
critic
care
review
patient
subsequ
admit
critic
care
total
ew
score
less
still
deem
requir
admiss
critic
care
conclus
regardless
ew
critic
care
team
heavili
involv
manag
patient
outsid
critic
care
unit
fifti
per
cent
patient
review
critic
care
team
subsequ
requir
admiss
critic
care
unit
trigger
threshold
referr
critic
care
team
current
recommend
ew
escal
protocol
like
predict
need
critic
care
admiss
howev
one
four
patient
refer
threshold
also
requir
admiss
critic
care
environ
studi
question
safeti
introduc
protocol
acut
hospit
noncrit
care
staff
forc
wait
patient
deterior
reach
trigger
threshold
referr
role
critic
care
team
expand
look
patient
abnorm
ew
hospit
introduct
aim
assess
action
taken
respons
variat
nation
earli
warn
new
score
identifi
factor
associ
poor
respons
new
score
physiolog
score
prescrib
appropri
respons
deterior
patient
need
urgent
medic
care
allow
enhanc
observ
clinic
review
patient
identifi
patient
risk
acut
mortal
method
perform
prospect
observ
studi
adult
patient
admit
acut
medic
ward
london
district
gener
hospit
period
patient
characterist
new
score
time
day
day
week
clinic
respons
data
collect
fi
rst
hour
admiss
patient
less
hospit
stay
exclud
primari
outcom
measur
qualiti
clinic
respons
data
analys
univari
multivari
logist
regress
result
studi
period
patient
includ
median
age
year
new
score
evenli
distribut
day
night
vs
greater
proport
weekday
compar
weekend
day
vs
major
patient
score
vs
fortyseven
patient
receiv
inadequ
clinic
respons
univari
analysi
show
associ
time
day
night
vs
day
p
howev
day
week
weekend
vs
weekday
p
increas
score
news
vs
news
p
signifi
cantli
associ
inadequ
respons
day
week
independ
associ
inadequ
respons
adjust
confound
p
conclus
clinic
respons
new
score
trigger
signifi
cantli
wors
weekend
highlight
import
patient
safeti
concern
refer
introduct
purpos
studi
evalu
impact
obes
outcom
patient
sever
sepsi
sinc
obes
consid
infl
ammatori
diseas
associ
elev
sever
infl
ammatori
mediat
import
outcom
sepsi
relationship
obes
outcom
septic
patient
studi
method
retrospect
cohort
studi
includ
patient
age
confi
rmed
diagnosi
sever
sepsi
icu
stay
academ
medic
center
januari
march
obes
defi
ned
bodi
mass
index
greater
data
patient
demograph
apach
ii
score
time
sepsi
collect
patient
chart
outcom
measur
includ
inhospit
mortal
develop
acut
respiratori
distress
syndrom
ard
day
mechan
ventil
hospit
cost
length
stay
identifi
ed
patient
met
inclus
criteria
studi
patient
classifi
ed
obes
mean
apach
ii
score
similar
obes
nonobes
patient
vs
p
obes
patient
similar
rate
inhospit
mortal
vs
p
compar
nonobes
patient
signifi
cantli
higher
rate
develop
ard
vs
p
obes
patient
also
signifi
cantli
critic
care
volum
suppl
http
day
mechan
ventil
day
vs
day
p
relationship
mortal
obes
patient
mechan
ventil
vs
p
ard
vs
p
compar
nonobes
patient
hospit
cost
length
stay
diff
er
group
conclus
obes
signifi
cantli
increas
incid
ard
day
mechan
ventil
patient
sepsi
previou
work
report
obes
associ
elev
infl
ammatori
cytokin
adipokin
particularli
known
risk
factor
ard
higher
rate
ard
obes
patient
sepsi
identifi
es
highrisk
group
new
therapi
may
benefi
cial
new
method
prevent
ard
target
introduct
studi
suggest
obes
may
infl
uenc
mortal
patient
develop
sepsi
howev
mechan
link
improv
outcom
unclear
aim
assess
impact
obes
mortal
day
cytokin
express
method
use
platform
neg
random
control
trial
subject
n
diagnosi
sever
sepsi
organ
failur
cohort
sever
septic
subject
stratifi
ed
obes
statu
base
bodi
mass
index
bmi
primari
outcom
mortal
secondari
outcom
diff
erenc
median
iqr
fi
infl
ammatori
cytokin
includ
tumor
necrosi
factor
alpha
interleukin
il
measur
median
baselin
cytokin
level
done
serum
luminex
technolog
statist
signifi
canc
defi
ned
p
result
fiftyon
subject
sever
sepsi
includ
studi
patient
obes
bmi
paradox
obes
sever
septic
patient
lower
mortal
n
vs
n
p
mortal
n
vs
n
p
compar
nonobes
express
statist
signifi
cant
diff
erent
among
obes
versu
nonobes
sever
septic
patient
conclus
obes
associ
lower
mortal
rate
day
patient
diagnos
sever
sepsi
surviv
benefi
associ
lower
cytokin
product
among
obes
patient
studi
need
assess
mechan
associ
surviv
benefi
relat
obes
patient
sever
sepsi
introduct
predict
longterm
outcom
patient
surviv
pneumon
nonpneumon
copd
exacerb
remain
challeng
studi
investig
associ
clinic
paramet
prognost
blood
marker
proadrenomedullin
proadm
measur
upon
hospit
discharg
mortal
welldefi
ned
cohort
copd
patient
method
prospect
follow
consecut
copd
patient
previou
swiss
multicent
trial
followup
investig
allcaus
mortal
follow
hospit
discharg
patient
andor
treat
gener
practition
contact
telephon
interview
assess
vital
statu
patient
use
cox
regress
model
area
receiv
oper
characterist
curv
auc
investig
associ
baselin
predictor
mortal
overal
mortal
includ
copd
patient
ci
ci
mortal
incid
rate
per
year
patient
pneumon
copd
exacerb
pronounc
infl
ammatori
respons
compar
patient
nonpneumon
exacerb
regard
level
initi
creactiv
protein
level
median
mgdl
vs
mgdl
p
procalctionin
median
vs
p
proadm
median
nmoll
vs
nmoll
p
longterm
surviv
similar
hr
ci
univari
regress
model
proadm
signifi
cantli
associ
mortal
year
hr
ci
ci
ci
respect
eff
ect
modifi
cation
type
exacerb
model
includ
clinic
paramet
age
coronari
heart
diseas
heart
failur
diabet
mellitu
chronic
renal
failur
neoplast
diseas
pneumonia
smoker
proadm
show
good
discrimin
longterm
survivor
nonsurvivor
auc
ci
conclus
clinic
paramet
discharg
level
proadm
allow
accur
longterm
prognost
copd
patient
independ
initi
type
exacerb
focu
best
use
longterm
prognost
inform
improv
patient
care
clinic
outcom
seem
promisingr
refer
introduct
base
expert
opinion
case
note
review
uk
nation
confi
dential
enquiri
periop
outcom
recommend
provis
periop
level
care
support
major
surgeri
older
peopl
particularli
comorbid
wish
identifi
whether
could
predict
need
uniform
whether
factor
could
predict
degre
organ
support
need
method
retrospect
note
review
patient
admit
level
critic
care
unit
period
januari
decemb
undergo
revis
hip
surgeri
either
twostag
singlestag
process
surgeri
undertaken
nation
referr
unit
chosen
repres
appropri
group
older
comorbid
patient
predefi
ned
preoper
periop
data
collect
chart
review
along
postop
physiolog
data
whilst
patient
critic
care
includ
frailti
comorbid
oper
blood
loss
anaesthet
techniqu
level
durat
organ
support
includ
need
addit
medic
review
whilst
unit
frailti
assess
preoper
use
rockwood
assess
tool
train
staff
data
analys
use
microsoft
excel
mac
stataic
mac
result
total
patient
mean
age
year
rang
identifi
ed
frail
patient
signifi
cantli
like
need
addit
medic
input
postop
period
whilst
critic
care
figur
p
signifi
cantli
link
need
vasopressor
evid
sepsi
choic
anaesthet
techniqu
conclus
complex
revis
orthopaed
surgeri
need
postop
level
support
predict
preoper
intraop
factor
patient
frailti
indic
need
medic
input
postop
period
refer
introduct
icu
hospit
mortal
rate
report
endpoint
icu
therapi
mani
year
aim
studi
determin
mortal
discharg
icu
patient
treat
icu
hour
identifi
predictor
mortal
method
studi
conduct
mix
icu
teach
hospit
studi
sampl
extract
dataset
icu
patient
treat
hour
januari
octob
demograph
characterist
clinic
characterist
admiss
icu
stay
collect
characterist
patient
aliv
year
icu
discharg
compar
patient
die
within
fi
rst
year
icu
discharg
descript
statist
calcul
multivari
analysi
mortal
perform
use
logist
regress
model
backward
elimin
surviv
analys
kaplanmei
method
use
time
interv
day
icu
discharg
death
result
studi
period
patient
treat
hour
icu
icu
mortal
data
icu
survivor
analys
patient
lost
follow
conclus
patient
treat
hour
icu
die
within
year
icu
discharg
onehalf
within
hospit
stay
icu
discharg
high
age
icu
admiss
high
apach
iv
predict
mortal
score
high
number
comorbid
readmiss
admiss
diagnosi
within
categori
cardiovascular
sepsi
associ
increas
mortal
icu
discharg
popul
burden
patient
die
icu
discharg
underlin
necess
clear
icu
discharg
criteria
posticu
care
physic
composit
score
pc
mental
composit
score
nation
averag
reduc
muscl
strength
associ
low
score
physic
function
gener
health
domain
perform
correl
includ
pc
p
screen
posit
anxieti
associ
poor
perform
report
dysfunct
domain
icuhospit
length
stay
number
day
ventil
sever
ill
organ
dysfunct
found
predict
muscl
strength
physic
function
conclus
studi
give
qualit
evid
survivor
critic
ill
reduc
muscl
strength
physic
function
hrql
hospit
discharg
also
shown
muscl
weak
predict
overal
physic
function
turn
impact
hrql
mental
health
icu
risk
factor
identifi
ed
predict
defi
cit
muscl
strength
physic
function
introduct
aim
studi
determin
appropri
risk
model
identifi
patient
high
risk
prolong
icu
stay
aid
patient
consent
prior
cardiac
surgeri
method
data
prospect
collect
consecut
cardiac
surgeri
case
april
march
primari
outcom
measur
combin
outcom
prolong
icu
stay
length
stay
greater
day
andor
inhospit
mortal
logist
regress
perform
assess
predict
logist
euroscor
primari
outcom
lowrisk
mediumrisk
highrisk
group
identifi
ed
subsequ
risk
mortal
assess
surviv
statu
determin
year
result
total
patient
prolong
icu
stay
inhospit
death
occur
result
combin
primari
outcom
year
death
occur
risk
death
inhospit
year
signifi
cantli
higher
patient
prolong
icu
stay
inhospit
mortal
vs
p
year
vs
p
mean
logist
euroscor
patient
patient
prolong
icu
stay
signifi
cantli
higher
logist
euroscor
vs
p
logist
euroscor
reason
predictor
prolong
icu
inhospit
mortal
ci
p
receiv
oper
characterist
roc
curv
relationship
patient
logist
euroscor
predict
risk
prolong
icu
shown
fi
gure
includ
lowrisk
mediumrisk
high
risk
group
around
entir
cohort
patient
logist
euroscor
less
associ
risk
prolong
icu
stay
less
see
figur
conclus
use
exist
risk
predict
model
patient
risk
prolong
icu
stay
calcul
use
contemporan
data
inform
could
relev
aid
provid
inform
consent
cardiac
surgeri
patient
introduct
inform
lung
cancer
patient
surviv
critic
ill
scarc
aim
evalu
outcom
continu
anticanc
treatment
lung
cancer
patient
surviv
icu
admiss
method
secondari
analysi
prospect
multicent
studi
includ
patient
admit
hour
icu
six
countri
europ
south
america
readmiss
patient
cancer
remiss
year
exclud
logist
regress
use
identifi
predictor
hospit
mortal
result
total
patient
smallcel
sclc
nonsclc
admit
icu
sclc
nsclc
discharg
aliv
hospit
among
patient
aliv
die
month
three
patient
lost
followup
mortal
rate
far
lower
patient
subset
nonrecurrentprogress
cancer
good
perform
statu
ps
even
sepsi
multipl
organ
dysfunct
need
ventilatori
support
cancer
recurr
progress
occur
hospit
survivor
anticanc
treatment
recommend
hospit
survivor
administ
treatment
use
variabl
combin
surgic
resect
radiat
therapi
chemotherapi
initi
treatment
plan
requir
reduct
modifi
cation
patient
posthospit
mortal
nonsignifi
cantli
lower
patient
given
initi
treatment
plan
patient
vs
p
poor
ps
factor
associ
lower
probabl
receiv
initi
treatment
plan
ci
p
month
patient
home
hospit
hospic
care
locat
unknown
patient
ps
month
survivor
conclus
posthospit
mortal
critic
ill
lung
cancer
patient
rel
high
mani
patient
requir
anticanc
treatment
discharg
ps
icu
admiss
major
determin
mortal
abil
receiv
optim
anticanc
treatment
patient
popul
uk
age
fastest
increas
year
increas
age
repeatedli
associ
advers
outcom
uncertain
extent
relat
chang
age
due
consider
age
key
variabl
major
score
system
relat
patient
characterist
advers
outcom
aim
assess
chang
age
distribut
patient
admit
icu
year
examin
relationship
age
patient
mortal
length
stay
lo
conclus
increas
number
older
patient
icu
uk
analys
uncorrect
sever
ill
comorbid
older
patient
like
die
icu
ward
icu
also
spend
longer
hospit
prior
discharg
introduct
uk
militari
personnel
injur
oversea
repatri
royal
centr
defenc
medicin
rcdm
base
queen
elizabeth
hospit
birmingham
qehb
birmingham
uk
report
demograph
outcom
militari
patient
treat
icu
rcdm
use
data
intens
care
nation
audit
research
centr
period
method
data
admiss
patient
icu
rcdm
qehb
analys
icnarc
use
standard
methodolog
result
physiolog
ccmd
data
miss
patient
age
sex
mortal
describ
tabl
total
patient
traumat
injuri
receiv
cpr
prior
icu
admiss
prehospit
total
head
neck
spinal
trauma
total
transfer
directli
icu
militari
hospit
oversea
other
come
icu
follow
surgeri
rcdm
patient
apach
ii
score
data
mean
score
sd
probabl
refl
ect
stabilis
militari
hospit
oversea
aeromed
critic
care
transfer
mean
number
icu
day
level
sd
level
sd
total
patient
requir
advanc
respiratori
support
mean
day
requir
advanc
cardiovascular
support
mean
day
data
resourc
utilis
group
patient
may
inform
plan
critic
care
support
militari
oper
oversea
introduct
rate
old
patient
year
old
admit
intens
care
increas
last
year
older
age
associ
higher
preval
chronic
diseas
includ
cancer
aim
present
studi
describ
characterist
outcom
predict
factor
mortal
old
patient
admit
icu
method
perform
retrospect
analysi
cancer
patient
year
older
admit
icu
januari
decemb
tertiari
refer
cancer
center
data
collect
medic
record
result
total
patient
cancer
includ
analysi
hospit
mortal
patient
like
solid
tumor
local
diseas
underw
surgeri
chemotherapi
radiotherapi
recent
variabl
associ
hospit
mortal
patient
lung
cancer
metastat
cancer
icu
admiss
vasopressor
requir
acut
respiratori
failur
low
hemoglobin
level
elev
creatinin
level
elev
bilirubin
level
acidosi
hyperlactatemia
multivari
analysi
follow
factor
independ
factor
associ
hospit
mortal
lung
cancer
odd
ratio
ci
p
lactat
level
icu
admiss
ci
p
bilirubin
level
icu
admiss
ci
p
creatinin
level
icu
admiss
ci
p
conclus
old
patient
cancer
present
accept
rate
surviv
icu
admiss
similarli
younger
patient
organ
function
evalu
fi
rst
hour
icu
predict
outcom
specifi
c
popul
refer
introduct
cur
oesophagectomi
carri
uk
annual
although
inhospit
mortal
rate
fallen
complic
rate
remain
high
anastomot
failur
respiratori
failur
common
postop
aim
retrospect
review
examin
outcom
patient
underw
oesophagectomi
unit
januari
octob
method
examin
demograph
data
surviv
day
year
length
icu
hospit
stay
case
note
review
identifi
postop
complic
includ
anastomot
breakdown
reintub
respiratori
failur
data
analys
examin
relationship
use
postop
noninvas
ventil
intraop
fl
uid
volum
incid
postop
complic
result
seventytwo
patient
identifi
ed
undergon
oesophagectomi
januari
octob
median
age
male
one
patient
die
within
day
critic
care
volum
suppl
http
nine
patient
die
year
median
length
icu
hospit
stay
day
day
respect
six
patient
anastomot
leak
two
chyle
leak
use
noninvas
ventil
patient
associ
anastomot
leak
chisquar
p
amount
fl
uid
given
intraop
mannwhitney
u
p
six
patient
reintub
associ
signifi
cantli
increas
length
icu
hospit
stay
mannwhitney
u
p
respect
lower
pf
ratio
also
associ
signifi
cant
increas
length
icu
hospit
stay
p
conclus
overal
mortal
morbid
rate
compar
seen
nation
data
suggest
use
noninvas
ventil
associ
anastomot
breakdown
lower
pf
ratio
postop
period
associ
prolong
icu
hospit
stay
fi
rst
descript
sap
ii
date
back
littl
known
score
accuraci
daili
practic
factor
possibl
aff
ect
purpos
studi
evalu
accuraci
sap
ii
score
mean
nationwid
survey
method
twenti
clinic
scenario
cover
broad
rang
ill
sever
randomli
assign
conveni
sampl
clinician
nurs
swiss
adult
icu
ask
assign
sap
ii
score
includ
detail
item
score
one
scenario
result
compar
refer
defi
ned
fi
experienc
research
use
delphi
method
crossmatch
data
relat
train
qualiti
control
score
inform
daili
practic
score
structur
organiz
properti
particip
icu
result
sixtythre
adult
icu
particip
survey
perfect
match
singl
refer
item
found
score
particip
mean
sap
ii
score
bia
ci
compar
refer
score
evid
variat
bia
accord
case
sever
number
bed
unit
number
resid
workshift
linguist
area
profess
physician
vs
nurs
experi
initi
sap
ii
train
presenc
qualiti
control
system
item
highest
score
accuraci
bilirubin
temperatur
chronic
diseas
respect
wherea
lowest
agreement
found
urinari
output
glasgow
coma
scale
conclus
nationwid
survey
suggest
wide
variabl
sap
ii
score
result
averag
sap
ii
overestim
irrespect
profess
experi
scorer
structur
characterist
icu
least
one
person
per
unit
involv
score
train
nation
societi
respons
score
qualiti
introduct
earli
warn
score
ew
use
uk
hospit
identifi
patient
acut
unwel
need
urgent
review
nation
ew
news
implement
institut
led
notic
increas
number
patient
trigger
escal
medic
care
although
clinic
thought
unwarr
led
potenti
danger
lack
faith
news
clinic
staff
assess
whether
safe
move
ew
view
commerci
avail
electron
ew
method
patient
score
high
risk
news
score
snapshot
audit
patient
acut
district
gener
hospit
identifi
ed
review
clinic
patient
recategoris
use
view
clinic
safeti
recategoris
assess
result
fortysix
patient
identifi
ed
hospit
time
snapshot
high
risk
accord
news
recategoris
cohort
patient
use
view
classifi
ed
high
risk
instanc
mean
score
subject
author
clinic
concern
creat
move
patient
highrisk
classifi
cation
conclus
view
specifi
c
without
less
sensit
replac
news
view
feel
clinic
safe
introduct
blunt
chest
wall
trauma
account
trauma
admiss
emerg
depart
worldwid
report
mortal
rate
vari
manag
patient
group
challeng
result
delay
onset
complic
aim
studi
develop
valid
prognost
model
use
assist
manag
blunt
chest
wall
trauma
method
two
distinct
phase
overal
studi
develop
valid
phase
fi
rst
studi
phase
prognost
model
develop
retrospect
analysi
blunt
chest
wall
trauma
patient
n
present
emerg
depart
region
trauma
centr
wale
multivari
logist
regress
use
develop
model
identifi
signifi
cant
predictor
develop
complic
model
accuraci
predict
capabl
assess
second
studi
phase
extern
valid
model
complet
multicentr
prospect
studi
n
model
accuraci
predict
capabl
reassess
valid
sampl
risk
score
develop
use
clinic
set
result
signifi
cant
predictor
develop
complic
age
number
rib
fractur
chronic
lung
diseas
use
preinjuri
anticoagul
oxygen
satur
level
fi
nal
model
demonstr
excel
cindex
conclus
twophas
studi
develop
valid
prognost
model
use
assist
manag
blunt
chest
wall
trauma
patient
fi
nal
risk
score
provid
clinician
probabl
develop
complic
individu
patient
introduct
crush
syndrom
often
encount
natur
disast
critic
condit
lead
multipl
organ
failur
howev
mechan
local
traumat
injuri
aff
ect
distant
organ
remain
unknown
paid
attent
bone
marrowderiv
mononuclear
cell
bmmnc
therapeut
strategi
crush
injuri
transplant
bmmnc
elicit
protect
regener
damag
organ
paracrin
properti
clinic
applic
realiz
treat
ischemia
reperfusionrel
variou
diseas
previous
report
multipl
organ
damag
base
system
infl
ammatori
respons
induc
crush
injuri
pathogenesi
larg
depend
massiv
ischemiareperfus
investig
whether
bmmnc
could
suppress
system
infl
ammat
improv
mortal
rat
model
crush
injuri
method
develop
crush
syndrom
hind
limb
rat
compress
hour
weight
kg
rat
treat
group
intraven
administr
bmmnc
cell
ml
phosphatebuff
ere
salin
pb
immedi
weight
remov
bmmnc
group
pb
alon
administ
control
group
cr
group
sham
group
underw
procedur
without
compress
hind
limb
sh
group
rat
observ
day
injuri
evalu
surviv
estim
antiinfl
ammatori
eff
ect
bmmnc
sera
collect
hour
hour
hour
injuri
level
interleukin
tumor
necrosi
factor
alpha
measur
elisa
statist
analyz
surviv
rate
day
bmmnc
group
cr
group
reveal
surviv
signifi
cantli
improv
bmmnc
inject
p
crush
injuryinduc
upregul
serum
signifi
cantli
reduc
bmmnc
treatment
time
point
p
level
decreas
signifi
cantli
bmmnc
group
compar
cr
group
hour
compress
releas
p
fi
nding
suggest
transplant
bmmnc
abil
evad
devast
condit
follow
crush
injuri
suppress
system
infl
ammat
conclus
administr
bmmnc
reduc
product
infl
ammatori
cytokin
improv
surviv
rate
rat
model
crush
injuri
cell
therapi
use
bmmnc
might
becom
novel
therapi
crush
injuri
introduct
patient
present
emerg
depart
ed
current
face
inaccept
delay
initi
treatment
due
suboptim
initi
triag
triag
score
manchest
triag
system
mt
well
valid
unselect
medic
patient
herein
perform
prospect
cohort
studi
assess
prognost
potenti
mt
prognost
biomark
proadrenomedullin
proadm
identifi
patient
high
initi
treatment
prioriti
patient
admiss
icu
patient
die
within
followup
method
prospect
observ
cohort
studi
includ
consecut
medic
patient
seek
ed
care
june
octob
except
nonadult
nonmed
patient
collect
detail
clinic
inform
includ
initi
mt
measur
proadm
level
admiss
patient
initi
treatment
prioriti
adjud
two
independ
blind
physician
base
avail
result
time
ed
discharg
medic
ward
assess
outcom
data
electron
medic
record
use
patient
contact
telephon
day
hospit
admiss
prognost
perform
mt
proadm
assess
multivari
regress
model
area
receiv
oper
curv
auc
overal
measur
discrimin
result
includ
total
patient
male
mean
age
year
total
n
classifi
ed
high
treatment
prioriti
n
admit
icu
n
die
within
day
initi
mt
show
good
prognost
accuraci
predict
treatment
prioriti
auc
icu
admiss
auc
mortal
predict
auc
initi
proadm
level
independ
predictor
three
outcom
signifi
cantli
improv
mt
score
auc
treatment
prioriti
icu
admiss
mortal
conclus
within
larg
cohort
consecut
unselect
medic
patient
seek
ed
care
mt
instrument
combin
prognost
biomark
proadm
allow
accur
initi
risk
assess
regard
treatment
prioriti
icu
admiss
mortal
combin
score
potenti
signifi
cantli
improv
initi
risk
assess
patient
may
translat
faster
target
care
better
clinic
patient
outcom
introduct
hospit
face
situat
violenc
whether
verbal
physic
especi
emerg
depart
ed
object
studi
evalu
phenomenon
violenc
hospit
lebanon
especi
ed
recommend
techniqu
prevent
method
questionnair
consist
question
sent
caregiv
ed
three
randomli
select
hospit
beirut
lebanon
total
peopl
nurs
aid
doctor
intern
resid
social
worker
secur
guard
respond
survey
questionnair
result
major
survey
peopl
young
women
age
year
nurs
degre
profession
experi
year
total
respond
experienc
violenc
ed
night
patient
companion
caregiv
aff
ect
violenc
nurs
employe
recept
violenc
verbal
threat
insult
critic
physic
hit
slap
stab
dissatisfact
patient
care
anxieti
import
factor
gener
violenc
may
repercuss
care
worker
psycholog
statu
conclus
violenc
ed
may
due
heavi
workload
caregiv
caus
delay
care
secondli
patient
ed
may
feel
insuffi
cientli
inform
heard
nurs
staff
prioriti
given
emerg
depend
sever
order
arriv
misunderstood
therefor
recommend
follow
action
encourag
caregiv
improv
knowledg
train
manag
patient
emerg
situat
train
emerg
caregiv
mediat
nonviol
commun
manag
stress
situat
increas
number
nurs
secur
guard
ed
motiv
ensur
better
qualiti
care
minim
delay
care
introduct
intent
selfpoison
one
common
present
acut
medic
unit
across
uk
knowledg
studi
publish
incid
admiss
critic
care
england
overdos
aim
investig
epidemiolog
clinic
featur
outcom
patient
admit
critic
care
intent
selfpoison
establish
pattern
commun
method
perform
retrospect
data
collect
use
critic
care
databas
metavis
select
patient
admit
diagnosi
overdos
record
scrutinis
collect
inform
patient
demograph
clinic
featur
medic
manag
result
thirtyeight
patient
male
femal
ratio
admit
critic
care
period
septemb
repres
total
admiss
critic
care
period
sampl
signifi
cantli
younger
median
age
year
standard
patient
popul
critic
care
year
period
p
despit
young
age
pauciti
comorbid
diff
erenc
length
stay
overdos
patient
day
patient
critic
care
day
p
median
number
agent
ingest
three
critic
care
volum
suppl
http
ingest
agent
hypnot
antidepress
made
agent
ingest
total
sampl
admit
outofhour
weekend
fifti
per
cent
past
histori
overdos
histori
alcohol
misus
total
patient
refer
critic
care
due
low
consciou
level
requir
ippv
receiv
vasopressorsinotrop
mortal
rate
one
death
month
discharg
due
alcohol
liver
diseas
estim
fi
nancial
cost
per
patient
level
bedday
level
bedday
conclus
intent
selfpoison
mortal
rate
low
spite
number
patient
admit
despit
young
age
patient
lack
comorbid
length
stay
similar
averag
length
stay
patient
admit
unit
repres
signifi
cant
fi
nancial
cost
selfpoison
requir
critic
care
support
common
outofhour
less
senior
expertis
avail
educ
junior
doctor
manag
overdos
therefor
vital
ensur
earli
identifi
cation
appropri
treatment
patient
introduct
number
studi
demonstr
signifi
cant
increas
morbid
mortal
associ
alcoholrel
diseas
uk
correspond
impact
critic
care
servic
studi
design
similarli
evalu
current
burden
alcoholrel
diseas
admiss
rate
region
icu
also
calcul
fi
nancial
cost
admiss
method
dataentri
fi
eld
deriv
recommend
public
heath
public
introduc
local
electron
record
system
enabl
prospect
data
collect
admiss
either
wholli
partial
attribut
alcohol
consumpt
use
local
defi
ned
valu
cost
per
day
admiss
icu
depend
maximum
level
organ
support
requir
admiss
possibl
calcul
total
expens
incur
unit
alcoholrel
admiss
year
decemb
novemb
inclus
icu
record
alcoholrel
admiss
account
approxim
annual
unplan
admiss
averag
length
stay
day
similar
unplan
admiss
total
icu
bedday
total
patient
alcoholrel
condit
male
averag
age
year
rang
year
major
present
chronic
condit
partial
attribut
alcohol
consumpt
number
admiss
per
month
vari
zero
may
peak
novemb
major
admiss
occur
autumn
month
figur
eightynin
per
cent
patient
alcoholrel
condit
requir
support
least
two
organ
failur
subsequ
equat
overal
cost
unit
approxim
million
annual
budget
result
studi
support
hypothesi
alcoholrel
diseas
contribut
consider
admiss
icu
furthermor
shown
fi
nancial
impact
proport
greater
percentag
number
admiss
attribut
alcohol
consumpt
refl
ect
high
frequenc
multiorgan
failur
patient
cohort
refer
introduct
object
analyz
clinic
featur
multipl
organ
dysfunct
syndrom
mod
induc
sever
heat
stroke
investig
pathogenesi
diagnosi
prevent
strategi
patient
mod
caus
sever
heat
stroke
method
retrospect
studi
nine
case
mod
caus
sever
heat
stroke
system
review
relev
literatur
result
nine
patient
mod
caus
sever
heat
stroke
expos
hot
humid
environ
nine
patient
sever
heat
stroke
includ
seven
case
classic
heat
stroke
two
case
exert
heat
stroke
among
nine
case
mod
caus
sever
heat
stroke
eight
patient
met
diagnost
criteria
sir
addit
signifi
cant
increas
blood
pmn
proport
serum
crp
nine
patient
note
also
mark
increas
serum
averag
pgml
refer
rang
pgml
level
averag
pgml
refer
rang
pgml
normal
averag
pg
ml
refer
rang
pgml
organ
damag
involv
nine
patient
mod
induc
sever
heat
stroke
kidney
circulatori
liver
account
organ
dysfunct
incid
sever
heatstrokeinduc
organ
dysfunct
turn
kidney
circul
liver
blood
coagul
metabol
brain
lung
gastrointestin
tract
hospit
common
complic
pulmonari
infect
patient
mod
caus
heat
stroke
earli
intens
care
organ
support
treatment
quick
improv
recoveri
case
sever
day
seven
patient
surviv
averag
length
stay
hospit
day
conclus
sever
heat
stroke
result
signifi
cant
abnorm
chang
infl
ammatori
marker
patient
mod
induc
heat
stroke
type
organ
dysfunct
heat
strokeinduc
mod
usual
distinct
infect
trauma
activ
cool
intens
organ
function
support
treatment
patient
recov
rel
short
period
shock
patient
need
vasopressor
infus
maintain
adequ
deliveri
oxygen
could
deleteri
eff
ect
skin
perfus
worsen
burn
depth
shock
could
result
interplay
initi
hypovolemia
releas
multipl
infl
ammatori
mediat
shown
lowdos
hydrocortison
could
reduc
shock
durat
mechan
involv
remain
unclear
investig
system
genom
respons
sever
burn
injuri
determin
whether
pattern
gene
express
could
associ
low
dose
glucocorticoid
method
thirti
burn
patient
total
bodi
surfac
area
enrol
random
doubleblind
clinic
studi
fifteen
patient
treat
low
dose
hydrocortison
patient
treat
placebo
whole
blood
sampl
collect
shock
onset
treatment
day
treatment
begin
hour
hour
burn
injuri
blood
sampl
healthi
volunt
collect
pangenom
express
evalu
aff
ymetrix
microarray
moder
test
f
test
use
compar
burn
patient
control
gene
express
profi
le
two
group
bh
correct
p
result
sever
burn
injuri
induc
deregul
consider
number
gene
n
comparison
control
increas
number
deregul
gene
time
within
burn
patient
gene
deregul
hydrocortison
time
treatment
rapid
eff
ect
gene
express
gene
diff
erenti
express
respect
howev
number
gene
decreas
drastic
gene
signifi
cant
gene
identifi
ed
mostli
relat
decreas
growth
develop
quantiti
leukocyt
biolog
process
found
signifi
cant
indic
action
glucocorticoid
respons
burn
injuri
short
live
time
depend
conclus
studi
inform
overview
genom
respons
burn
injuri
importantli
fi
rst
studi
provid
inform
mechan
involv
glucocorticoid
reduc
shock
durat
burn
refer
introduct
manag
clinic
network
care
burn
scotland
cobi
launch
april
primari
aim
includ
establish
maintain
registri
complex
burn
injuri
scotland
set
mechan
regularli
audit
outcom
burn
treatment
nation
agre
standard
care
behalf
cobi
present
incid
mortal
data
scottish
patient
admit
complex
burn
injuri
abstract
method
januari
onward
data
prospect
collect
patient
scotland
complex
burn
injuri
admit
scottish
burn
unit
data
collect
initi
paper
pro
forma
subsequ
evolv
webbas
audit
data
captur
system
secur
link
hospit
site
involv
deliveri
care
complex
burn
data
collect
includ
extent
mechan
burn
presenc
airway
burn
smoke
inhal
injuri
comorbid
complic
length
stay
intervent
mortal
qualiti
complet
consist
data
collect
audit
feedback
individu
unit
result
popul
approxim
million
annual
incid
complex
burn
injuri
per
incid
major
burn
burn
admiss
hospit
mortal
burn
see
tabl
conclus
data
scotland
comprehens
nation
fi
gure
complex
burn
injuri
allow
benchmark
intern
indic
provid
comprehens
data
cobi
data
also
correl
mortal
data
sourc
data
qualiti
improv
detail
analysi
mortal
data
allow
cobi
identifi
contribut
issu
aff
ect
burn
patient
issu
identifi
ed
alreadi
patient
burn
often
die
soon
discharg
hospit
relat
unrel
caus
subsequ
analysi
allow
cobi
identifi
address
issu
may
contribut
statist
major
burn
injuri
consid
accident
although
previou
studi
identifi
ed
demograph
factor
associ
higher
risk
burn
socioeconom
depriv
ethnic
minor
group
studi
aim
identifi
popul
subgroup
london
high
risk
burn
injuri
requir
admiss
burn
centr
geograph
map
socioeconom
statist
hemodynam
endpoint
prefer
tissu
perfus
target
earli
antimicrobi
therapi
deescal
routin
practic
without
use
infect
biomark
crystalloid
prefer
rather
colloid
initi
resuscit
cvp
fl
uid
challeng
still
popular
new
fl
uid
respons
method
preload
assess
hydrocortison
common
steroid
prescript
septic
shock
threshold
initi
frequenc
discontinu
vari
shown
patient
trigger
clinic
ew
prior
cardiac
arrest
jarvi
colleagu
propos
ew
base
common
laboratori
fi
nding
predict
patient
mortal
aim
studi
part
wider
review
cardiac
arrest
hospit
determin
whether
laboratori
earli
warn
score
lew
might
use
identifi
patient
risk
cardiac
arrest
trust
method
retrospect
data
collect
identifi
ed
cardiac
arrest
call
lead
cpr
defi
brillat
month
lew
calcul
accord
formula
devis
jarvi
colleagu
lew
male
femal
taken
trigger
suggest
jarvi
colleagu
introduct
aim
audit
evalu
whether
guidelin
produc
local
intens
therapi
unit
itu
regard
blood
sampl
practic
adher
volum
blood
taken
cost
also
evalu
method
retrospect
audit
investig
number
routin
blood
test
order
itu
januari
perform
exclus
criteria
computerbas
data
collect
system
use
gather
data
regard
patient
detail
blood
test
process
collect
bottl
use
examin
see
much
blood
need
fi
thirti
nurs
ask
much
dead
space
blood
discard
averag
record
cost
blood
test
also
calcul
follow
period
educ
regard
content
guidelin
reaudit
juli
retrospect
initi
audit
examin
patientday
urea
electrolyt
u
es
full
blood
count
fbc
request
line
guidelin
liver
function
test
lft
bone
profi
le
magnesium
clot
screen
order
approxim
four
time
advoc
shown
mani
bone
profi
le
magnesium
test
probabl
inappropri
request
moreov
twice
much
blood
taken
patient
compar
recommend
guidelin
almost
litr
total
januari
cost
routin
blood
test
januari
guidelin
follow
estim
yearli
save
would
repeat
audit
patientday
examin
amount
time
u
e
fbc
request
larg
unchang
amount
time
lft
bone
profi
le
magnesium
clot
screen
order
reduc
approxim
almost
onethird
blood
taken
patient
compar
suggest
volum
guidelin
cost
blood
test
done
juli
despit
improv
frequenc
blood
test
estim
per
year
could
still
save
result
underlin
unit
guidelin
follow
reaudit
show
improv
adher
patient
expos
unnecessari
blood
test
implic
iatrogen
anaemia
also
place
signifi
cant
fi
nancial
burden
depart
continu
staff
educ
encourag
requir
order
aid
transit
current
recommend
practic
direct
central
line
entri
rate
believ
major
contributor
risk
central
line
infect
mayo
clinic
histor
schedul
obtain
blood
analysi
pediatr
icu
polici
implement
may
restrict
blood
draw
three
time
daili
nonemerg
blood
draw
subsequ
conduct
studi
determin
whether
implement
polici
associ
reduct
blood
draw
well
centrallin
uniqu
entri
method
data
laboratori
well
databas
central
line
uniqu
entri
analyz
baselin
implement
polici
chang
identifi
cation
decreas
line
entryblood
draw
rate
per
mayo
clinic
polici
irb
approv
requir
qi
project
preimplement
phase
total
blood
draw
total
patientday
blood
drawspatientday
consolid
blood
draw
patientday
blood
drawspatientday
reduct
line
entri
arteri
line
entri
central
line
entri
peripher
venipunctur
polici
implement
number
respect
averag
central
line
uniqu
entri
blood
draw
consolid
decreas
line
entriescentr
lineday
consolid
blood
draw
associ
cost
save
conclus
consolid
time
frame
blood
draw
picu
associ
decreas
central
line
entri
decreas
util
vascular
access
team
decreas
phlebotomi
cost
hypothes
polici
associ
decreas
incid
clabsi
patient
includ
analysi
introduc
although
variou
techniqu
reduc
intraop
blood
loss
describ
absenc
uniform
consist
applic
literatur
blood
loss
burn
surgeri
estim
least
ml
per
percentag
bodi
surfac
area
excis
recent
develop
novel
hemostat
techniqu
use
silicon
gel
dress
alcar
co
ltd
tokyo
japan
stop
intraop
bleed
briefl
soon
tangenti
excis
humbi
knife
wound
spray
thrombin
adrenalin
solut
wrap
tightli
full
minut
burn
wound
limb
tangenti
excis
tourniquet
control
wrap
defl
ation
tourniquet
defl
ation
tourniquet
wait
full
minut
remov
major
bleeder
cauter
graft
appli
rins
wound
warm
salin
method
prospect
observ
studi
januari
octob
collect
preoper
postop
hemoglobin
level
patient
underw
tangenti
excis
burn
injuri
calcul
blood
loss
periop
period
data
amount
blood
transfus
excis
area
harvest
area
also
collect
introduct
massiv
bleed
remain
lead
caus
potenti
prevent
death
cardiovascular
surgeri
convent
coagul
test
cct
fail
character
multipl
hemostat
abnorm
observ
surgic
patient
limit
slow
result
poor
correl
transfus
requir
assess
clinic
impact
goaldirect
coagul
manag
base
rotat
thromboelastometri
rotem
patient
undergo
emerg
cardiovascular
surgic
procedur
method
period
data
patient
collect
prospect
blood
sampl
obtain
coagul
test
administr
pack
red
blood
cell
prbc
hemostat
product
guid
algorithm
use
rotemderiv
inform
hemoglobin
level
base
amount
prbc
transfus
two
group
consid
high
bleeder
prbc
hb
low
bleeder
prbc
lb
data
analyz
use
chisquar
test
unpair
test
anova
appropri
result
preoper
hb
group
n
character
lower
blood
fi
brinogen
decreas
clot
amplitud
rotem
compar
lb
group
n
intraop
larger
amount
fi
brinogen
fresh
frozen
plasma
platelet
deem
necessari
normal
coagul
paramet
hb
group
postop
incid
major
thromboembol
ischem
event
diff
er
two
group
observ
inhospit
mortal
signifi
cantli
less
expect
possum
score
vs
hb
group
vs
lb
group
conclus
rotemderiv
inform
help
detect
earli
coagul
abnorm
monitor
respons
hemostat
therapi
earli
goaldirect
manag
coagulopathi
may
contribut
improv
outcom
cardiovascular
surgeri
refer
need
clarifi
cation
around
coagulopathi
intervent
radiolog
critic
care
set
low
absolut
incid
bleed
complic
risk
complic
transfus
lend
support
view
ffp
use
therapeut
rather
prophylact
cover
introduct
studi
investig
use
viscoelast
devic
monitor
treatment
lmwh
knowledg
studi
compar
diff
erent
lmwh
diff
erent
visocoelast
method
method
enoxaparin
klexan
tinzaparin
innohep
ad
ml
citrat
blood
intens
care
patient
obtain
plasma
concentr
iuml
enoxaparin
tinzaparin
respect
studi
approv
local
ethic
committe
written
consent
rel
clot
format
clot
retract
studi
use
rotem
reorox
result
rotem
analysi
show
prolong
clot
format
ct
increas
concentr
enoxaparin
tinzaparin
reorox
analysi
show
initi
clot
format
increas
increas
dose
enoxaparin
tinzaparin
progress
clot
format
thu
result
prolong
complet
clot
format
see
tabl
conclus
clot
initi
prolong
drug
detect
rotem
reorox
clot
format
decreas
tinzaparin
enozaparin
detect
reorox
introduct
heparin
commonli
given
neonat
icu
nicu
continu
intraven
infus
heparin
dilut
parenter
nutrit
bag
administ
period
hour
inlin
fi
ltration
howev
data
heparin
stabil
parenter
nutrit
bag
especi
compat
dextros
mainli
present
bag
aim
vitro
studi
determin
heparin
stabil
parenter
nutrit
bag
prepar
nicu
infus
assess
interact
dextros
method
prepar
type
bag
parenter
nutrit
bag
whose
composit
defi
ned
unit
includ
sodium
heparin
uiml
bag
contain
sodium
heparin
dilut
dextros
uiml
bag
n
per
type
infus
period
hour
without
inlin
fi
ltration
heparin
activ
measur
use
chromogen
antixa
method
bag
prepar
refer
measur
infus
effl
uent
end
infus
line
hour
result
show
valu
heparin
activ
measur
bag
effl
uent
without
inlin
fi
ltration
infus
type
bag
assess
tabl
result
express
median
valu
minimum
maximum
percent
oral
direct
select
factor
xa
inhibitor
edoxaban
daiichi
sankyo
current
avail
japan
prophylaxi
venou
thromboembol
vte
patient
undergo
major
orthoped
surgeri
undergo
investig
phase
iii
trial
prevent
stroke
patient
atrial
fi
brillat
treatment
secondari
prevent
vte
primari
complic
avail
anticoagul
therapi
risk
bleed
rapid
revers
anticoagul
may
necessari
patient
requir
emerg
treatment
due
uncontrol
bleed
prothrombin
complex
concentr
pcc
frequent
use
revers
eff
ect
vitamin
k
antagonist
warfarin
also
suggest
potenti
eff
ectiv
revers
eff
ect
new
oral
anticoagul
present
studi
therefor
design
determin
whether
fourfactor
pcc
eff
ectiv
revers
bleed
normal
coagul
follow
edoxaban
administr
rabbit
kidney
injuri
model
method
rabbit
treat
high
intraven
bolu
dose
edoxaban
follow
administr
iukg
bleed
assess
base
time
hemostasi
total
blood
loss
induct
standard
kidney
injuri
parallel
follow
biomark
hemostasi
determin
factor
xa
inhibit
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
whole
blood
clot
time
wbct
thrombin
gener
tga
result
confi
rmed
increas
prolong
bleed
edoxabantr
anim
follow
standard
kidney
injuri
compar
vehicl
administr
parallel
monitor
biomark
hemostasi
show
prolong
pt
aptt
wbct
chang
thrombin
gener
paramet
subsequ
administr
result
dosedepend
revers
edoxabaninduc
bleed
indic
reduc
time
hemostasi
total
blood
loss
paramet
achiev
statist
signifi
canc
compar
placebo
dose
iukg
fulli
blind
studi
condit
biomark
correl
best
edoxaban
anticoagul
revers
includ
pt
wbct
endogen
thrombin
potenti
conclus
summari
treatment
eff
ectiv
revers
edoxabaninduc
anticoagul
anim
model
acut
bleed
clinic
relev
dose
level
dabigatrantr
anim
random
n
singl
inject
idarucizumab
mgkg
iv
vehicl
control
anim
blood
loss
hemodynam
variabl
monitor
hour
time
death
data
analyz
anova
sd
logrank
test
result
dabigatran
level
ngml
diff
erenc
group
prior
injuri
bl
sham
anim
ml
minut
injuri
ml
hour
surviv
rate
anticoagul
dabigatran
control
anim
result
signifi
cantli
higher
bl
minut
injuri
ml
p
mortal
anim
mean
surviv
time
minut
rang
minut
p
vs
sham
idarucizumabtr
anim
total
bl
dabigatrantr
anim
ml
contrast
treatment
idarucizumab
associ
dosedepend
reduct
bl
conclus
bivalirudin
valuabl
option
anticoagul
patient
vad
easili
monitor
aptt
use
bivalirudinbas
anticoagul
strategi
earli
postop
period
may
overcom
mani
limit
heparin
risk
hit
higher
patient
undergo
cardiac
surgeri
bivalirudin
longer
regard
secondlin
therapi
anticoagul
patient
vad
introduct
free
hemoglobin
fhb
scaveng
nitric
oxid
induc
vasoconstrict
fhb
content
may
higher
older
blood
bag
studi
whether
old
red
blood
cell
rbc
transfus
increas
plasma
fhb
septic
patient
aff
ect
microvascular
respons
method
twenti
septic
patient
randomli
receiv
either
fresh
day
storag
old
day
rbc
transfus
plasma
fhb
measur
hour
transfus
sublingu
microcircul
assess
sidestream
darkfi
eld
imag
perfus
boundari
region
pbr
measur
index
glycocalyx
damag
thenar
tissu
hb
index
thi
measur
nearinfrar
spectroscopi
result
fhb
increas
old
rbc
group
figur
thi
increas
group
sdf
paramet
unalt
neg
correl
found
chang
total
vessel
densiti
r
p
figur
thi
r
p
relat
lack
patient
pbr
present
studi
investig
relationship
age
biomark
coagul
fi
brinolysi
impact
outcom
sever
sepsi
patient
method
prospect
observ
studi
adult
patient
sever
sepsi
conduct
singl
academ
hospit
plasma
analyz
coagul
fi
brinolysi
marker
day
patient
stratifi
ed
accord
age
year
point
youden
index
maximum
sensit
specifi
citi
receiv
oper
characterist
plot
logist
regress
model
inhospit
mortal
result
inhospit
surviv
rate
older
sepsi
patient
signifi
cantli
lower
younger
patient
versu
p
older
patient
markedli
higher
total
plasmin
activ
day
thrombinantithrombin
complex
tat
day
fi
brin
monom
complex
day
markedli
lower
plasminogen
pmg
day
alphaplasmin
inhibitor
day
compar
younger
patient
p
age
independ
predictor
high
tat
day
high
fi
brin
monom
complex
day
low
pmg
day
low
day
adjust
cofactor
covari
day
tat
day
pmg
day
risk
factor
inhospit
mortal
older
sepsi
patient
tabl
tabl
show
improv
outcom
dialysi
discontinu
among
patient
requir
dialysi
inclus
ecu
gener
well
toler
death
unexpect
safeti
concern
meningococc
infect
occur
two
patient
one
continu
treatment
introduct
restrict
transfus
practic
recent
random
trial
systemat
review
continu
favor
outcom
despit
substanti
variabl
transfus
practic
persist
import
identifi
contemporari
variabl
patient
provid
institut
factor
drive
variabl
therefor
perform
retrospect
analysi
hypothes
red
blood
cell
conclus
anemia
elev
hematocrit
seem
associ
inhospit
mortal
among
patient
suspect
infect
treatment
high
low
hematocrit
part
ed
resuscit
could
subject
investig
introduct
sever
predict
model
describ
identifi
necess
massiv
transfus
mt
trauma
patient
purpos
studi
valid
simplifi
ed
score
system
report
previous
establish
new
criteria
emerg
icu
japan
retrospect
analyz
trauma
patient
transport
center
recent
year
patient
transfer
hospit
minor
injuri
confi
rmed
cardiac
arrest
scene
exclud
result
total
trauma
patient
includ
studi
thirtyon
patient
requir
mt
sensit
specifi
citi
assess
blood
consumpt
abc
score
respect
blunt
injuri
account
trauma
patient
japan
establish
new
simpl
criteria
use
signifi
cant
factor
deriv
examin
arriv
trauma
patient
met
follow
condit
shock
index
si
base
excess
mmoll
posit
focus
assess
sonographi
trauma
fast
sensit
specifi
citi
respect
conclus
patient
sepsi
receiv
blood
product
particularli
platelet
signifi
cantli
like
develop
ard
day
mechan
ventil
higher
mortal
lack
increas
mortal
associ
prbc
transfus
may
due
benefi
oxygen
deliveri
sampl
size
introduct
periop
red
blood
cell
transfus
commonli
use
address
anemia
independ
risk
factor
morbid
mortal
critic
ill
patient
howev
evid
regard
optim
blood
transfus
practic
septic
shock
lack
aim
studi
defi
ne
best
transfus
strategi
septic
shock
patient
regard
mortal
clinic
outcom
restrict
liber
method
transfus
requir
cardiac
surgeri
trac
studi
prospect
random
control
clinic
noninferior
trial
conduct
februari
februari
icu
univers
hospit
cardiac
surgeri
referr
center
brazil
consecut
adult
patient
n
underw
cardiac
surgeri
cardiopulmonari
bypass
elig
analysi
intent
treat
random
control
parallelgroup
trial
includ
patient
admit
cancer
icu
diagnosi
septic
shock
patient
randomli
assign
liber
strategi
blood
transfus
maintain
hemoglobin
gdl
restrict
strategi
hemoglobin
gdl
mortal
day
main
outcom
secondari
outcom
clinic
complic
day
free
organ
dysfunct
icu
hospit
length
stay
advers
eff
ect
transfus
mortal
result
total
patient
includ
fi
rst
part
trial
mean
age
year
sap
admiss
patient
diagnosi
solid
neoplasm
sixtythre
patient
includ
liber
strategi
patient
restrict
strategi
occurr
mortal
similar
group
liber
group
vs
restrict
group
p
conclus
among
cancer
patient
septic
shock
use
restrict
periop
transfus
strategi
compar
liber
strategi
result
similar
rate
refer
introduct
blood
transfus
associ
increas
morbid
mortal
critic
ill
advers
eff
ect
transfus
may
mediat
chang
blood
product
accumul
storag
time
mechan
howev
larg
unknown
erythrocytederiv
microparticl
mp
found
transfus
bag
concentr
increas
storag
durat
hypothes
accumul
mp
storag
induc
proinfl
ammatori
state
recipi
capillari
leakag
subsequ
pulmonari
edema
trali
clinic
diagnosi
follow
criteria
acut
onset
within
hour
blood
transfus
pao
fio
ratio
mmhg
worsen
p
f
ratio
bilater
infi
ltrativ
chang
chest
radiograph
sign
hydrostat
pulmonari
edema
pulmonari
arteri
occlus
pressur
mmhg
central
venou
pressur
mmhg
risk
factor
acut
lung
injuri
method
describ
fatal
trali
patient
infl
uenza
suggest
relationship
fi
rsthit
lung
injuri
follow
second
lung
impair
blood
transfus
report
femal
without
previou
medic
record
acut
onset
fever
cough
muscl
pain
progress
dyspnea
lead
acut
respiratori
distress
syndrom
test
infl
uenza
posit
recov
day
admiss
hour
platelet
transfus
start
intens
tachycardia
dyspnea
hypoxemia
mechan
ventil
paramet
increas
dramat
plan
extub
fio
posit
endexpiratori
pressur
becam
respect
p
f
ratio
drop
leukocyt
l
hour
earlier
went
l
onset
previou
lactat
normal
jump
mgdl
free
vasopressor
end
transfus
went
refractori
shock
die
approxim
hour
blood
transfus
conclus
knowledg
fi
rst
case
report
trali
infl
uenza
patient
although
blood
transfus
life
save
also
lifethreaten
intervent
prevent
still
best
hit
refer
introduct
prothrombin
complex
concentr
pcc
suggest
measur
termin
trauma
dabigatraninduc
bleed
owe
confl
ict
data
concern
therapi
investig
impact
fourfactor
pcc
termin
massiv
bleed
follow
infl
iction
multipl
trauma
dabigatran
anticoagul
pig
method
ethic
approv
male
pig
administ
dabigatran
etexil
mgkg
bid
po
day
day
dabigatran
anaesthetis
anim
infus
prior
injuri
achiev
supratherapeut
level
twelv
minut
infl
iction
bilater
femur
fractur
standardis
blunt
liver
injuri
anim
randomli
receiv
pcc
iukg
n
placebo
n
timeadjust
blood
loss
primari
endpoint
observ
period
minut
panel
coagul
variabl
continu
measur
data
analys
twoway
anova
data
mean
sem
result
concentr
dabigatran
prior
infl
iction
trauma
compar
group
ngml
anticoagul
dabigatran
trauma
caus
sever
coagulopathi
shown
prolong
tem
variabl
ct
cft
pt
aptt
follow
pcc
applic
eff
ect
partial
revers
due
ongo
blood
loss
pt
tem
variabl
prolong
time
pcc
iukg
substitut
anim
accordingli
nopcc
mlminut
pcc
iukg
mlminut
anim
show
highest
blood
loss
p
vs
pcc
iukg
pcc
iukg
mean
surviv
time
minut
nopcc
anim
minut
pcc
iukg
anim
respect
anim
pcc
iukg
pcc
iukg
group
surviv
blood
loss
group
compar
pcc
iu
kg
mlminut
pcc
iukg
mlminut
use
high
dose
pcc
revers
anticoagul
eff
ect
dabigatran
associ
signifi
cant
reduct
blood
loss
howev
result
studi
show
suffi
cient
concentr
pcc
necessari
overcom
thrombin
inhibit
introduct
fresh
frozen
plasma
ffp
associ
onset
acut
lung
injuri
mechan
larg
unknown
hand
ffp
may
benefi
cial
higher
ratio
ffp
red
blood
cell
decreas
mortal
bleed
trauma
patient
associ
endotheli
stabil
eff
ect
vitro
investig
eff
ect
transfus
ffp
host
respons
marker
endotheli
damag
nonbleed
critic
ill
patient
method
substudi
multicent
trial
nonbleed
critic
ill
patient
increas
intern
normal
ratio
random
omit
administ
prophylact
transfus
ffp
mlkg
prior
invas
procedur
patient
random
receiv
ffp
transfus
measur
level
factor
viii
von
willebrand
factor
marker
proinfl
ammatori
respons
transfus
data
present
median
result
ffp
transfus
result
signifi
cant
decreas
pgml
p
von
willebrand
factor
p
factor
viii
p
ffp
alter
level
patient
degre
lung
injuri
baselin
refl
ect
lung
injuri
score
chang
follow
transfus
none
patient
develop
trali
conclus
ffp
transfus
associ
proinfl
ammatori
respons
critic
ill
rather
ffp
seem
endotheli
stabil
eff
ect
introduct
treat
trauma
patient
sever
hemorrhag
massiv
blood
transfus
often
need
damag
control
resuscit
strategi
use
patient
adequ
fresh
frozen
plasma
pack
red
blood
cell
ffp
prbc
administr
ratio
must
establish
method
retrospect
review
medic
record
trauma
patient
treat
massiv
transfus
march
octob
divid
patient
two
group
accord
ffp
prbc
ratio
highratio
group
lowratio
group
patient
demograph
fl
uid
transfus
quantiti
laboratori
valu
complic
outcom
group
analyz
compar
result
patient
highratio
group
lowratio
group
statist
signifi
cant
diff
erenc
group
quantiti
ffp
ffp
prbc
platelet
crystalloid
administ
well
initi
diastol
blood
pressur
compar
incid
complic
bloodstream
infect
note
highratio
group
diff
erenc
statist
signifi
cant
p
kaplanmei
plot
reveal
surviv
rate
signifi
cantli
higher
highratio
group
vs
p
surviv
rate
also
higher
highratio
group
vs
diff
erenc
statist
signifi
cant
p
critic
care
volum
suppl
http
conclus
treat
patient
sever
hemorrhag
trauma
rais
ffp
prbc
ratio
higher
may
increas
chanc
surviv
especi
surviv
rate
eff
ort
minim
bloodstream
infect
resuscit
process
must
increas
refer
pt
second
follow
infus
dabigatran
mean
plasma
level
dabigatran
increas
ng
ml
supratherapeut
level
associ
prolong
pt
aptt
extem
variabl
ct
cft
chang
coagul
paramet
compound
blood
loss
follow
trauma
total
blood
loss
minut
ml
sixti
minut
trauma
four
fi
anim
measur
clot
format
extem
cft
second
clot
strength
extem
mcf
reduc
mm
pcc
adabifab
rfviia
revers
eff
ect
dabigatran
thromboelastometri
paramet
clot
time
clot
format
time
pt
time
point
contrast
aptt
normalis
idarucizumab
plasma
concentr
dabigatran
remain
elev
pcc
therapi
measur
idarucizumab
introduct
fluid
resuscit
hemorrhag
shock
frequent
associ
reperfus
injuri
secondari
organ
damag
studi
suggest
low
dose
nitrit
carbon
monoxid
may
protect
tissu
organ
reperfus
injuri
limit
mitochondri
free
radic
product
explor
eff
ect
small
dose
nitrit
carbon
monoxid
tissu
injuri
porcin
model
hemorrhag
shock
method
fluid
resuscit
hemorrhag
shock
frequent
associ
reperfus
injuri
secondari
organ
damag
studi
suggest
low
dose
nitrit
carbon
monoxid
may
protect
tissu
organ
reperfus
injuri
limit
mitochondri
free
radic
product
explor
eff
ect
small
dose
nitrit
carbon
monoxid
tissu
injuri
porcin
model
hemorrhag
shock
result
although
increas
blood
nitrit
concentr
observ
inhal
nitrit
associ
signifi
cant
decreas
blood
muscl
periton
fl
uid
lactat
concentr
p
wherea
nitrit
carbon
monoxid
associ
signifi
cant
decreas
glycerol
periton
fl
uid
p
follow
resuscit
muscl
mitochondri
respiratori
control
ratio
preserv
nitrit
carbon
monoxid
group
reduc
control
group
adjuv
drug
eff
ect
gross
hemodynam
paramet
conclud
low
dose
nebul
sodium
nitrit
inhal
carbon
monoxid
associ
tissu
protect
resuscit
sever
hemorrhag
shock
introduct
current
noninvas
blood
pressur
nibp
monitor
base
oscillometr
method
determin
blood
pressur
cuff
defl
ation
hand
measur
cuff
infl
ation
may
advantag
cuff
infl
ation
requir
lower
cuff
pressur
shorter
durat
defl
ation
surgic
patient
anesthesia
infl
ationari
nibp
reason
accuraci
compar
convent
defl
ationari
nibp
studi
report
nibp
monitor
use
infl
ationari
nibp
er
patient
variou
unstabl
condit
purpos
studi
verifi
use
infl
ationari
nibp
monitor
emerg
depart
method
total
nibp
data
collect
patient
age
year
accommod
resuscit
area
er
keio
univers
hospit
use
altern
two
algorithm
standard
monitor
nihon
kohden
inc
tokyo
japan
one
algorithm
consist
continu
infl
ationari
defl
ationari
measur
singl
cycl
dual
algorithm
data
perform
order
verifi
success
rate
precis
data
defl
ationari
algorithm
data
consist
convent
defl
ationari
measur
perform
order
verifi
durat
measur
cycl
success
rate
infl
ationari
nibp
complet
infl
ationari
method
bia
precis
systol
pressur
diastol
pressur
diff
erenc
systol
diastol
pressur
infl
ationari
defl
ationari
nibp
mmhg
respect
figur
infl
ationari
nibp
could
also
determin
nibp
quickli
compar
defl
ationari
nibp
vs
second
median
figur
conclus
data
suggest
infl
ationari
nibp
reason
accuraci
suffi
cient
rapid
compar
defl
ationari
nibp
emerg
room
patient
refer
introduct
time
profi
le
arteri
puls
known
featur
dicrot
notch
subsidiari
peak
featur
may
provid
use
inform
vascular
system
tradit
explain
term
aortic
valv
closur
multipl
refl
ection
imped
mismatch
within
arteri
system
howev
experiment
evid
refl
ection
elus
propos
arteri
dynam
may
obey
nonlinear
equat
model
predict
exist
multipeak
soliton
travel
long
distanc
without
dissip
demonstr
within
soliton
model
necessari
model
valv
closur
wave
refl
ection
singl
multipl
notch
aris
de
novo
even
featureless
theoret
lv
pressur
puls
profi
le
show
number
clinic
relev
featur
invas
blood
pressur
reproduc
soliton
model
examin
role
lv
puls
energi
puls
wave
shape
progress
method
model
arteri
pressur
given
solut
kdv
equat
constant
depend
properti
arteri
solv
initi
condit
parabol
left
ventricular
pressur
puls
evolut
arteri
puls
along
arteri
tree
shown
figur
also
predict
arteri
puls
increas
left
ventricular
eject
energi
conclus
simpl
model
explain
mani
featur
arteri
puls
observ
clinic
practic
develop
dicrot
notch
chang
shape
along
arteri
tree
steepen
acceler
hypertens
phenomena
tradit
attribut
arteri
wave
refl
ection
reson
invas
arteri
pressur
measur
instead
explain
intrins
properti
arteri
puls
critic
care
volum
suppl
http
introduct
payforperform
program
econom
constraint
call
solut
improv
qualiti
healthcar
without
increas
cost
mani
studi
shown
decreas
morbid
major
surgeri
periop
goaldirect
therapi
pgdt
use
assess
clinic
econom
burden
postsurg
complic
univers
healthsystem
consortium
uhc
order
predict
potenti
save
pgdt
method
data
adult
major
surgic
procedur
screen
uhc
databas
thirteen
postsurg
complic
tabul
inhospit
mortal
hospit
length
stay
cost
patient
without
complic
compar
risk
ratio
report
recent
metaanalysi
use
estim
potenti
reduct
postsurg
morbid
pgdt
potenti
cost
save
calcul
actual
anticip
morbid
rate
patient
randomli
select
catheter
perform
neutral
posit
head
n
turn
head
opposit
side
n
usguid
catheter
procedur
perform
accord
gener
principl
needl
enter
ijv
blood
aspir
us
probe
releas
hand
cathet
place
fi
xed
accord
selding
techniqu
data
intervent
side
process
count
number
success
cathet
insert
whether
arteri
access
durat
procedur
skin
contact
needl
cathet
insert
record
local
ijv
relat
ca
anterolater
anterior
later
neutral
posit
anterolater
anterior
later
posit
rotat
chang
signifi
cant
proport
patient
local
ijv
relat
ca
anterior
placement
rate
increas
risk
ca
punctur
signifi
cantli
higher
posit
rotat
compar
neutral
posit
p
signifi
cant
diff
erenc
found
procedur
durat
complic
record
observ
conclus
studi
shown
anterior
placement
ijv
neutral
posit
less
advantag
avoid
arteri
punctur
smaller
area
procedur
neutral
posit
caus
diffi
culti
practic
howev
process
time
head
posit
diff
erent
nevertheless
studi
evalu
whether
compar
complic
rate
durat
procedur
emerg
trauma
patient
head
rotat
possibl
need
pere
recent
lum
develop
anthropometr
formula
correl
patient
height
h
ideal
length
central
venou
cathet
cvc
order
identifi
optim
tip
posit
aim
studi
compar
reliabl
anthropometr
formula
method
base
intracavitari
ecg
method
enrol
patient
admit
icu
candid
elect
cvc
insert
detect
p
wave
surfac
ecg
intracavitari
ecg
use
identifi
optimum
tip
locat
sinc
maxim
p
wave
indic
cavoatri
junction
postinsert
chest
xray
cxr
perform
patient
verifi
tip
posit
assum
cavoatri
junction
cm
carina
tip
posit
consid
correct
cm
carina
lower
superior
vena
cava
upper
right
atrium
patient
retrospect
evalu
whether
cathet
length
calcul
lum
pere
formula
estim
height
would
accept
result
sixtyfi
cvc
place
right
intern
jugular
vein
ijv
left
ijv
mean
cathet
length
intracavitari
ecg
signifi
cantli
deeper
predict
lum
formula
vs
cm
p
diff
erent
pere
formula
vs
cm
p
postprocedur
cxr
tip
target
zone
three
case
cathet
went
wrong
direct
immedi
correct
procedur
sinc
intracavitari
p
wave
chang
amplitud
compar
intracavitari
ecg
incid
malposit
would
signifi
cantli
higher
lum
formula
vs
p
pere
formula
vs
p
conclus
intracavitari
ecg
associ
lower
incid
tip
malposit
pere
lum
formula
also
techniqu
allow
one
immedi
correct
primari
malposit
cathet
insert
introduct
ultrasoundguid
ug
techniqu
recom
mend
procedur
central
venou
catheter
cvc
ultrasound
may
avail
emerg
situat
therefor
guidelin
also
propos
physician
remain
skill
landmark
lm
placement
conduct
prospect
observ
studi
determin
learn
curv
lm
techniqu
resid
learn
ug
techniqu
method
fi
rst
month
rotat
icu
resid
inexperienc
cvc
use
realtim
ug
techniqu
follow
month
resid
allow
place
cvc
mean
lm
techniqu
author
attend
physician
result
total
procedur
ug
lm
perform
inexperienc
resid
studi
success
rate
lower
vs
p
complic
rate
higher
vs
p
lm
compar
ug
procedur
comparison
fi
last
ug
procedur
fi
rst
fi
lm
procedur
perform
demonstr
transit
two
techniqu
associ
mark
decreas
success
rate
vs
p
increas
complic
rate
vs
p
lm
procedur
resid
achiev
success
rate
complic
rate
respect
conclus
resid
learn
ug
techniqu
immedi
abl
perform
lm
techniqu
requir
specifi
c
train
base
least
lm
procedur
whether
lm
techniqu
still
taught
ultrasound
devic
avail
must
therefor
address
introduct
bedsid
insert
peripher
insert
central
cathet
picc
result
tip
malposit
cathet
frequent
termin
intern
jugular
vein
ijv
peripher
vein
attempt
reduc
tip
malposit
develop
standard
approach
picc
instal
studi
aim
valid
method
method
adult
icu
retrospect
review
picc
insert
period
intervent
program
control
group
design
prospect
intervent
pilot
studi
consecut
patient
intervent
group
patient
intervent
group
posit
standard
fashion
picc
length
measur
easili
identifi
ed
anatom
landmark
picc
insert
patient
head
either
rotat
ipsilater
site
picc
insert
ipsilater
ijv
manual
compress
depend
patient
capac
collabor
picc
insert
ultrasound
survey
conduct
identifi
cathet
subclavian
vein
sc
ensur
absenc
ipsilater
ijv
primari
endpoint
defi
ned
picc
tip
posit
obtain
postprocedur
chest
xray
cathet
consid
optim
posit
tip
resid
distal
third
superior
vena
cava
svc
adequ
resid
subclavian
vein
sc
distal
third
svc
aberr
locat
retrospect
control
arm
picc
review
tip
posit
optim
adequ
aberr
posit
found
respect
comparison
eight
intervent
group
p
group
control
arm
picc
termin
outsid
central
venou
system
wherea
none
fail
achiev
central
venou
access
intervent
arm
conclus
use
standard
method
describ
picc
tip
posit
greatli
improv
result
cathet
place
use
standard
method
allow
central
venou
access
pilot
studi
pave
way
larger
multicentr
evalu
bedsid
instal
method
picc
refer
introduct
accord
european
societi
parenter
enter
nutrit
guidelin
postinsert
chest
xray
cxr
necessari
locat
tip
verifi
ed
procedur
pleurapulmonari
damag
rule
method
aim
studi
assess
feasibl
safeti
echoecgguid
method
central
venou
cathet
cvc
insert
evalu
whether
postinsert
cxr
avoid
method
enrol
patient
admit
icu
candid
elect
cvc
insert
detect
p
wave
surfac
ecg
insert
protocol
includ
preliminari
ultrasound
us
scan
central
vein
pleural
space
usguid
punctur
us
control
correct
direct
guidewir
intracavitari
ecg
method
tip
locat
cavoatri
junction
caj
maxim
p
wave
us
scan
pleural
space
rule
pneumothorax
pnx
postinsert
cxr
perform
patient
rule
pnx
verifi
tip
locat
close
caj
caj
cm
carina
tip
locat
cm
carina
lower
superior
vena
cava
svc
higher
right
atrium
ra
consid
accept
introduct
chest
auscult
chest
xray
commonli
use
detect
postop
abnorm
complic
patient
admit
intens
care
cardiac
surgeri
aim
studi
evalu
whether
chest
ultrasound
repres
eff
ectiv
altern
bedsid
chest
xray
identifi
earli
postop
abnorm
method
total
consecut
patient
male
femal
studi
chest
auscult
ultrasound
xray
upon
admiss
intens
care
cardiac
surgeri
six
patholog
entiti
explor
method
posterolater
pleural
eff
usion
alveolar
consolid
plap
alveolarinterstiti
syndrom
ai
alveolar
consolid
ac
pneumothorax
ptx
pleural
eff
usion
pe
pericardi
eff
usion
without
cardiac
tamponad
posit
endotrach
tube
central
venou
cathet
also
check
result
ninetyfour
patient
includ
show
abnorm
chest
xray
ac
ai
plap
pe
ptx
compar
chest
xray
chest
ultrasound
sensit
specifi
citi
ac
sensit
specifi
citi
ai
sensit
specifi
citi
plap
sensit
specifi
citi
pe
sensit
specifi
citi
ptx
furthermor
chest
ultrasound
detect
pericardi
eff
usion
neither
chest
xray
chest
auscult
abl
identifi
chest
ultrasound
identifi
ed
case
endotrach
tube
two
patient
central
venou
cathet
two
patient
highli
signifi
cant
correl
abnorm
detect
chest
ultrasound
xray
k
poor
correl
chest
auscult
xray
abnorm
k
conclus
chest
auscult
may
help
identifi
endotrach
misplac
tension
pneumothorax
may
miss
major
abnorm
chest
ultrasound
repres
valid
altern
chest
xray
detect
postop
abnorm
misplac
introduct
assess
volum
statu
respons
guid
resuscit
strategi
noninvas
techniqu
desir
chang
carotid
fl
ow
time
propos
marker
volum
statu
data
support
use
sought
determin
whether
carotid
fl
ow
time
decreas
volumedeplet
state
acut
blood
loss
whether
volumedeplet
individu
would
demonstr
increas
carotid
fl
ow
time
passiv
leg
rais
plr
maneuv
method
volunt
age
present
hospit
blood
donor
center
whole
blood
donat
elig
particip
individu
histori
aortic
carotid
arteri
diseas
atrial
fi
brillat
contraind
blood
donat
exclud
prior
blood
donat
investig
perform
ultrasound
right
common
carotid
arteri
highfrequ
linear
transduc
obtain
doppler
trace
carotid
arteri
fl
ow
measur
peak
veloc
systol
time
carotid
fl
ow
time
obtain
plr
perform
second
follow
repeat
measur
carotid
veloc
fl
ow
time
whole
blood
collect
accord
blood
donor
center
protocol
immedi
blood
donat
repeat
measur
carotid
fl
ow
veloc
obtain
supin
posit
plr
carotid
fl
ow
time
correct
heart
rate
ftc
analyz
student
test
institut
review
board
approv
studi
result
eighti
donor
screen
particip
two
investig
consent
complet
donat
femal
mean
age
donor
mean
blood
loss
ml
mean
ftc
supin
blood
donat
ms
signifi
cantli
diff
erent
ftc
prior
donat
supin
ms
plr
ms
p
mean
ftc
follow
blood
donat
plr
ms
signifi
cantli
diff
erent
supin
posit
donat
p
predon
measur
conclus
ultrasound
measur
carotid
fl
ow
time
signifi
cantli
decreas
set
acut
blood
loss
autobolu
plr
blood
loss
restor
ftc
predon
level
investig
ftc
noninvas
predictor
volum
respons
warrant
introduct
central
venou
cathet
play
import
role
patient
care
howev
use
associ
variou
complic
frequent
subclavian
vein
scv
rout
previou
studi
show
ultrasoundguid
cannul
scv
critic
care
patient
superior
landmark
method
method
choic
patient
aim
studi
compar
shortaxi
longaxi
approach
ultrasoundguid
subclavian
vein
cannul
respect
indic
success
method
eightythre
patient
undergo
cardiac
surgeri
requir
central
venou
cannul
random
receiv
longaxi
shortaxi
ultrasoundguid
cannul
subclavian
vein
skill
anesthesiologist
firstpass
success
unsuccess
placement
number
attempt
number
needl
pass
skin
vessel
punctur
time
success
catheter
complic
consid
outcom
subclavian
vein
success
cannul
ultrasoundguid
techniqu
patient
central
venou
cannul
fail
two
case
respect
shortaxi
longaxi
view
view
use
success
fi
rstpass
success
rate
signifi
cantli
higher
shortaxi
group
compar
longaxi
group
p
procedur
time
number
attempt
needl
redirect
skin
vessel
punctur
signifi
cantli
lower
shortaxi
longaxi
group
p
overal
number
complic
diff
er
signifi
cantli
group
even
arteri
punctur
hematoma
occur
frequent
longaxi
group
moreov
need
chang
ultrasoundguid
insert
techniqu
frequent
longaxi
group
conclus
ultrasoundguid
subclavian
vein
cannul
experienc
oper
higher
fi
rstpass
success
rate
lower
access
time
use
shortaxi
longaxi
approach
refer
figur
blandaltman
plot
show
limit
agreement
mean
diff
erenc
bia
figur
conclus
may
use
measur
tte
plr
predict
fr
noninvas
less
timeconsum
invas
techniqu
introduct
echocardiographi
commonli
use
venoarteri
va
venoven
extracorpor
membran
oxygen
ecmo
mani
circumst
transoesophag
echocardiographi
toe
prefer
monitor
tool
aid
cannula
posit
especi
doublelumen
cannula
placement
vv
ecmo
wean
va
ecmo
diagnos
caus
highaccess
pressur
circuit
fl
ow
problem
use
toe
prefer
monitor
equip
establish
ecmo
sought
investig
often
inform
gain
toe
imag
major
impact
manag
decis
method
singlecentr
observ
studi
tertiari
referr
institut
patient
support
va
vv
ecmo
period
includ
routin
procedur
wire
posit
check
cannul
inform
gain
assist
wean
va
support
includ
result
twenti
patient
support
either
va
peripher
vv
ecmo
observ
period
patient
toe
instrument
diagnos
potenti
fatal
complic
alter
clinic
manag
three
patient
va
support
afterload
reduct
modul
inotrop
support
necessari
due
extens
spontan
echo
contrast
format
left
ventricl
stagnant
pulmonari
blood
fl
ow
two
three
patient
immedi
establish
support
requir
intraaort
balloon
counterpuls
revers
clot
format
around
aortic
valv
root
introduct
rightsid
precordi
lead
posterior
chest
lead
provid
import
inform
right
ventricl
posterior
wall
addit
lead
electrocardiogram
ecg
improv
diagnost
valu
acut
coronari
syndrom
patient
howev
addit
electrocardiogram
routin
record
due
timeconsum
procedur
involv
recent
synthes
six
addit
lead
ecg
use
standard
ecg
system
nihonkoden
co
ltd
develop
accuraci
clear
purpos
present
studi
evalu
accuraci
synthes
ecg
st
part
method
standard
actual
lead
ecg
tokyo
medic
univers
hospit
success
record
compar
synthes
ecg
j
point
point
defi
ned
point
rr
interv
wave
amplitud
ecg
complet
right
branch
block
complet
left
branch
block
pace
rhythm
exclud
result
total
ecg
correctli
record
diff
erenc
actual
synthes
j
point
point
wave
amplitud
small
mean
diff
erenc
j
point
point
wave
amplitud
posit
correl
actual
synthes
ecg
j
point
point
wave
amplitud
figur
conclus
st
part
synthes
lead
ecg
appear
highli
reliabl
synthes
addit
lead
ecg
might
use
diagnos
ischem
heart
diseas
introduct
acut
chronic
system
infl
ammatori
condit
associ
aortic
stiff
ene
carotidfemor
puls
wave
veloc
pwv
marker
aortic
stiff
ness
increas
patient
infl
ammatori
diseas
independ
correl
level
creactiv
protein
crp
eff
ect
massiv
infl
ammatori
respons
earli
sepsi
mechan
properti
aorta
investig
object
current
studi
prospect
assess
aortic
stiff
ness
patient
earli
sever
sepsi
septic
shock
relat
infl
ammatori
haemodynam
variabl
outcom
method
recruit
patient
meet
criteria
sever
sepsi
septic
shock
within
hour
admiss
icu
haemodynam
stabilis
pwv
record
inclus
hour
use
dualchannel
plethysmographi
sever
ill
assess
apach
ii
serial
sofa
score
haemodynam
infl
ammatori
paramet
crp
procalcitonin
fi
brinogen
record
followup
perform
distinguish
survivor
nonsurvivor
result
twenti
consecut
gener
icu
patient
six
sever
sepsi
septic
shock
enrol
studi
median
age
year
iqr
apach
ii
score
sofa
score
iqr
day
six
patient
die
median
initi
pwv
iqr
msecond
patient
sever
sepsi
iqr
msecond
patient
septic
shock
p
hour
pwv
sever
sepsi
septic
shock
group
becom
similar
iqr
msecond
iqr
msecond
respect
p
pwv
signifi
cantli
increas
survivor
msecond
p
versu
nonsurvivor
msecond
p
higher
pwv
correl
increas
systol
pressur
lower
crp
level
r
p
conclus
earli
sepsi
aortic
stiff
ness
decreas
patient
greater
diseas
sever
survivor
increas
median
level
within
hour
main
factor
associ
lower
puls
wave
veloc
lower
systol
pressur
higher
crp
level
associ
high
serum
crp
level
low
aortic
stiff
ness
patient
sepsi
match
data
describ
literatur
refer
approxim
million
peopl
worldwid
suff
er
congest
heart
failur
chf
sever
symptom
chf
pulmonari
congest
acut
increas
extravascular
lung
fl
uid
due
acut
decompens
heart
failur
date
direct
reliabl
simpl
noninvas
method
avail
assess
thorac
fl
uid
continu
depend
monitor
pulmonari
edema
hospit
patient
improv
manag
reduc
durat
hospit
kyma
solut
base
matchboxs
monitor
devic
monitor
thorac
fl
uid
content
trend
monitor
transmit
receiv
electromagnet
signal
propag
tissu
layer
conduct
highli
relat
amount
accumul
fl
uid
tissu
trial
investig
correl
kyma
lung
water
index
lwi
directli
assess
extravascular
lung
water
evlw
scenario
acut
pulmonari
edema
induc
seven
sheep
method
acut
pulmonari
edema
induc
intraven
infus
noradrenalin
dextran
stepwis
increas
dosag
kyma
measur
lwi
compar
picco
extravascular
lung
volum
refer
gold
standard
experi
continu
maximum
increas
evlw
complet
heart
failur
reach
result
seven
sheep
develop
pulmonari
edema
valid
increas
lvedp
evlw
linear
correl
found
invas
measur
evlw
picco
noninvas
klwi
conclus
kyma
fl
uid
index
demonstr
excel
correl
invas
lung
water
measur
r
p
abl
detect
dynam
accumul
evlw
rang
cm
increment
figur
sinc
chang
fl
uid
content
normal
congest
lung
rang
cm
demonstr
sensit
refl
ect
studi
support
use
highresolut
accur
thorac
fl
uid
monitor
aim
work
verifi
low
incid
hemodynam
intervent
hemodynam
monitor
patient
postop
icu
caus
insuffi
cient
attent
paid
drop
noncalibr
cardiac
index
nci
last
year
need
hemodynam
intervent
patient
periop
cardiac
output
monitor
patient
need
least
one
hemodynam
intervent
postop
icu
method
highrisk
patient
plan
undergo
elect
major
abdomin
surgeri
routin
monitor
lidcorapid
monitor
continu
overnight
surgeri
target
nci
postop
monitor
well
hemodynam
intervent
case
drop
prescrib
anesthetist
protocol
upon
handov
patient
postop
icu
hemodynam
protocol
icu
nurs
driven
compulsori
record
patient
hemodynam
data
patient
document
everi
hour
time
intervent
data
memori
lidcorapid
monitor
analyz
use
lidcoview
softwar
compar
patient
document
result
total
hour
hemodynam
record
analyz
patient
chosen
random
patient
monitor
last
year
found
drop
nci
notic
nurs
staff
led
volum
challeng
accord
protocol
onehalf
intervent
carri
outsid
interv
protocolrequir
monitor
document
entri
identifi
ed
nine
drop
nci
react
none
happen
within
fi
rst
hour
postop
outsid
interv
protocolrequir
monitor
fi
episod
puls
pressur
also
drop
suggest
impair
read
waveform
arteri
line
need
hemodynam
intervent
postop
care
quit
rare
patient
drop
nci
notic
case
patient
treat
accord
protocol
howev
isol
episod
nci
drop
miss
night
oper
result
point
nurs
staff
compar
survey
conduct
monitor
modal
non
adher
protocol
may
becom
limit
issu
benefi
patient
aim
work
evalu
periop
hemodynam
monitor
major
abdomin
surgeri
use
estim
continu
cardiac
output
escco
techniqu
avail
nihon
kohden
vismo
monitor
compar
lidcorapid
hemodynam
monitor
system
method
escco
techniqu
novel
noncalibr
noninvas
method
cardiac
output
monitor
base
estim
puls
pressur
speed
puls
wave
propag
measur
time
delay
ecg
rwave
correspond
peripher
puls
wave
detect
puls
oximetri
delay
call
puls
wave
transit
time
pwtt
lidcorapid
estim
noncalibr
cardiac
output
nco
puls
wave
contour
analysi
arteri
line
wellestablish
monitor
modal
depart
patient
plan
elect
major
abdomin
surgeri
asa
score
iii
expect
oper
durat
minut
routin
monitor
lidcorapid
periop
hemodynam
optim
protocol
accord
protocol
arteri
line
insert
lidcorapid
monitor
start
induct
anesthesia
time
noninvas
escco
monitor
start
result
ten
patient
monitor
total
escconco
measur
pair
correl
coeffi
cient
escco
nco
blandaltman
diff
erenc
analysi
bia
lminut
limit
agreement
lminut
chang
cardiac
output
two
consecut
measur
detect
lidcorapid
detect
escco
case
conclus
hemodynam
monitor
escco
yield
cardiac
output
valu
diff
erent
measur
lidcorapid
reliabl
pwtt
question
system
vascular
resist
aim
anim
studi
determin
feasibl
accuraci
new
noninvas
system
determin
cardiac
output
co
compar
known
devic
picco
pulsion
medic
icu
or
hemodynam
manag
use
goaldirect
therapi
shown
improv
patient
outcom
invas
current
technolog
may
prevent
clinician
obtain
hemodynam
inform
develop
noninvas
system
detect
hemodynam
variabl
util
photoacoust
sensor
pa
indic
dilut
pa
util
combin
miniatur
ultrasound
sensor
laser
diod
optic
detector
accomplish
measur
method
five
pig
weigh
kg
use
studi
approv
local
anim
use
care
committe
anim
anesthet
medic
paralyz
intub
mechan
ventil
central
venou
arteri
cathet
place
inject
indic
connect
picco
system
pa
place
contact
skin
saphen
arteri
anim
adjust
receiv
maximum
acoust
signal
adjust
includ
depth
ultrason
penetr
exact
locat
top
blood
vessel
indic
dilut
accomplish
use
three
central
venou
inject
ml
normal
salin
room
temperatur
variat
co
accomplish
remov
blood
volum
splenectomi
pa
result
obtain
use
empir
regress
method
result
cardiac
output
read
pa
compar
picco
read
correl
pa
picco
system
r
rang
co
lminut
blandaltman
analysi
demonstr
bia
lminut
precis
l
minut
conclus
anim
studi
demonstr
feasibl
new
pa
determin
indic
dilut
co
limit
rang
system
show
good
correl
picco
system
even
case
vasoconstrict
result
blood
loss
sinc
pa
util
transpulmonari
indic
dilut
variabl
intrathorac
blood
volum
global
enddiastol
volum
extravascular
lung
water
calcul
addit
continu
co
obtain
optic
sensor
signal
util
arteri
waveform
analysi
refer
aim
evalu
perform
arteri
pressurebas
cardiac
output
apco
puls
wave
transit
timebas
cardiac
output
escco
monitor
thai
patient
undergo
coronari
arteri
bypass
graft
surgeri
cabg
cardiopulmonari
bypass
method
studi
thai
surgic
patient
undergo
cabg
cardiopulmonari
bypass
requir
pulmonari
arteri
cathet
radial
arteri
cathet
placement
standard
clinic
care
patient
measur
apco
use
vigileoflotrac
escco
use
escco
monitor
system
data
compar
thermodilut
cardiac
output
tdco
monitor
refer
method
simultan
preinduct
postinduct
everi
minut
thereaft
complet
surgeri
bia
precis
assess
use
blandaltman
analysi
result
total
pair
simultan
measur
apco
versu
tdco
pair
escco
versu
tdco
obtain
patient
apco
r
p
escco
valu
r
p
correl
tdco
valu
either
chang
apco
r
p
chang
escco
r
p
correl
chang
tdco
apco
rel
tdco
bia
precis
limit
agreement
lminut
escco
l
minut
respect
comparison
bia
apco
escco
reveal
level
signifi
canc
p
conclus
despit
overestim
cardiac
output
measur
apco
escco
calibr
patient
inform
shown
accept
trend
compar
tdco
thai
patient
undergo
cabg
cardiopulmonari
bypass
compar
escco
apco
demonstr
signifi
cant
diff
erenc
precis
howev
lower
mean
bia
exhibit
introduct
transpulmonari
thermodilut
use
critic
care
follow
picco
volumeview
avail
although
previou
studi
conclud
signifi
cant
correl
found
volumeview
picco
experi
data
analysi
done
edward
lifesci
aim
present
studi
compar
new
volumeview
picco
clarifi
compat
give
neutral
answer
method
six
pig
kg
use
made
sepsi
model
lp
administr
pig
instrument
right
pulsiocath
left
volumeview
thermomistortip
femor
arteri
cathet
central
venou
cathet
insert
right
jugular
vein
co
gedv
evlw
measur
two
system
perform
measur
point
good
correl
two
devic
regard
co
gedv
volumeview
show
higher
gedv
picco
regard
evlw
signifi
cant
correl
two
system
volumeview
show
signifi
cantli
higher
evlw
picco
figur
tabl
introduct
goaldirect
therapi
use
periop
period
patient
undergo
cardiac
surgeri
shorten
length
icu
stay
aim
compar
postop
result
liber
restrict
fl
uid
strategi
use
patient
undergo
pulmonari
resect
surgeri
prc
method
use
restrict
fl
uid
strategi
sinc
march
institut
patient
liber
fl
uid
regim
analyz
retrospect
march
today
patient
restrict
fl
uid
strategi
analyz
prospect
total
patient
includ
studi
age
durat
anesthesia
type
fl
uid
given
intraop
fl
uid
index
mlkghour
fl
uid
intakeoutput
balanc
creatinin
lactat
level
compar
pulmonari
renal
morbid
length
stay
icu
use
multivari
analysi
result
signifi
cant
correl
p
establish
amount
crystalloid
given
intraop
fl
uid
index
fl
uid
balanc
pulmonari
morbid
n
fl
uid
index
inotrop
usag
correl
postop
creatinin
level
p
correl
periop
lactat
level
fl
uid
balanc
fl
uid
index
intraop
blood
loss
amount
given
crystalloid
colloid
blood
ffp
fl
uid
balanc
durat
anesthesia
postop
blood
transfus
found
relat
p
length
icu
stay
four
percent
patient
requir
renal
replac
therapi
overal
mortal
conclus
reduc
morbid
patient
undergo
major
surgeri
protocol
use
restrict
fl
uid
strategi
periop
period
simultan
protect
end
organ
especi
kidney
current
subject
discuss
observ
restrict
fl
uid
strategi
lead
global
organ
hypoperfus
monitor
lactat
even
though
neg
correl
fl
uid
index
creatinin
level
renal
failur
need
renal
replac
therapi
observ
one
case
conclus
postop
pulmonari
morbid
length
icu
stay
reduc
patient
undergo
prc
use
restrict
fl
uid
strategi
mlkghour
without
caus
vital
organ
dysfunct
rational
periop
fl
uid
therapi
preserv
organ
perfus
howev
conserv
postop
fl
uid
balanc
fb
encourag
avoid
eff
ect
iatrogen
fl
uid
overload
addit
fl
uid
expans
describ
confound
acut
kidney
injuri
aki
diagnosi
dilut
serum
creatinin
scr
conduct
prospect
audit
fb
renal
function
patient
undergo
major
elect
surgeri
admit
critic
care
period
fluid
overload
defi
ned
posit
fb
weight
result
thirtytwo
patient
femal
median
age
studi
median
critic
care
day
rang
total
fb
l
discharg
howev
occur
intraop
posit
fb
critic
care
mlday
patient
median
fl
uid
overload
discharg
two
patient
transient
aki
stage
overal
scr
decreas
signifi
cantli
preoper
discharg
p
median
decreas
occur
postop
critic
care
stay
figur
conclus
achiev
nearneutr
fl
uid
balanc
admiss
resolv
intraop
fl
uid
accumul
scr
fell
signifi
cantli
even
net
fl
uid
accumul
suggest
decreas
creatinin
gener
major
surgeri
rather
fl
uid
expans
may
larg
account
scr
decreas
patient
aim
studi
assess
use
puls
pressur
variat
ppv
predict
marker
fl
uid
respons
estim
valu
central
venousarteri
diff
erenc
carbon
dioxid
pco
cva
predict
outcom
critic
ill
septic
patient
question
whether
septic
patient
need
fl
uid
crucial
although
ppv
reliabl
predictor
volum
respons
mani
limit
applic
cardiac
arrhythmia
spontan
breath
low
tidal
volum
ventil
prevent
extend
use
index
method
posthoc
analysi
data
prospect
observ
studi
includ
popul
patient
sever
sepsi
septic
shock
main
reason
icu
admitt
echo
assess
cardiac
systol
perform
measur
ppv
central
venou
oxygen
satur
blood
gase
arteri
central
venou
line
central
venou
pressur
systol
diastol
mean
puls
pressur
volum
challeng
calcul
chang
puls
pressur
volum
challeng
increas
use
criterion
defi
ne
volum
respons
result
among
patient
men
apach
ii
score
includ
studi
respond
due
spontan
breath
cardiac
arrhythmia
abl
calcul
ppv
patient
moreov
eight
calcul
ppv
prove
use
applic
low
tidal
ventil
mlkg
ideal
bodi
weight
remain
patient
fi
nd
valu
pco
cva
predict
outcom
patient
mortal
sinc
diff
erenc
survivor
nonsurvivor
statist
signifi
cant
vs
p
conclus
use
ppv
marker
best
perform
predict
volum
respons
due
limit
limit
renal
resist
index
ri
determin
doppler
ultrasonographi
allow
semiquantit
evalu
kidney
vasculatur
bedsid
interpret
ri
clinic
practic
diffi
cult
due
interact
cardiac
output
heart
rate
hr
blood
pressur
impact
global
hemodynam
ri
remain
evalu
studi
aim
investig
relationship
ri
chang
central
hemodynam
central
hypovolemia
model
healthi
volunt
hv
method
eleven
healthi
volunt
year
eight
male
particip
studi
two
diff
erent
model
perform
fi
rst
model
perform
appli
headup
tilt
hut
test
complet
maneuv
done
step
consist
tilt
tabl
supin
posit
sup
angl
hut
back
supin
sup
second
model
perform
appli
three
consecut
valsalva
maneuv
global
hemodynam
includ
stroke
volum
sv
hr
mean
arteri
pressur
continu
measur
noninvas
finomet
least
three
ri
read
obtain
averag
right
left
kidney
hv
result
hv
signifi
cant
decreas
sv
ml
ml
increas
hr
bpm
bpm
hut
figur
show
tempor
chang
mean
ri
kidney
signifi
cant
decreas
ri
kidney
seen
hut
move
back
supin
ri
return
baselin
valu
signifi
cant
variat
ri
earli
measur
right
kidney
compar
late
measur
left
kidney
vs
p
valsalva
maneuv
signifi
cantli
increas
ri
right
left
kidney
p
respect
conclus
preliminari
result
show
doppler
renal
ri
aff
ect
equal
kidney
hut
suggest
eff
ect
hemodynam
alter
model
central
hypovolemia
introduct
tissu
hypoxia
occur
frequent
surgeri
may
contribut
postop
organ
dysfunct
hypothesis
intraop
optimis
tissu
oxygen
reduc
postop
complic
evalu
feasibl
optimis
protocol
use
method
randomis
highrisk
patient
underw
major
abdomin
surgeri
tissu
oxygen
monitor
thenar
emin
use
nearinfrar
spectroscopi
patient
treat
accord
standard
care
algorithm
addit
patient
intervent
group
receiv
dobutamin
necessari
keep
tissu
oxygen
data
record
continu
complic
record
hospit
stay
maximum
day
number
complic
tend
lower
intervent
group
vs
eleven
patient
intervent
group
complic
versu
seven
control
group
signifi
cant
diff
erenc
group
length
stay
icu
hospit
administr
result
increas
tissu
oxygen
cardiac
index
increas
lminutem
figur
overal
protocol
adher
conclus
intraop
optimis
tissu
oxygen
potenti
result
better
outcom
highrisk
abdomin
surgeri
protocol
use
may
consid
feasibl
clinic
practic
introduct
passiv
leg
rais
plr
suggest
simpl
diagnost
tool
guid
fl
uid
administr
critic
ill
patient
although
basic
principl
plr
well
studi
littl
known
impact
introduct
techniqu
daili
clinic
practic
aim
studi
describ
chang
fl
uid
balanc
icu
patient
introduct
plr
determin
complianc
medic
personnel
plrdriven
protocol
fl
uid
administr
method
singlecentr
prospect
studi
mix
icu
patient
equip
picco
system
receiv
fl
uid
therapi
basi
plr
test
result
fi
rst
hour
treatment
care
introduct
new
plrdriven
protocol
exclus
criteria
increas
abdomin
pressur
fractur
leg
pelvi
deep
vein
thrombosi
head
trauma
pregnanc
control
group
exist
patient
admit
icu
year
prior
introduct
protocol
includ
patient
group
signifi
cant
diff
erenc
fl
uid
balanc
control
studi
group
hour
l
vs
l
p
hour
l
vs
l
p
howev
complianc
protocol
poor
posit
test
fl
uid
administ
test
fl
uid
administ
despit
neg
test
result
figur
implement
plrdriven
protocol
fl
uid
administr
chang
mean
fl
uid
balanc
fi
rst
hour
noncompli
protocol
import
confound
refer
identifi
patient
fl
uid
respond
crucial
aim
prospect
studi
evalu
patient
fl
uid
respond
septic
shock
use
dynam
echocardiographi
distens
index
inferior
vena
cava
diivc
shown
predict
increas
ci
method
period
year
adult
patient
admit
icu
septic
shock
patient
treat
accord
guidelin
surviv
sepsi
campaign
intern
guidelin
manag
sever
sepsi
septic
shock
patient
mechan
ventil
subject
transesophag
echocardiographi
bicaval
project
calcul
diivc
mmode
measur
chang
diamet
act
posit
pressur
ventil
use
formula
maximum
diamet
minimum
diamet
minimum
diamet
valu
consid
predictor
increas
ci
ci
measur
continu
use
pressur
record
analyt
method
mostcar
vytech
monitor
patient
subject
bolu
ml
crystalloid
central
venou
cathet
reach
central
venou
pressur
cvp
mmhg
treatment
result
express
mean
standard
deviat
percentag
result
sixteen
patient
chang
diivc
averag
subject
fl
uid
challeng
increas
ci
averag
prove
fl
uid
respond
twentysix
patient
chang
diivc
averag
subject
fl
uid
challeng
increas
ci
averag
prove
fl
uid
respond
introduct
dynam
arteri
elast
eadyn
defi
ned
puls
pressur
variat
ppv
stroke
volum
variat
svv
ratio
suggest
predictor
arteri
pressur
respons
fl
uid
administr
rather
steadyst
assess
eadyn
depict
actual
slope
pressurevolum
relationship
provid
dynam
evalu
arteri
load
higher
eadyn
valu
like
arteri
blood
pressur
improv
fl
uid
challeng
fc
aim
studi
assess
eff
ectiv
eadyn
measur
noninvas
preloaddepend
spontan
breath
patient
method
patient
admit
postop
monitor
nexfi
n
monitor
enrol
studi
patient
includ
spontan
breath
increas
cardiac
output
fc
classifi
ed
accord
increas
mean
arteri
pressur
map
fc
maprespond
map
increas
mapnonrespond
map
increas
eadyn
calcul
ppv
svv
valu
obtain
monitor
result
total
fc
patient
studi
seventeen
fc
induc
posit
map
respons
preinfus
eadyn
signifi
cantli
higher
maprespond
vs
p
figur
preinfus
eadyn
predict
posit
map
respons
fc
area
roc
curv
se
ci
p
preinfus
eadyn
valu
grey
zone
discrimin
maprespond
sensit
specifi
citi
ci
conclus
noninvas
dynam
arteri
elast
defi
ned
ppv
svv
ratio
predict
arteri
pressur
increas
fl
uid
administr
spontan
preloaddepend
patient
introduct
accord
guyton
colleagu
expans
blood
volum
increas
cardiac
output
co
far
chang
volum
aff
ect
mean
system
fi
lling
pressur
pmsf
howev
rapid
stress
relax
occur
acut
intravascular
volum
expans
eff
ect
volum
pmsf
co
may
disappear
minut
object
present
studi
describ
extent
haemodynam
chang
gener
fl
uid
challeng
minut
critic
ill
patient
method
patient
admit
icu
monitor
calibr
lidcoplu
lidco
uk
navig
appli
physiolog
australia
estim
pmsf
analogu
pmsa
ml
hartmann
solut
volplex
infus
minut
data
record
automat
baselin
minut
end
fl
uid
infus
time
maximum
respons
percentag
chang
baselin
last
valu
diff
erent
haemodynam
paramet
also
report
result
sixti
fl
uid
challeng
studi
patient
mean
durat
minut
event
co
increas
respond
chang
baselin
last
valu
greater
nonrespond
heart
effi
cienci
eh
vs
p
haemodynam
variabl
time
maxim
respons
co
minut
end
infus
figur
conclus
stress
relax
damp
eff
ect
fl
uid
challeng
minut
except
term
heart
effi
cienci
eff
ect
fl
uid
challeng
assess
minut
end
fl
uid
infus
failur
may
mislead
clinician
patient
fl
uid
respons
latest
sepsi
guidelin
emphas
earli
resuscit
fl
uid
manag
earli
goaldirect
therapi
egdt
shown
improv
mortal
recent
studi
strategi
base
improv
tissu
perfus
oxygen
spite
support
therapeut
measur
technic
histor
central
venou
pressur
cvp
measur
one
depend
method
estim
fl
uid
respons
intravascular
volum
statu
resuscit
surviv
sepsi
campaign
ssc
guidelin
recommend
goal
level
cvp
mmhg
order
obtain
appropri
tissu
perfus
studi
object
reevalu
eff
ectiv
fl
uid
resuscit
strategi
sepsi
compar
eff
ect
patient
daili
fl
uid
balanc
dfb
cvp
patient
surviv
method
patient
record
apach
ii
length
stay
lo
cvp
dfb
vasopressor
ventil
need
retrospect
collabor
randomlyassign
men
women
age
year
statist
analyz
surviv
function
result
mean
apach
ii
score
lo
day
intub
period
day
vasopressor
period
day
cvp
mmhg
dfb
ml
surviv
kaplanmei
surviv
cox
regress
analysi
show
cvp
level
mmhg
dfb
ml
signifi
cantli
predict
surviv
also
shorter
lo
intub
day
lower
vasopressor
need
earlier
discharg
possibl
hand
overincreas
dfb
cvp
level
strictli
correl
longer
lo
higher
mortal
rate
fi
rst
mean
fl
uid
balanc
alon
surprisingli
predict
conclus
fluid
resuscit
therapi
doubleedgesword
despit
lower
volum
higher
volum
also
increas
mortal
overal
dfb
seem
import
fi
rst
dfb
introduct
previou
vitro
studi
shown
photometr
assay
may
overestim
fi
brinogen
level
hemodilut
he
vivo
eff
ect
he
fi
brinogen
assay
therefor
studi
method
forti
patient
intracrani
tumor
gave
consent
particip
ethic
approv
studi
plasma
fi
brinogen
level
analyz
elisa
two
photometr
assay
dade
multifi
bren
one
mechan
hook
addit
rotem
fibtemmcf
analyz
result
twentyfi
patient
receiv
l
he
mean
reduct
hematocrit
elisa
lower
hook
multifi
bren
fibtem
rel
decreas
diff
ere
signifi
cantli
assay
see
result
imit
earli
resuscit
hypovolem
shock
medium
replac
vv
lr
dipyridyl
plu
h
hour
follow
replac
complet
medium
hour
vs
ml
p
receiv
mean
volum
hypoton
crystalloid
administ
fi
rst
hour
p
hour
p
hour
p
icu
admiss
serum
sodium
chlorid
lactat
creatinin
level
signifi
cantli
diff
erent
two
group
conclus
administr
hypoton
fl
uid
fi
rst
hour
liver
transplant
may
risk
factor
prolong
icu
admiss
eff
ect
appear
independ
serum
electrolyt
level
renal
dysfunct
refer
introduct
vasopressin
frequent
use
maintain
blood
pressur
refractori
septic
shock
studi
look
hypothesi
vasopressin
compar
norepinephrin
would
decreas
sever
septic
statu
evolut
multipl
organ
dysfunct
length
hospit
mortal
among
patient
septic
shock
method
random
doubleblind
studi
assign
patient
still
need
vasopressor
restor
tissu
perfus
fl
uid
resuscit
receiv
norepinephrin
vasopressin
uminut
low
dose
norepinephrin
group
vasoact
drug
infus
titrat
taper
maintain
target
mean
blood
pressur
analysi
includ
total
time
use
dosag
vasopressor
everi
hour
move
singl
organ
dysfunct
multipl
organ
failur
length
icu
stay
hospit
mortal
day
start
infus
result
total
patient
underw
random
patient
includ
studi
patient
receiv
vasopressin
receiv
norepinephrin
total
time
vasopressor
hour
hour
vasopressin
norepinephrin
group
p
singl
organ
dysfunct
multipl
organ
dysfunct
use
vasopressin
norepinephrin
respect
vs
p
vs
p
length
stay
icu
day
p
time
hospit
day
p
respect
signifi
cant
diff
erenc
vasopressin
norepinephrin
group
mortal
rate
day
vs
p
p
signifi
cant
diff
erenc
overal
rate
mortal
vs
respect
p
conclus
earli
applic
vasopressin
reduc
time
vasopressor
use
progress
multipl
organ
dysfunct
length
stay
icu
mortal
rate
day
compar
norepinephrin
observ
diff
erenc
attribut
earli
restor
tissu
perfus
control
group
make
state
septic
shock
shorter
reduc
potenti
multipl
organ
dysfunct
directli
infl
uenc
patient
surviv
refer
method
man
admit
icu
follow
intub
sedat
seizur
due
acut
alcohol
withdraw
ct
scan
brain
normal
icu
patient
becam
haemodynam
unstabl
fresh
blood
aspir
nasogastr
tube
gastroscopi
show
bleed
oesphag
varici
hypertens
portal
gastropathi
patient
treat
varic
band
tazobactampipacillin
g
three
time
daili
terlipressin
g
four
time
daili
per
protocol
varic
bleed
success
extub
hour
later
result
admiss
patient
serum
sodium
mmoll
patient
receiv
terlipressin
day
follow
regimen
g
four
time
daili
hour
mg
four
time
daili
hour
mg
four
time
daili
hour
stop
last
day
terlipressin
therapi
patient
gc
drop
serum
sodium
fallen
acut
mmoll
last
two
dose
terlipressin
cancel
treatment
hyponatraemia
administ
serum
sodium
gc
return
normal
limit
within
hour
terlipressin
cessat
neurolog
consequ
conclus
case
report
terlipressininduc
hyponatraemia
hyponatraemia
consid
rare
side
eff
ect
brought
partial
agonist
eff
ect
terlipressin
renal
vasopressin
receptor
sola
colleagu
monitor
serum
sodium
concentr
patient
acut
varic
bleed
found
rapid
reduct
serum
sodium
common
one
patient
develop
osmot
demyelin
syndrom
hyponatraemia
resolv
cessat
terlipressin
close
monitor
serum
sodium
level
essenti
patient
terlipressin
therapi
rapid
drop
sodium
identifi
ed
manag
stop
associ
neurolog
complic
introduct
patient
distribut
shock
requir
highdos
vasopressor
high
mortal
vasopressor
belong
two
class
catecholamin
vasopressin
analog
class
limit
patient
receiv
catecholamin
often
develop
tachyphylaxi
metabol
complic
exampl
lactic
acidosi
vasopressin
analog
caus
mesenter
myocardi
ischemia
oliguria
angiotensin
ii
atii
endogen
peptid
increas
blood
pressur
aldosteron
product
preclin
data
suggest
role
atii
treatment
sepsisassoci
acut
kidney
injuri
atii
may
prove
use
patient
remain
hypotens
despit
catecholamin
vasopressin
therapi
fi
rst
random
clinic
trial
date
seek
evalu
atii
use
distribut
shock
method
twenti
patient
distribut
shock
cardiovascular
sequenti
organ
failur
assess
score
random
either
atii
infus
n
placebo
n
plu
standard
care
atii
start
dose
ngkgminut
titrat
per
protocol
schedul
goal
maintain
mean
arteri
pressur
map
mmhg
infus
either
atii
placebo
continu
hour
titrat
primari
endpoint
eff
ect
atii
stand
dose
norepinephrin
requir
maintain
map
mmhg
secondari
endpoint
includ
eff
ect
atii
urin
output
serum
lactat
creatinin
clearanc
well
mortal
mean
age
year
patient
male
caucasian
african
american
mortal
two
group
similar
atii
cohort
placebo
cohort
vs
p
atii
result
mark
reduct
norepinephrin
dose
patient
mean
norepinephrin
dose
placebo
cohort
minut
vs
atii
cohort
p
common
advers
event
hypertens
occur
patient
receiv
atii
conclus
atii
eff
ectiv
vasopressor
agent
patient
distribut
shock
requir
multipl
vasopressor
initi
dose
rang
atii
appear
appropri
patient
distribut
shock
ngkgminut
studi
assess
use
atii
patient
distribut
shock
warrant
introduct
patient
septic
shock
die
mainli
due
refractori
shock
vasopressin
commonli
use
adjunct
catecholamin
support
blood
pressur
refractori
septic
shock
eff
ect
mortal
unknown
hypothes
vasopressin
compar
norepinephrin
would
decreas
mortal
among
cancer
patient
septic
shock
method
random
doubleblind
trial
assign
patient
cancer
septic
shock
need
vasopressor
receiv
norepinephrin
vasopressin
addit
openlabel
vasopressor
vasopressor
infus
titrat
taper
accord
protocol
maintain
target
blood
pressur
primari
endpoint
mortal
rate
day
start
infus
result
total
patient
underw
random
fi
rst
part
trial
infus
studi
drug
patient
receiv
vasopressin
norepinephrin
includ
analysi
signifi
cant
diff
erenc
vasopressin
norepinephrin
group
mortal
rate
respect
p
signifi
cant
diff
erenc
overal
rate
seriou
advers
event
respect
p
conclus
vasopressin
reduc
mortal
rate
compar
norepinephrin
among
patient
cancer
septic
shock
treat
catecholamin
vasopressor
introduct
clinic
studi
suggest
betablock
decreas
heart
rate
hr
togeth
increas
stroke
volum
sv
neg
aff
ect
cardiac
output
co
allow
econom
cardiac
work
oxygen
consumpt
patient
septic
shock
whether
hemodynam
profi
le
lead
amelior
myocardi
perform
still
unclear
object
present
studi
therefor
elucid
whether
reduct
hr
esmolol
associ
improv
cardiac
effi
cienci
patient
septic
shock
remain
tachycard
hemodynam
optim
method
hour
initi
hemodynam
stabil
septic
shock
patient
hr
bpm
requir
norepinephrin
ne
maintain
mean
arteri
pressur
map
mmhg
critic
care
volum
suppl
http
despit
adequ
volum
resuscit
receiv
continu
esmolol
infus
maintain
hr
bpm
ne
titrat
achiev
map
mmhg
investig
myocardi
perform
simultan
assess
lv
eject
fraction
lvef
tricuspid
annular
plane
solid
excurs
taps
echocardiographi
dpdt
max
cardiac
cycl
effi
cienci
cce
estim
arteri
pressur
waveform
data
obtain
baselin
achiev
predefi
ned
hr
threshold
result
map
mmhg
esmolol
administr
signifi
cantli
decreas
hr
bpm
ne
dpdt
max
ms
mmhg
convers
taps
mm
cce
unit
sv
ml
signifi
cantli
increas
end
studi
period
p
co
l
minut
lvef
chang
conclus
patient
establish
septic
shock
remain
tachycard
hemodynam
optim
titrat
esmolol
reduc
hr
predefi
ned
threshold
econom
cardiac
function
result
maintain
co
lower
hr
higher
stroke
volum
hemodynam
profi
le
character
improv
cardiac
effi
cienci
indic
decreas
dpdt
max
associ
increas
cce
final
echocardiograph
data
suggest
reduc
hr
esmolol
posit
aff
ect
right
ventricular
function
intens
care
set
physiolog
paramet
monitor
automat
howev
urin
output
uo
still
monitor
hourli
manual
handl
urinomet
studi
evalu
automat
urinomet
au
compar
manual
urinomet
mu
method
prospect
studi
icu
cardiothorac
surgic
clinic
postop
patient
n
indwel
urinari
cathet
expect
stay
hour
hourli
uo
sampl
measur
au
n
observ
medic
gothenburg
sweden
mu
n
unomed
birkero
denmark
thereaft
valid
cylind
measur
malposit
instrument
read
exclud
measur
data
analyz
blandaltman
method
perform
mu
use
minimum
criteria
accept
au
evalu
loss
precis
mu
due
tempor
deviat
fi
xed
hourli
measur
record
n
questionnair
fi
lled
ward
staff
n
evalu
eas
use
au
compar
mu
result
analysi
accord
blandaltman
show
smaller
mean
bia
au
ml
compar
mu
ml
p
statist
diff
erenc
measur
precis
two
urinomet
defi
ned
limit
agreement
ml
vs
ml
p
mean
tempor
variat
mu
minut
limit
agreement
minut
compar
tempor
variat
au
p
total
ward
staff
consid
au
superior
mu
p
conclus
au
signifi
cantli
lower
bia
mu
loss
precis
hourli
uo
due
tempor
deviat
use
mu
avoid
au
au
also
evalu
higher
ward
staff
refl
ect
percept
higher
reliabl
easier
use
less
contact
urin
bag
less
time
usag
measur
featur
au
may
also
indic
favor
clinic
impact
normal
ward
staffi
ng
allow
hourli
measur
mu
introduct
fall
mean
arteri
blood
pressur
map
anaesthet
induct
common
may
result
profound
hypotens
use
lidcorapid
lidco
ltd
uk
previous
demonstr
fall
map
usual
driven
reduct
stroke
volum
sv
presum
due
venodil
lowdos
phenylephrin
pe
venoconstrictor
commenc
immedi
prior
induct
amelior
eff
ect
signifi
cant
degre
howev
import
preinduct
administr
pe
caus
mark
chang
map
co
retrospect
studi
group
highrisk
patient
undergo
major
peripher
vascular
surgeri
pe
commenc
immedi
preinduct
haemodynam
eff
ect
dose
pe
map
sv
co
analys
method
radial
arteri
line
insert
prior
induct
anaesthesia
baselin
map
co
sv
obtain
use
lidcorapid
pe
infus
commenc
rate
mg
hour
remifentanil
administ
use
targetcontrol
infus
pump
ngml
predict
eff
ect
site
concentr
ceff
reach
propofol
administ
induc
anaesthesia
haemodynam
chang
prepe
baselin
commenc
propofol
record
interv
chang
map
sv
co
assess
percent
chang
valu
obtain
immedi
prior
pe
follow
least
minut
commenc
propofol
result
patient
demograph
mean
rang
age
year
male
weight
kg
asa
chang
map
co
clinic
statist
signifi
cant
map
increas
averag
rang
co
rang
p
p
respect
conclus
previou
studi
pe
administ
prospect
prior
induct
markedli
reduc
haemodynam
chang
follow
induct
anaesthesia
highrisk
patient
use
remifentanil
propofol
eff
ect
achiev
without
signifi
cant
chang
map
co
period
commenc
pe
induct
anaesthesia
refer
introduct
acetaminophen
apap
commonli
administ
surgic
icu
sicu
analges
antipyret
eff
ect
case
report
describ
potenti
apap
caus
allerg
reaction
without
hypotens
furthermor
case
report
apap
caus
isol
hypotens
absenc
allerg
respons
well
describ
follow
intraven
administr
howev
rout
administr
caus
hypotens
associ
diagnos
remain
elucid
present
case
seri
describ
patient
apapinduc
hypotens
sicu
level
trauma
center
critic
care
volum
suppl
http
method
patient
admit
sicu
time
frame
report
nurs
staff
experienc
hypotens
follow
oral
rectal
administr
apap
includ
electron
medic
record
retrospect
review
describ
chang
systol
blood
pressur
sbp
mean
arteri
pressur
map
within
fi
rst
hour
follow
administr
apap
addit
data
collect
consist
patient
age
sex
admiss
diagnos
formulationrout
apap
administr
conclus
appear
small
case
seri
patient
ich
may
experi
isol
hypotens
follow
administr
apap
compar
other
chang
seem
greater
previous
report
intraven
administr
may
also
possibl
apap
solut
exud
hypotens
eff
ect
commonli
compar
tablet
rectal
formul
introduct
profound
myocardi
depress
occur
cardiac
surgeri
use
ventricular
assist
support
venoarteri
extracorpor
membran
oxygen
ecmo
posit
report
studi
focu
outcom
patient
upon
suff
ere
hemodynam
failur
cardiac
surgeri
support
use
ecmo
stay
surgic
icu
incor
fmusp
method
retrospect
singlecent
observ
studi
record
patient
underw
cardiac
surgeri
subsequ
need
percutan
surgic
implant
ventricular
assist
devic
evalu
evalu
consid
follow
criteria
basal
characterist
indic
ventricular
assist
durat
length
icu
hospit
stay
hospit
mortal
data
collect
form
patient
includ
studi
male
younger
year
old
patient
develop
cardiogen
shock
hour
cardiac
surgeri
case
ecmo
insert
cardiac
surgeri
patient
central
ecmo
insert
oper
room
percutan
insert
icu
median
durat
ventricular
assist
day
iqr
length
icu
stay
day
iqr
hospit
stay
day
iqr
twenti
patient
surviv
discharg
hospit
conclus
use
mechan
circulatori
assist
devic
effi
cient
tool
manag
serious
ill
patient
cardiac
surgeri
tool
consid
earli
diagnosi
cardiogen
shock
cardiac
surgeri
introduct
mortal
cardiogen
shock
remain
high
despit
physiolog
rational
intraaort
balloon
counterpuls
iabp
recent
shown
ineff
ectiv
reduc
mortal
venoarteri
extracorpor
membran
oxygen
va
ecmo
may
er
surviv
advantag
iabp
object
studi
describ
characterist
outcom
patient
support
iabp
impella
identifi
characterist
patient
die
despit
mechan
assist
propos
va
ecmo
programm
may
benefi
cial
method
retrospect
cohort
studi
medicalsurg
icu
adult
patient
support
iabp
impella
year
march
identifi
ed
data
extract
casenot
review
subgroup
analysi
carri
patient
age
fulfi
lled
modifi
ed
melbourn
criteria
va
ecmo
data
collect
includ
demograph
data
physiolog
organ
support
baselin
hour
icu
hospit
outcom
caus
death
comparison
survivor
nonsurvivor
made
testchisquar
test
appropri
result
total
patient
identifi
ed
male
mean
age
year
sd
mean
apach
ii
score
icu
mortal
compar
survivor
nonsurvivor
statist
signifi
cant
diff
erenc
metabol
acidosi
vs
meql
p
heart
rate
mean
arteri
pressur
lactat
central
venou
oxygen
satur
cardiac
index
arteri
blood
ph
mechan
ventil
fail
show
signifi
cant
diff
erenc
eleven
patient
would
fulfi
lled
propos
criteria
va
ecmo
icu
mortal
conclus
metabol
acidosi
associ
mortal
patient
support
mechan
assist
devic
data
allow
discrimin
survivor
nonsurvivor
patient
fulfi
lled
propos
criteria
va
ecmo
show
similar
mortal
recent
seri
treat
va
ecmo
propos
criteria
identifi
cohort
popul
would
expect
mortal
benefi
va
ecmo
normobar
oxygen
paradox
nop
recent
concept
postul
use
intermitt
hyperoxia
stimul
erythropoietin
epo
product
hyperoxia
increas
oxygen
free
radic
may
lead
endotheli
damag
vasoconstrict
evalu
microvascular
respons
transient
hyperoxia
eff
ect
epo
product
method
six
patient
hemodynam
stabil
mechan
ventil
fio
includ
prospect
observ
studi
patient
underw
period
hyperoxia
fio
sublingu
microcircul
sidestream
darkfi
eld
imag
sdf
evalu
baselin
hour
hyperoxia
hour
return
basal
fio
sdf
monitor
continu
perform
also
variat
fio
minut
epo
level
assay
baselin
day
critic
care
volum
suppl
http
result
earli
vasoconstrict
trend
toward
total
vessel
densiti
tvd
reduct
observ
figur
tvd
tend
increas
without
return
baselin
level
epo
increas
four
patient
p
ns
neg
correl
found
chang
tvd
hyperoxia
chang
epo
r
p
conclus
hyperoxia
lead
vasoconstrict
seem
revers
hyperoxia
cessat
data
need
verifi
effi
caci
nop
stimul
erythropoiesi
critic
ill
might
relat
hyperoxiainduc
reduct
vessel
densiti
epo
increas
introduct
unknown
whether
lactat
monitor
aim
decreas
level
fi
rst
hour
patient
undergo
cardiac
surgeri
improv
outcom
aim
studi
evalu
eff
ect
lactat
monitor
resuscit
direct
decreas
lactat
level
patient
admit
icu
fi
rst
hour
lactat
level
meql
method
patient
randomli
alloc
two
group
lactat
group
treatment
guid
lactat
level
object
decreas
lactat
per
hour
initi
hour
icu
stay
control
group
treatment
team
knowledg
lactat
level
except
admiss
valu
period
primari
outcom
measur
incid
complic
day
lactat
group
receiv
fl
uid
dobutamin
howev
signifi
cant
diff
erenc
lactat
level
group
rate
complic
similar
group
vs
p
length
icu
stay
higher
lactat
group
vs
day
p
compar
control
group
conclus
patient
hyperlactatemia
icu
admiss
lactateguid
therapi
reduc
complic
relat
longer
icu
length
stay
studi
suggest
goaldirect
therapi
aim
decreas
initi
lactat
level
result
clinic
benefi
introduct
blood
lactat
clearanc
surrog
tissu
hypoxia
associ
increas
mortal
septic
patient
howev
studi
directli
measur
lactat
clearanc
tissu
level
postresuscit
period
sepsi
studi
aim
examin
rel
kinet
blood
tissu
lactat
clearanc
investig
whether
associ
outcom
icu
patient
sever
sepsi
septic
shock
postresuscit
phase
method
microdialysi
cathet
insert
subcutan
adipos
tissu
upper
thigh
interstiti
fl
uid
sampl
collect
serial
measur
blood
interstiti
fl
uid
lactat
level
perform
period
lactat
clearanc
calcul
accord
formula
lactat
initi
lactat
delay
lactat
initi
lactat
initi
blood
tissu
lactat
within
fi
rst
hour
icu
admiss
lactat
delay
blood
tissu
lactat
h
hour
result
total
patient
septic
shock
n
sever
sepsi
n
examin
tissu
lactat
clearanc
higher
compar
blood
lactat
clearanc
p
p
p
p
p
tissu
lactat
clearanc
higher
survivor
compar
nonsurvivor
p
multivari
analysi
show
arach
ii
along
tissu
clearanc
independ
outcom
predictor
blood
lactat
clearanc
relat
surviv
conclus
critic
ill
septic
patient
initi
resuscit
phase
adipos
tissu
clear
lactat
earlier
blood
high
tissu
lactat
clearanc
blood
lactat
clearanc
associ
favor
clinic
outcom
introduct
aim
studi
determin
correl
level
serum
lactat
sl
convent
hemodynam
paramet
hp
mean
arteri
pressur
map
heart
rate
hr
central
venou
pressur
cvp
urinari
output
patient
sever
sepsi
subgroup
advanc
hp
central
venou
satur
svo
peripher
temperatur
pt
cardiac
index
ci
global
enddiastol
volum
index
gedi
extravascular
lung
water
elwi
compar
level
sl
method
observ
prospect
singlecent
pilot
studi
perform
intens
care
ic
mediums
teach
hospit
adult
patient
sever
sepsi
includ
receiv
standard
goaldirect
therapi
surviv
sepsi
guidelin
everi
patient
receiv
arteri
line
central
venou
line
upper
diaphragm
posit
subgroup
receiv
puls
contour
cardiac
output
picco
guid
resuscit
pt
measur
pearson
correl
coeffi
cient
pcc
calcul
hp
sl
measur
everi
hour
fi
rst
hour
inclus
p
consid
statist
signifi
cant
result
twentyfi
patient
men
includ
mean
age
year
mean
apach
ii
score
frequent
reason
ic
admiss
abdomin
sepsi
n
pneumosepsi
n
mean
hp
sd
rang
respect
figur
show
relat
two
hp
highest
correl
sl
conclus
convent
hp
map
hr
svo
signifi
cantli
correl
level
sl
clinic
valu
might
limit
due
rel
low
correl
coeffi
cient
small
subgroup
pt
better
correl
level
sl
delay
assess
serum
lactat
sepsi
associ
increas
mortal
rate
r
arnold
introduct
lactat
assess
earli
resuscit
sepsi
recommend
diagnost
biomark
abnorm
lactat
independ
blood
pressur
indic
aggress
fl
uid
resuscit
normal
recommend
endpoint
resuscit
object
studi
evalu
eff
ect
time
lactat
assess
patient
outcom
sepsi
method
data
compil
use
clinic
vigil
sepsi
electron
health
record
ehr
screen
tool
identifi
ed
consecut
patient
two
hospit
system
month
commun
hospit
month
academ
tertiari
care
center
cv
sepsi
alert
screen
ehr
identifi
presenc
infect
base
multifactor
alert
system
includ
lab
vital
sign
treatment
team
document
physician
order
intraven
antibiot
use
surrog
suspect
infect
databas
identifi
ed
consecut
patient
treat
infect
total
patient
measur
lactat
divid
rel
measur
within
hour
elac
greater
hour
dlac
sepsi
identifi
cation
recommend
surviv
sepsi
campaign
cv
sepsi
alert
refer
standard
time
zero
patient
compar
group
occurr
primari
outcom
inhospit
mortal
result
total
consecut
patient
measur
lactat
sepsi
patient
experienc
overal
mortal
rate
total
patient
measur
lactat
within
hour
delay
decreas
moral
rate
elac
vs
dlac
p
diff
erenc
averag
lactat
level
group
elac
dlac
p
ns
larger
ratio
delayedlact
patient
lactat
mmoll
dlac
vs
elac
conclus
delay
lactat
assess
rel
clinic
evid
infect
associ
increas
mortal
rate
averag
lactat
level
group
account
eff
ect
time
assess
lactat
level
prognost
outcom
mortal
benefi
associ
lactat
assess
within
guidelin
suggest
increas
clinic
awar
may
lead
earli
initi
timesensit
intervent
known
improv
outcom
introduct
object
studi
determin
whether
lactat
clearanc
lc
signifi
cant
indic
mortal
patient
colorect
perfor
lc
associ
mortal
heterogen
critic
ill
patient
role
predictor
mortal
homogen
patient
colorect
perfor
unclear
retrospect
analyz
clinic
data
patient
underw
emerg
surgeri
colorect
perfor
admit
icu
hospit
januari
august
patient
traumat
iatrogen
append
perfor
exclud
primari
endpoint
surviv
hospit
discharg
modifi
ed
sequenti
organ
failur
assess
msofa
score
custom
sofa
score
exclud
central
nervou
system
compon
use
prognost
score
msofa
score
sever
clinic
factor
analyz
univari
analysi
possibl
predictor
surviv
collect
lactat
level
base
excess
measur
surgeri
hour
fi
rst
measur
calcul
respect
lc
valu
associ
initi
blood
lactat
level
lc
mortal
assess
receiv
oper
characterist
roc
curv
logist
regress
analys
introduct
measur
arteri
lactat
alact
level
use
monitor
poor
tissu
perfus
predict
mortal
guid
resuscit
peripher
venou
lactat
vlact
regard
unreli
test
less
invas
approach
aim
determin
correl
alact
vlact
agreement
order
determin
use
vlact
biomark
assess
sepsi
arteri
lactat
venou
lactat
level
strongli
correl
condit
sepsi
septic
shock
consequ
vlact
may
use
substitut
alact
particularli
lactat
level
higher
mmoll
howev
trend
gener
appli
instead
absolut
valu
hyperdynam
left
ventricular
eject
fraction
hdlvef
icu
common
fi
nding
thought
associ
critic
ill
possibl
sepsi
exact
etiolog
hyperdynam
eject
fraction
yet
determin
prognosi
patient
well
defi
ned
method
cohort
consist
adult
admit
icu
echocardiogram
report
use
mimicii
databas
divid
hdlvef
normal
left
ventricular
eject
fraction
nlvef
impair
eject
fraction
exclud
analysi
baselin
comparison
perform
use
chisquar
test
equal
proport
result
report
number
percentag
ci
continu
variabl
compar
use
test
report
mean
ci
nonnorm
distribut
data
compar
use
wilcoxon
ranksum
test
report
median
result
patient
hdlvef
increas
mortal
hospit
day
year
compar
patient
nlvef
hdlvef
patient
frequent
requir
renal
replac
therapi
rrt
vasopressor
mechan
ventil
patient
septic
increas
proport
hdlvef
septic
compar
nonsept
group
vs
p
interestingli
statist
signifi
cant
associ
comorbid
cancer
chf
arrhythmia
hypertens
commonli
seen
hdlvef
group
see
tabl
introduct
pulmonari
regurgit
pr
develop
right
ventricular
rv
outfl
ow
reconstruct
includ
rastelli
norwood
procedur
may
often
result
seriou
cardiac
event
earli
surgeri
hypothes
pr
may
associ
pulmonari
vascular
resist
pvr
rv
contract
accordingli
assess
impact
pvr
pr
rv
function
use
swine
model
method
eight
pig
kg
underw
total
resect
pulmonari
valv
cusp
cardiopulmonari
bypass
pr
group
compar
control
group
n
underw
bypass
group
pulmonari
regurgit
fraction
prf
cardiac
output
measur
puls
doppler
fl
ow
meter
percent
segment
shorten
rv
rvss
rv
enddiastol
dimens
rvdd
measur
sonomicrometri
also
perform
dobutamin
stress
evalu
well
chang
pvr
carbon
dioxid
paco
inhal
nitric
oxid
result
bypass
time
minut
pr
group
prf
rvdd
mm
vs
control
mm
p
signifi
cant
reduct
rvss
vs
control
cardiac
output
lminut
vs
control
lminut
observ
prf
paco
mmhg
paco
mmhg
ppm
paco
mmhg
posit
correl
pvr
figur
dobutamin
stress
rvss
increas
baselin
neg
correl
prf
figur
conclus
result
indic
massiv
pr
result
mark
deterior
rv
perform
howev
low
pvr
high
rv
contractil
may
contribut
reduc
sever
pr
improv
cardiac
function
nitric
oxid
may
use
treatment
modal
introduct
cardiogen
oscil
fl
uctuat
fl
ow
trace
mechan
ventil
patient
larg
cardiogen
oscil
may
caus
autotrigg
adult
patient
cardiac
surgeri
inaccur
volum
monitor
howev
unknown
cardiogen
oscil
problemat
pediatr
patient
therefor
prospect
survey
cardiogen
oscil
pediatr
patient
cardiac
surgeri
method
enrol
pediatr
patient
underw
cardiac
surgeri
use
cardiopulmonari
bypass
mechan
ventil
pressurecontrol
ventil
measur
amplitud
cardiogen
oscil
compar
admiss
icu
extub
perform
statist
analysi
test
consid
p
signifi
cant
result
cardiogen
oscil
lminut
surgeri
figur
autotrigg
occur
seven
patient
trigger
sensit
set
lminut
extub
cardiogen
oscil
signifi
cantli
decreas
introduct
postop
newonset
atrial
fi
brillat
pnaf
common
cardiac
surgeri
infl
ammatori
respons
due
surgeri
cardiopulmonari
bypass
cpb
may
contribut
pnaf
induc
atrial
dysfunct
corticosteroid
reduc
infl
ammatori
respons
may
thu
reduc
atrial
dysfunct
pnaf
aim
studi
determin
whether
dexamethason
protect
left
atrial
dysfunct
pnaf
cardiac
surgic
patient
method
patient
undergo
cardiac
surgeri
random
singl
dose
dexamethason
mgkg
placebo
induc
anesthesia
transesophag
echocardiographi
perform
patient
cpb
primari
outcom
left
atrial
total
eject
fraction
latef
sternal
closur
secondari
outcom
includ
left
atrial
diamet
pnaf
detect
holter
monitor
result
sixtytwo
patient
includ
baselin
characterist
well
balanc
postop
latef
dexamethason
group
placebo
group
p
figur
secondari
echocardiograph
outcom
also
insignifi
cant
tabl
incid
pnaf
dexamethason
group
placebo
group
p
conclus
intraop
highdos
dexamethason
protect
eff
ect
postop
latef
dimens
reduc
risk
pnaf
cardiac
surgic
patient
introduct
ranolazin
piperazin
deriv
use
antiangin
drug
treat
patient
chronic
angina
clinic
practic
may
improv
coronari
blood
fl
ow
reduc
compress
eff
ect
ischem
contractur
improv
endotheli
function
present
studi
investig
vascular
eff
ect
ranolazin
endothelium
adrenerg
system
ca
isol
rat
aorta
method
rat
aortic
segment
mm
long
without
endothelium
mount
isometr
tension
record
organ
bath
contain
krebshenseleit
solut
electr
fi
eld
stimul
hz
v
ms
durat
second
provid
grass
stimul
via
two
platinum
electrod
posit
side
parallel
axi
aortic
segment
concentrationrespons
curv
ranolazin
obtain
cumul
manner
use
noradrenalin
thromboxan
kcl
constrictor
agent
contractil
respons
electr
fi
eld
stimul
abolish
tetrodotoxin
guanethidin
prazosin
indic
contractil
eff
ect
due
action
noradrenalin
alpha
adrenoreceptor
ranolazin
diminish
p
neurogen
adrenerg
contract
induc
electr
fi
eld
stimul
aortic
ring
without
endothelium
ranolazin
produc
concentrationdepend
relax
ring
precontract
noradrenalin
emax
n
p
ring
precontract
thromboxan
kcl
neither
lname
inhibitor
nitric
oxid
synthas
indomethacin
inhibitor
cyclooxygenas
modifi
ed
relax
induc
ranolazin
calcium
antagonist
nifedipin
reduc
relax
induc
ranolazin
conclus
result
indic
ranolazin
diminish
contractil
respons
induc
adrenerg
stimul
suggest
eff
ect
adrenerg
blocker
relax
eff
ect
ranolazin
rat
aortic
vessel
depend
endotheliumderiv
factor
nitric
oxid
dilat
prostanoid
involv
interfer
entri
calcium
dihydropyridin
calcium
channel
introduct
earli
extub
post
coronari
arteri
bypass
graft
increas
periop
morbid
reduc
length
stay
lo
icu
hospit
use
lowdos
opioidbas
gener
anaesthesia
timedirect
protocol
fasttrack
intervent
increas
mortal
postop
complic
lowmoderaterisk
patient
found
reduc
time
extub
shorten
icu
stay
mean
time
extub
hour
although
patient
assess
safe
wean
mechan
ventil
hour
follow
arriv
icu
studi
aim
identifi
factor
delay
extub
patient
undergo
routin
cardiac
surgeri
institut
method
prospect
analysi
perform
patient
post
adult
cardiac
surgeri
may
juli
emerg
surgic
patient
intraop
complic
exclud
result
twosampl
test
use
analys
data
patient
demograph
present
tabl
signifi
cant
delay
time
extub
receiv
morphin
prior
extub
compar
p
tabl
signifi
cant
diff
erenc
lo
icu
hospit
factor
age
euroscor
type
oper
infl
uenc
time
extub
conclus
administ
morphin
prior
extub
caus
signifi
cant
delay
wean
mechan
ventil
plan
introduc
intraop
postop
protocol
facilit
rapid
wean
mechan
ventil
elect
cardiac
surgic
patient
introduct
takotsubo
cardiomyopathi
tcm
acut
cardiac
syndrom
region
hypokinesia
left
ventricl
lv
often
aff
ect
apex
caus
apic
balloon
tcm
frequent
patient
adrenerg
overstimul
probabl
common
icu
patient
tcm
rat
model
evalu
whether
diff
erent
anesthet
agent
could
attenu
lv
akinesia
tcm
method
isoprenalin
intraperiton
ip
inject
induc
lv
akinesia
apic
balloon
within
minut
perform
studi
two
diff
erent
set
fi
rst
set
spontan
breath
rat
n
group
sedat
either
pentobarbit
ketamin
isofl
uran
anesthet
ip
isoprenalin
one
addit
group
receiv
katp
blocker
glyburid
sedat
isofl
uran
second
set
rat
anaesthet
ketamin
midazolam
mechan
ventil
carotid
arteri
cannul
ip
isoprenalin
anim
random
either
isofl
uran
mac
isofl
uran
mac
isofl
uran
mac
n
group
arteri
blood
ga
obtain
isoprenalin
minut
isoprenalin
heart
rate
hr
systol
blood
pressur
sbp
bodi
temperatur
bt
record
continu
minut
echocardiographi
perform
extent
akinesia
express
percentag
total
lv
endocardi
length
enddiastol
endsystol
lv
volum
measur
stroke
volum
sv
cardiac
output
co
calcul
result
spontan
breath
rat
degre
akinesia
signifi
cantli
lower
pentobarbit
isofl
uran
glyburid
ketamin
compar
control
degre
akinesia
lowest
isofl
uran
ventil
rat
degre
apic
akinesia
signifi
cantli
lower
mac
mac
versu
mac
accompani
higher
co
sv
hr
lower
mac
sbp
lower
mac
mac
versu
mac
bt
ph
lower
isofl
uran
group
multivari
model
isofl
uran
variabl
independ
associ
degre
lv
akinesia
conclus
isofl
uran
prevent
experiment
tcm
preserv
lv
function
eff
ect
mediat
via
open
katp
channel
eff
ect
explain
entir
attenu
myocardi
stress
isofl
uran
sedat
icu
might
interest
approach
patient
suff
ere
hyperadrenerg
condit
risk
develop
tcm
introduct
preoper
therapi
angiotensinconvert
enzym
inhibitor
acei
common
patient
undergo
cardiac
surgeri
aim
studi
evalu
stilldeb
impact
preoper
use
acei
postop
renal
function
cardiac
surgeri
patient
method
total
consecut
patient
underw
cardiac
surgeri
juli
octob
evalu
data
prospect
collect
clinic
electron
databas
retrospect
analyz
preoper
acei
therapi
chisquar
test
use
correl
endpoint
studi
develop
postop
acut
kidney
injuri
aki
diff
erenc
hospit
admiss
discharg
glomerular
fi
ltration
rate
gfr
inhospit
mortal
higher
group
vs
p
conclus
primari
visit
local
hospit
associ
longer
reperfus
time
associ
higher
mortal
therefor
reperfus
time
could
reduc
patient
educ
manag
commun
healthcar
system
introduct
potenti
measur
postischem
milieu
myocardium
subject
acut
ischem
injuri
assess
socal
myocardi
salvag
index
si
relat
fi
nal
infarct
size
initi
myocardium
risk
mar
cardiac
magnet
reson
cmr
previous
shown
enabl
determin
infarct
size
use
late
gadolinium
enhanc
mar
use
imag
techniqu
could
thu
potenti
use
identifi
infl
ammatori
respons
could
target
accomplish
cardioprotect
aim
studi
relat
si
determin
cmr
infl
ammatori
respons
patient
acut
myocardi
infarct
method
fifteen
patient
fi
rsttime
stelev
myocardi
infarct
includ
studi
patient
underw
primari
pci
due
acut
occlus
one
branch
left
coronari
arteri
final
infarct
size
mar
determin
cmr
perform
week
acut
event
ischem
time
defi
ned
time
pain
onset
open
occlud
vessel
blood
sampl
taken
assess
infl
ammatori
respons
infl
ammatori
cell
analyz
fl
ow
cytometri
bd
fac
aria
paramet
gate
control
antibodi
fl
uoresc
minu
one
strategi
cytokin
pattern
analyz
biorad
bioplex
multiplex
protein
analysi
technolog
si
correl
mar
p
r
popul
divid
lowest
half
si
repres
hostil
milieu
si
upper
half
si
repres
friendliest
postinfarct
milieu
si
patient
profi
le
adapt
infl
ammatori
respons
character
fl
ow
cytometri
two
group
diff
er
regard
tregulatori
respons
p
nkcell
introduct
elev
cardiac
troponin
level
common
icu
patient
even
absenc
acut
coronari
syndrom
may
predict
mortal
recent
introduc
highsensit
cardiac
troponin
hs
ctnt
assay
result
increas
detect
elev
ctnt
icu
patient
aim
studi
determin
preval
elev
ctnt
use
hs
assay
relationship
mortal
method
retrospect
observ
studi
perform
icu
admiss
period
data
obtain
clinic
inform
system
icip
philip
icu
audit
databas
acubas
data
collect
includ
patient
demograph
peak
ctnt
valu
apach
ii
score
requir
organ
support
mortal
primari
outcom
measur
hospit
mortal
data
analys
use
spss
ctnt
level
divid
categori
analysi
normal
ngl
elev
elev
categori
subdivid
quartil
univari
analysi
perform
potenti
risk
factor
mortal
follow
multivari
regress
analysi
ascertain
independ
predictor
mortal
result
admiss
icu
studi
period
exclud
absent
ctnt
valu
leav
patient
includ
analysi
ctnt
elev
patient
icu
mortal
hospit
mortal
hospit
mortal
per
ctnt
categori
ngl
ngl
ngl
ngl
ngl
univari
analysi
ctnt
level
age
ventil
apach
ii
score
signifi
cantli
associ
mortal
ctnt
level
signifi
cant
multivari
regress
independ
age
ventil
reach
signifi
canc
p
multivari
analysi
includ
apach
ii
score
conclus
gener
icu
patient
troponin
measur
hs
ctnt
assay
elev
ctnt
level
signifi
cantli
associ
mortal
predict
mortal
independ
age
mechan
ventil
independ
apach
ii
score
high
correl
troponin
level
apach
ii
score
refer
view
robust
consequ
follow
cardiac
surgeri
acut
kidney
injuri
aki
remain
major
concern
rhabdomyolysi
rml
follow
cardiac
surgeri
relat
aki
need
investig
aim
studi
preval
rml
develop
follow
cardiac
surgeri
periop
risk
factor
may
expedit
occurr
rml
method
patient
undergo
cardiac
surgeri
hospit
enrol
studi
period
year
prospect
descript
studi
measur
occurr
rml
associ
aki
patient
studi
underw
serial
assess
serum
creatinin
kinas
ck
serum
myoglobin
serial
renal
function
prior
statin
treatment
cardiac
injuri
length
ventil
length
stay
icu
hospit
monitor
conclus
icu
hospit
mortal
rate
high
respect
increas
age
correl
mortal
howev
invas
ventil
time
hospit
icu
admiss
associ
higher
mortal
may
due
delay
diagnosi
surgic
intervent
suggest
one
consid
earli
intervent
patient
age
function
outcom
measur
discharg
may
clinic
relev
endpoint
refer
introduct
aim
studi
clarifi
risk
factor
acut
renal
impair
ari
patient
sever
acut
pancreat
sap
introduct
controversi
surround
empir
use
antibiot
sever
acut
pancreat
sap
concern
widespread
use
antibiot
therapi
absenc
document
infect
may
lead
select
drugresist
organ
aim
studi
review
profi
le
pancreat
fl
uid
isol
patient
sap
admit
icu
method
data
review
patient
admit
icu
period
evalu
organ
cultur
pancreat
specimen
well
preval
drugresist
organ
group
patient
result
aspir
pancreat
materi
cultur
obtain
patient
n
mean
time
acquisit
sampl
cultur
admiss
icu
day
fluid
steril
n
initi
sampl
gramposit
organ
cultur
n
sampl
gramneg
organ
n
yeast
n
antibiot
therapi
administ
patient
prior
sampl
obtain
cultur
review
sampl
receiv
patient
includ
nonpancreat
specimen
vancomycinresist
enterococci
vre
isol
patient
linezolidresist
enterococci
lre
isol
six
patient
fi
vre
isol
prior
cultur
lre
extendedspectrum
betalactamas
organ
isol
two
patient
carbapenem
nonsuscept
gramneg
organ
three
patient
mean
apach
ii
score
overal
hospit
mortal
conclus
major
patient
initi
aspir
pancreat
materi
steril
may
result
prior
antibiot
usag
organ
cultur
initi
aspir
gramposit
organ
predomin
possibl
result
prior
antigramneg
antibiot
use
therefor
patient
ongo
sepsi
receiv
broadspectrum
antibiot
therapi
consider
need
given
empir
treatment
gramposit
infect
particular
drugresist
organ
vre
local
epidemiolog
taken
account
rational
use
antibiot
accord
bestpractic
guidelin
may
limit
develop
drug
resist
howev
risk
factor
resist
may
exist
group
would
need
evalu
refer
introduct
liver
transplant
lt
acetaminopheninduc
acut
liver
failur
apapalf
patient
often
present
signifi
cant
challeng
king
colleg
criteria
kcc
valid
admiss
later
phase
ill
aim
improv
determin
prognosi
admiss
apapalf
patient
use
classifi
cation
regress
tree
cart
methodolog
construct
optim
binari
split
independ
variabl
predict
outcom
method
cart
model
appli
us
alfsg
registri
data
predict
spontan
surviv
admiss
late
stage
day
analys
carri
use
r
softwar
packag
rpart
n
apapalf
patient
enrol
januari
septemb
complet
outcom
data
train
data
use
build
cart
tree
test
data
use
evalu
predict
accuraci
ac
sensit
sn
specifi
citi
sp
introduct
extracorpor
membran
oxygen
ecmo
increasingli
use
treatment
refractori
potenti
revers
respiratori
andor
cardiac
failur
data
periop
support
venoarteri
va
venoven
vv
ecmo
adult
liver
transplant
recipi
scarc
report
experi
ecmo
support
patient
acut
liver
failur
alf
bridg
transplant
postop
ecmo
use
follow
complic
surgeri
method
retrospect
studi
specialist
tertiari
referr
icu
patient
support
vv
va
ecmo
orthotop
liver
transplant
olt
identifi
ed
result
total
four
patient
support
period
two
patient
requir
vv
two
patient
va
support
two
patient
alf
bridg
olt
one
patient
vv
ecmo
refractori
respiratori
failur
patient
requir
emerg
va
support
treatment
intraop
arrest
patient
success
transplant
die
subsequ
ecmo
dissemin
aspergillosi
haemophagocyt
syndrom
anox
brain
injuri
respect
two
patient
receiv
postop
ecmo
support
fi
rst
treat
vv
ecmo
refractori
persist
hypoxaemia
follow
olt
hepatopulmonari
syndrom
second
receiv
emerg
va
support
ecpr
follow
cardiac
tamponad
arrest
postop
day
patient
made
full
recoveri
conclus
emerg
ecmo
support
liver
transplant
feasibl
despit
poor
outcom
patient
alf
consid
ecmo
valuabl
option
bridg
select
patient
transplant
refer
frequent
observ
term
postreperfus
syndrom
recent
studi
show
exist
specifi
c
heart
diseas
associ
cirrhosi
term
cirrhot
cardiomyopathi
ccm
aim
studi
investig
whether
ccm
infl
uenc
develop
sever
postreperfus
syndrom
method
fiftytwo
consecut
liver
transplant
patient
includ
retrospect
observ
studi
variabl
record
age
etiolog
liver
diseas
meld
meld
na
score
associ
patholog
length
qt
interv
plasma
level
brain
natriuret
peptid
bnp
patient
known
renal
heart
diseas
recipi
organ
extend
criteria
donor
exclud
studi
qt
interv
correct
heart
rate
use
bazett
formula
qtc
statist
analysi
perform
use
spss
statist
result
studi
criteria
use
defi
ne
postreperfus
syndrom
reli
hemodynam
chang
occur
reperfus
preoper
echocardiographi
show
normal
systol
diastol
function
rest
patient
identifi
cation
patient
risk
ccm
use
two
support
criteria
recent
defi
nition
ccm
prolong
qtc
interv
increas
bnp
level
studi
group
includ
men
women
mean
sd
age
mean
meld
meld
na
score
respect
valu
bnp
correl
well
length
qtc
interv
p
meld
meld
na
score
p
p
studi
postreperfus
syndrom
occur
patient
could
fi
nd
correl
postreperfus
syndrom
bnp
level
p
prolong
qtc
interv
p
postreperfus
syndrom
correl
sever
liver
diseas
assess
meld
meld
na
score
sever
postreperfus
syndrom
correl
qtc
prolong
bnp
level
conclus
reperfus
critic
time
liver
transplant
clinic
predictor
postreperfus
syndrom
still
debat
studi
show
postreperfus
syndrom
correl
sever
liver
diseas
presenc
risk
factor
indic
ccm
introduct
combin
heartliv
transplant
chlt
uncommonli
perform
procedur
patient
coexist
cardiac
liver
diseas
purpos
studi
examin
describ
periop
manag
patient
undergo
chlt
method
retrospect
review
perform
patient
undergo
chlt
institut
result
twentyseven
chlt
perform
includ
simultan
kidney
transplant
famili
amyloidosi
indic
chlt
explant
liver
use
domino
transplant
nineteen
patient
receiv
inotrop
infus
time
organ
avail
median
preoper
meld
score
elev
preoper
intern
normal
ratio
due
warfarin
one
patient
liver
transplant
immedi
preced
cardiac
transplant
case
reduc
hightit
donorspecifi
c
antibodi
venoven
bypass
util
oper
perform
caval
interposit
liver
transplant
approach
cardiopulmonari
bypass
liver
transplant
two
case
bypass
oper
perform
caval
spare
piggyback
surgic
techniqu
postop
median
durat
mechan
ventil
icu
stay
hospit
stay
discharg
day
day
day
respect
transfus
fi
rst
hour
follow
chlt
substanti
major
patient
one
patient
die
within
day
chlt
conclus
chlt
lifesav
oper
perform
rel
low
mortal
success
perform
select
patient
congenit
heart
diseas
patient
undergo
chlt
institut
rel
preserv
hepat
function
limit
cardiac
function
often
requir
inotrop
support
cardiac
transplant
typic
preced
liver
transplant
chlt
given
decreas
ischem
toler
cardiac
graft
howev
liver
transplant
prior
cardiac
transplant
may
serv
mitig
hightit
donorspecifi
c
antibodi
variou
aforement
oper
approach
may
success
util
liver
transplant
portion
procedur
attribut
favor
outcom
periop
cours
multidisciplinari
approach
care
chlt
patient
receiv
institut
refer
introduct
balanc
coagul
fi
brinolysi
promin
factor
pathophysiolog
sepsi
mechan
poorli
understood
aim
determin
whether
collaps
balanc
fi
rst
day
sepsi
correl
progress
organ
dysfunct
subsequ
death
method
studi
includ
patient
sepsi
admit
tertiari
referr
hospit
japan
global
coagul
test
hemostat
molecular
marker
fi
brinfi
brinogen
degrad
product
fdp
ddimer
thrombinantithrombin
complex
tat
plasminalpha
plasmin
inhibitor
complex
pic
measur
within
hour
admiss
sofa
apach
ii
score
inhospit
mortal
evalu
patient
divid
three
group
base
level
tatpic
fdpddimer
diff
erenc
clinic
outcom
group
assess
chisquar
analysi
anova
result
enrol
patient
patient
surviv
die
mortal
signifi
cantli
higher
high
tatpic
group
low
middl
high
tatpic
group
respect
p
addit
sofa
apach
ii
score
signifi
cantli
higher
low
fdpddimer
group
apach
ii
p
sofa
p
low
middl
high
fdp
ddimer
group
respect
see
figur
conclus
demonstr
balanc
coagul
fi
brinolysi
assess
fdpddimer
tatpic
ratio
correl
diseas
sever
clinic
outcom
sepsi
suggest
impair
balanc
hemostat
system
might
play
pivot
role
progress
sepsi
pathophysiolog
introduct
hemodynam
disord
critic
ill
patient
often
connect
bacteri
load
bacteri
load
usual
associ
bacteremia
lp
high
level
pct
also
aromat
microbi
metabolit
forth
opinion
microbi
metabolit
particip
hemodynam
disord
critic
ill
patient
particularli
due
infl
uenc
product
intestin
permeabl
method
prospect
studi
observ
critic
ill
patient
day
admiss
polyval
icu
sever
cardiac
patholog
exclud
level
phenylpropion
phenyllact
pohphenyllact
pohphenylacet
acid
total
phenylcarboxyl
acid
phca
measur
blood
serum
use
ga
chromatographi
gcfid
level
pct
ntprobnp
measur
use
elecsi
comparison
patient
hypotens
vasopressor
support
group
without
group
b
perform
studi
icu
patient
diff
erent
diseas
pneumonia
n
sever
kidney
failur
n
abdomin
surgic
patholog
n
alcohol
cirrhosi
n
softtissu
infect
n
group
median
phca
ir
group
b
ir
p
test
group
patient
without
document
infect
symptom
infect
manifest
die
group
b
symptom
infect
manifest
reveal
case
mortal
signifi
cantli
lower
p
gener
mortal
profi
le
phca
diff
ere
group
versu
b
conclus
total
level
phca
critic
ill
patient
hypotens
consider
higher
hemodynam
stabl
patient
particip
microbi
factor
pathogenesi
hemodynam
disord
presenc
system
infl
ammat
may
valid
load
microbi
metabolit
phca
introduct
coagul
abnorm
common
sever
sepsi
septic
shock
method
prospect
observ
cohort
studi
patient
year
age
diagnos
sever
sepsi
septic
shock
admiss
fi
rst
blood
sampl
collect
admiss
analyz
data
collect
predesign
pro
forma
previou
histori
coagul
disord
exclud
critic
care
volum
suppl
http
result
univari
analysi
show
signifi
cant
correl
apach
ii
platelet
pt
aptt
fi
brinogen
ddimer
mortal
patient
sever
sepsi
septic
shock
multivari
analysi
show
apach
ii
p
fi
brinogen
p
ddimer
p
independ
predictor
mortal
sever
sepsi
septic
shock
see
tabl
introduct
system
infl
ammat
caus
infect
trauma
often
lead
advers
outcom
critic
ill
patient
bind
ligand
receptor
advanc
glycat
end
product
rage
activ
sever
pathway
includ
nuclear
factorkappa
b
pathway
gener
infl
ammatori
cytokin
proteas
oxid
stress
rage
activ
suggest
link
amplifi
cation
perpetu
infl
ammat
subsequ
organ
damag
advers
outcom
sepsi
acut
lung
injuri
myocardi
dysfunct
solubl
receptor
srage
thought
act
decoy
thu
protect
rage
activ
high
mobil
group
box
nuclear
protein
releas
cellular
stress
damag
neutrophilderiv
protein
act
proinfl
ammatori
danger
signal
ligand
rage
hypothes
excess
rage
activ
link
advers
outcom
critic
ill
patient
diff
erent
pattern
rage
activ
infl
ammat
may
present
patient
accord
underli
patholog
method
measur
srage
serum
level
upon
admiss
day
last
day
icu
critic
ill
surgic
patient
need
intens
care
least
day
match
healthi
control
assess
relat
level
clinic
complic
outcom
comparison
creactiv
protein
crp
routin
measur
clinic
paramet
infl
ammat
result
upon
icu
admiss
level
srage
crp
higher
compar
healthi
level
crp
remain
elev
throughout
icu
stay
srage
decreas
level
lower
healthi
volunt
day
srage
crp
show
distinct
time
profi
le
icu
stay
patient
undergo
cardiac
versu
surgeri
patient
versu
without
sepsi
upon
admiss
elev
srage
upon
admiss
unlik
crp
associ
need
renal
replac
therapi
liver
dysfunct
circulatori
failur
mortal
except
mortal
associ
remain
multivari
logist
regress
analysi
correct
baselin
risk
factor
conclus
critic
ill
alter
sever
compon
rage
axi
elev
srage
level
upon
admiss
icu
associ
advers
outcom
independ
baselin
patholog
refer
endotoxin
activ
assay
eaa
newli
develop
rapid
assay
endotoxin
blood
endotoxin
level
ea
level
patient
admit
univers
hospit
icu
measur
within
hour
admiss
correl
diseas
sever
outcom
examin
method
studi
singlecent
retrospect
analysi
critic
ill
patient
admit
univers
hospit
icu
novemb
march
patient
whose
ea
procalcitonin
level
measur
sever
criteria
diseas
record
enrol
total
patient
analyz
result
mean
sd
icuadmit
patient
n
healthi
volunt
n
mean
apach
ii
score
admiss
increas
parallel
increas
ea
level
signifi
cant
diff
erenc
regard
baselin
demograph
clinic
data
apart
blood
pressur
lower
sepsi
group
serum
leptin
day
higher
sepsi
group
vs
p
diff
erenc
day
admiss
detect
serum
leptin
level
day
sensit
specifi
c
diagnos
sepsi
three
serum
crp
level
higher
sepsi
group
compar
sir
group
mgl
vs
mgl
p
day
mgl
mgl
sepsi
group
vs
mgl
mgl
sir
group
day
respect
p
found
crp
mgl
day
sensit
specifi
citi
diagnosi
sepsi
conclus
conclud
although
serum
leptin
may
benefi
cial
earli
diff
erenti
sepsi
noninfecti
sir
admiss
may
highli
specifi
c
second
day
figur
plasma
ccp
day
good
capac
diagnosi
pa
np
ccp
day
ngml
yield
sensit
specifi
citi
auc
ci
p
figur
conclus
plasma
ccp
level
ngml
sensit
specifi
c
candid
diagnost
biomark
pa
np
introduct
system
infl
ammat
gener
respons
intern
extern
infl
ammatori
stimuli
often
result
multipl
organ
failur
therefor
earli
diagnosi
system
infl
ammat
would
great
therapeut
prognost
import
variou
infl
ammat
biomark
use
clinic
experiment
practic
defi
nitiv
diagnost
tool
earli
detect
system
infl
ammat
remain
identifi
ed
neurotransmitt
acetylcholin
ach
shown
play
import
role
infl
ammatori
respons
serum
cholinesteras
butyrylcholinesteras
bche
synthes
liver
act
major
ach
hydrolyz
enzym
plasma
henc
bche
activ
wide
use
biomark
liver
function
howev
role
enzym
infl
ammatori
pathomechan
yet
fulli
understood
describ
strong
correl
bche
activ
system
infl
ammatori
respons
method
studi
measur
bche
activ
healthi
subject
critic
ill
patient
clinic
diagnos
system
infl
ammat
sepsi
furthermor
measur
level
routin
infl
ammat
biomark
liver
function
paramet
blood
critic
ill
patient
introduct
bloodstream
infect
bsi
associ
reduct
circul
lymphocyt
lymphopenia
propos
earli
marker
bsi
pyrexi
adult
emerg
depart
ed
set
aim
studi
compar
lymphocyt
valu
creactiv
protein
crp
procalcitonin
pct
investig
determin
eff
ect
postop
complic
patient
without
system
infl
ammatori
respons
syndrom
sir
patient
prospect
observ
studi
serum
crp
pct
valu
collect
everi
day
start
postop
day
day
defi
nition
sir
includ
two
follow
temperatur
heart
rate
beatsminut
respiratori
rate
arteri
carbon
dioxid
pressur
mmhg
white
blood
cell
count
introduct
occurr
sepsisinduc
immun
suppress
associ
multipl
organ
dysfunct
although
exact
role
tcell
malfunct
obscur
investig
impact
sepsi
adapt
immun
system
monitor
tcell
receptor
tcr
divers
method
tcr
divers
analyz
peripher
blood
mononuclear
cell
pbmc
isol
septic
shock
patient
three
time
point
day
diagnosi
septic
shock
tcr
divers
measur
genom
dna
isol
pbmc
use
human
immun
trackerb
test
immunid
technolog
grenobl
franc
multinplex
pcr
perform
use
primer
specifi
c
v
gene
famili
sever
primer
specifi
c
j
segment
signal
measur
function
fl
uoresc
intens
refer
marker
rearrang
valid
map
gener
detect
analyz
use
constelid
softwar
immunid
technolog
hladr
express
cell
measur
fl
ow
cytometri
result
tcr
divers
markedli
decreas
septic
patient
day
compar
healthi
volunt
recoveri
tcr
divers
observ
day
except
dead
patient
hladr
express
signifi
cantli
decreas
septic
patient
day
total
lymphocyt
count
reduc
septic
patient
day
lymphocyt
count
recov
day
except
dead
patient
introduct
sepsi
associ
immun
hyporespons
immunolog
process
behind
ill
defi
ned
method
studi
quantifi
ed
diff
erenc
plasma
concentr
cytokin
septic
patient
faecal
periton
age
gendermatch
surgic
patient
without
sepsi
age
gendermatch
healthi
particip
addit
cytokin
level
measur
supernat
peripher
blood
mononuclear
cell
stimul
incub
day
cytokin
concentr
determin
multiplex
cytometr
bead
array
result
plasma
level
lower
septic
patient
compar
healthi
particip
contrast
plasma
level
see
figur
increas
septic
patient
compar
surgic
patient
healthi
particip
plasma
level
signifi
cantli
higher
comparison
surgic
patient
follow
incub
concentr
see
figur
markedli
decreas
sampl
septic
patient
addit
stimul
result
lower
product
septic
patient
lower
concentr
detect
septic
patient
sampl
stimul
found
cytokin
level
remain
unaff
ect
across
group
stimuli
conclus
demonstr
proinfl
ammatori
cytokin
profi
le
blood
septic
patient
preced
pan
downregul
assess
cytokin
follow
vitro
tcell
stimul
knowledg
studi
fi
rst
perform
immun
function
assay
across
three
group
introduct
activ
protein
c
apc
defi
cienci
preval
sever
sepsi
septic
shock
patient
aim
studi
relat
anticoagul
activ
evalu
apc
coagul
paramet
adjust
mortal
method
cohort
studi
critic
ill
adult
age
sex
sourc
infect
coagul
marker
within
hour
sever
sepsi
septic
shock
onset
defi
ned
accord
surviv
sepsi
campaign
ssc
criteria
studi
analyz
apc
activ
use
hemostasi
laboratori
analyz
xp
siemen
descript
compar
statist
analysi
perform
use
spss
version
spss
inc
chicago
il
usa
analyz
consecut
episod
sever
sepsi
septic
shock
admit
uci
median
age
studi
sampl
interquartil
rang
iqr
year
male
main
sourc
infect
respiratori
tract
intraabdomen
introduct
flowcytometr
analysi
still
restrict
cancer
immunocompromis
patient
clinic
studi
evalu
immunolog
chang
traumat
brain
injuri
tbi
patient
object
studi
determin
whether
patient
sever
tbi
gc
manifest
earli
hour
injuri
sign
immunosuppress
whether
condit
increas
incid
infect
icu
stay
retrospect
analyz
data
patient
includ
patient
isol
brain
injuri
patient
brain
extracrani
injuri
fl
owcytometr
analysi
perform
within
hour
trauma
collect
data
shown
tabl
result
preliminari
analysi
limit
descript
statist
show
immedi
immunosuppress
condit
tbi
establish
reduct
lymphocyt
lymphocyt
signifi
cant
data
collect
tabl
conclus
sever
tbi
patient
immunosuppress
state
earli
develop
relev
establish
whether
condit
could
aff
ect
cours
prognosi
icu
patient
found
low
high
cl
na
ratio
p
p
figur
conclus
stewart
strong
ion
theori
provid
assess
etiolog
acidbas
disturb
evalu
perform
easier
faster
cl
na
ratio
studi
demonstr
disturb
cl
na
ratio
associ
increas
mortal
sepsi
sever
sepsi
patient
group
introduct
studi
demonstr
low
level
plasmalogen
pl
import
marker
peroxisom
dysfunct
primaryoh
group
glycerol
pl
substitut
acyl
group
fatti
acid
diacylphospholipid
aldehydogen
alkenyl
group
fatti
aldehyd
found
form
vinyl
ether
known
disrupt
sever
organ
system
diseas
connect
peroxisom
dysfunct
case
multipl
organ
failur
method
object
studi
peopl
multipl
organ
failur
year
variou
etiolog
blood
healthi
introduct
acut
alcohol
exposur
suppress
proinfl
ammatori
respons
may
relat
increas
suscept
infect
purpos
studi
investig
eff
ect
acut
exposur
alcohol
product
capac
receptor
tnfr
ex
vivo
model
wholeblood
stimul
lipopolysaccharid
lp
method
whole
blood
taken
healthi
volunt
place
tube
contain
edta
immedi
transfer
laboratori
heparin
blood
sampl
dilut
rpmi
cultur
medium
whole
blood
ad
rpmi
sampl
preincub
mm
alcohol
etoh
minut
room
temperatur
incub
pg
lp
ad
sampl
hour
end
process
sampl
centrifug
rpm
minut
rt
cultur
supernat
collect
store
measur
tnfr
level
determin
cultur
supernat
use
elisa
method
result
studi
healthi
male
volunt
age
x
sem
detect
sampl
treat
without
alcohol
absenc
lp
stimul
control
presenc
alcohol
alon
data
shown
product
signifi
cantli
decreas
dose
mm
alcohol
lp
stimul
p
compar
lpschalleng
sampl
figur
alcohol
eff
ect
tnfr
product
incub
without
lp
data
shown
alcohol
lower
dose
mm
seem
decreas
tnfr
ii
level
increas
tnfr
ii
level
observ
higher
dose
mm
alcohol
statist
signifi
cant
dose
mm
alcohol
lp
stimul
ex
vivo
p
figur
observ
indic
suppress
pro
infl
ammatori
respons
also
diff
erenti
eff
ect
alcohol
tnfr
ii
product
whole
blood
presenc
lp
challeng
depend
degre
alcohol
intox
introduct
neutrophil
play
central
role
elimin
bacteri
pathogen
may
also
contribut
endorgan
damag
key
modul
neutrophil
function
signal
neutrophil
specifi
c
surfac
receptor
express
surfac
receptor
alter
perfus
extracorpor
devic
extracorpor
method
immun
modul
shown
promis
treatment
sepsi
howev
achiev
appropri
respons
major
challeng
studi
mechanist
mathemat
model
use
evalu
deploy
extracorpor
sepsi
treatment
modul
level
conclus
prolactin
seem
stress
hormon
probabl
relat
sever
ill
increas
along
level
ss
also
patient
cortisol
correl
lactat
contrast
sir
immun
respons
depress
introduct
organ
injuri
hallmark
sepsi
particular
acut
kidney
injuri
aki
yet
mechan
involv
sepsisinduc
aki
well
understood
energi
priorit
import
cell
defens
mechan
thu
hypothes
exogen
activ
ampprotein
kinas
ampk
master
regul
cellular
energi
metabol
protect
sepsisinduc
aki
method
sixti
male
mice
week
age
weigh
g
divid
six
group
cecal
ligat
punctur
clp
clpaicar
ai
ampk
activ
mgkg
hour
clp
clpcompound
c
ampk
inhibitor
mgkg
coc
sham
shamai
shamcoc
bloodtissu
sampl
collect
hour
clp
renal
function
creatinin
cr
mgdl
bun
mgdl
cystatin
c
cysc
ngml
cytokin
express
elisa
endotheli
activ
express
neutrophil
adhes
pmn
fl
uoresc
mabtag
pmn
vascular
leak
evan
blue
assess
eff
ect
ai
given
hour
n
hour
n
clp
also
evalu
method
ninetyseven
male
mice
subject
multitrauma
crush
femur
chemic
pneumothorax
turpentin
mice
surviv
hour
injuri
challeng
intraven
one
logphas
inoculum
p
aeruginosa
surviv
record
separ
experi
mice
sacrifi
ced
post
injuri
splenocyt
isol
stimul
ng
ml
lp
cytokin
measur
supernat
enzym
immunoassay
quantit
cultur
right
lung
kidney
liver
perform
procedur
done
shamoper
mice
mice
subject
femur
crush
pneumothorax
result
initi
experi
mice
show
overal
death
rate
model
multitrauma
death
occur
fi
rst
hour
second
set
experi
mice
remain
aliv
hour
post
injuri
challeng
p
aeruginosa
mortal
compar
non
introduct
purpos
studi
evalu
whether
patient
sepsi
expos
clopidogrel
lower
mortal
fewer
day
mechan
ventil
compar
patient
expos
clopidogrel
recent
posthoc
analysi
plato
trial
suggest
antiplatelet
agent
ticagrelor
provid
signifi
cant
introduct
aim
studi
determin
correl
region
tissu
oxygen
sro
measur
nearinfrar
spectroscopi
nir
central
venou
oxygen
satur
svo
level
serum
lactat
sl
patient
sever
sepsi
method
observ
pilot
studi
perform
icu
mediums
teach
hospit
adult
patient
admit
sever
sepsi
includ
three
nir
electrod
attach
left
side
forehead
lf
right
side
forehead
rf
right
forearm
ra
critic
care
volum
suppl
http
method
posthoc
subgroup
analysi
multicent
retrospect
cohort
studi
conduct
three
tertiari
referr
hospit
japan
patient
sepsisinduc
dic
requir
ventil
manag
includ
stratifi
ed
patient
diff
erent
diseas
sever
defi
ned
apach
ii
sofa
score
three
strata
intervent
eff
ect
estim
hazard
ratio
analyz
cox
regress
analysi
adjust
propens
model
detect
subgroup
heterogen
eff
ect
rhtm
inhospit
mortal
result
elig
patient
sepsisinduc
dic
patient
receiv
rhtm
adjust
imbal
rhtm
administr
signifi
cantli
associ
reduc
mortal
patent
stratum
ii
group
apach
ii
adjust
hazard
ratio
confi
denc
interv
p
signifi
cant
stratum
stratum
iii
figur
similar
tendenc
observ
analysi
sofa
score
stratum
sofa
p
stratum
ii
sofa
p
stratum
iii
sofa
p
conclus
group
oncolog
patient
admit
icu
neutropenia
sever
sepsissept
shock
found
inhospit
mortal
less
similar
gener
popul
refer
icu
contact
respond
survey
icu
still
perform
daili
routin
cxr
patient
icu
say
never
perform
cxr
routin
basi
daili
meet
radiologist
establish
major
icu
judg
import
even
essenti
therapeut
effi
caci
routin
cxr
assum
intensivist
lower
effi
caci
ondemand
cxr
assum
consensu
intensivist
perform
routin
cxr
endotrachi
intub
chest
tube
placement
central
venou
catheter
conclus
strategi
daili
routin
cxr
critic
ill
patient
develop
common
practic
rare
practic
nowaday
intensivist
still
assum
valu
routin
cxr
higher
effi
caci
report
literatur
might
due
clinic
valu
neg
fi
nding
studi
investig
effi
caci
safeti
chest
radiograph
cxr
perform
specifi
ed
indic
directli
cardiac
surgeri
cxr
icu
frequent
obtain
routin
postop
cardiosurg
patient
despit
fact
diagnost
therapeut
effi
caci
cxr
known
low
routin
cxr
may
benefi
cial
certain
indic
discuss
regard
indic
safeti
abandon
routin
cxr
still
continu
method
prospect
includ
patient
underw
major
cardiac
surgeri
year
direct
postop
cxr
perform
certain
specifi
ed
indic
ondemand
cxr
could
obtain
postop
period
accord
specifi
ed
indic
patient
cxr
taken
morn
fi
rst
postop
day
control
cxr
perform
cxr
fi
nding
note
classifi
ed
includ
whether
led
intervent
diagnost
therapeut
effi
caci
valu
calcul
result
total
patient
includ
mainli
underw
coronari
arteri
bypass
graft
valv
surgeri
combin
eighteen
percent
patient
underw
minim
invas
cardiac
surgeri
diagnost
effi
caci
major
abnorm
clearli
higher
postop
ondemand
cxr
perform
indic
compar
nextmorn
routin
cxr
vs
p
therapeut
effi
caci
also
clearli
higher
postop
ondemand
cxr
need
intervent
morn
control
cxr
reduc
minim
p
produc
escal
respons
increas
score
use
eff
ectiv
within
trust
yet
mortal
high
patient
admit
diagnosi
pneumonia
score
may
eff
ectiv
risk
stratifi
cation
tool
predict
mortal
older
patient
guid
intens
care
admiss
jarvi
colleagu
develop
ew
base
laboratori
blood
test
use
conjunct
physiolog
ew
eff
ectiv
risk
stratifi
medic
patient
method
patient
admit
pneumonia
month
august
data
collect
receiv
requir
blood
test
data
includ
date
admiss
discharg
death
appropri
gender
haemoglobin
gdl
white
cell
count
l
sodium
mmoll
potassium
mmoll
urea
mmoll
creatinin
mmoll
albumin
gl
admiss
composit
ew
calcul
measur
outcom
result
patient
die
admiss
uncertain
whether
death
due
pneumonia
admiss
diagnosi
record
overal
mortal
analysi
data
show
strongli
posit
relationship
increas
ew
increas
risk
mortal
correl
coeffi
cient
conclus
observ
result
suggest
ew
base
laboratori
test
use
risk
stratifi
patient
pneumonia
could
use
treat
higher
score
aggress
earlier
ill
analysi
requir
determin
whether
age
contribut
factor
may
modifi
ew
need
determin
whether
laboratorybas
ew
risk
stratifi
cation
use
isol
whether
contribut
suffi
cientli
exist
physiolog
ew
combin
system
would
improv
outcom
patient
introduct
previou
studi
report
videoassist
thoracoscop
surgeri
vat
benefi
cial
pulmonari
lobectomi
concern
late
postop
period
open
thoracotomi
howev
earli
postop
period
rate
complic
highest
scarc
examin
studi
aim
compar
residu
pulmonari
function
pulmonari
lobectomi
patient
vat
standard
thoracotomi
approach
immedi
postop
period
conclus
preoper
lung
function
predict
sever
overestim
real
lung
capac
lobectomi
patient
immedi
postop
period
vat
lobectomi
seem
benefi
cial
point
earli
postop
lung
function
vat
lobectomi
consid
patient
poor
preoper
spirometri
result
ensur
better
postop
outcom
introduct
aim
studi
evalu
lung
ultrasound
lu
reaerat
score
re
predict
tool
noninvas
ventil
niv
effi
caci
gener
ward
acut
respiratori
failur
arf
treatment
even
icu
consid
safest
place
perform
niv
shortag
intens
bed
lead
niv
applic
outsid
icu
appropri
patient
select
treatmenttim
choic
adequ
monitor
staff
train
niv
applic
gener
ward
allow
one
safe
treat
patient
earli
stage
better
costeff
ectiv
data
assess
right
tool
evalu
niv
treatment
effi
caci
avail
method
present
preliminari
data
prospect
observ
ongo
studi
sixteen
patient
undergo
niv
treatment
outsid
icu
arf
origin
evalu
lu
three
time
niv
applic
minut
minut
niv
treatment
us
scan
perform
six
region
emithorax
lu
pattern
defi
ned
consolid
c
multipl
coalesc
bline
b
multipl
irregularli
space
bline
b
normal
aerat
lusr
calcul
detect
chang
us
pattern
compar
assess
outcom
defi
ned
niv
failur
case
tracheal
intub
death
within
week
arf
outset
otherwis
niv
success
ultrasound
societi
degum
ultrasonographi
surgeri
anaesthesia
medicin
invit
particip
onlin
survey
frequenc
exposur
patient
suspect
pneumothorax
frequenc
lu
use
assess
diagnost
accuraci
lu
rulingout
rulingin
pneumothorax
prefer
regard
technic
aspect
enquir
result
eightynin
physician
respond
averag
exposur
pneumothorax
case
fiftyfi
per
cent
respond
use
lu
alway
frequent
thirtyfour
per
cent
physician
rate
lu
alway
accur
accur
major
case
rule
pneumothorax
twentyon
per
cent
rate
lu
alway
accur
accur
major
case
rule
pneumothorax
physician
report
frequent
exposur
pneumothorax
patient
use
lu
higher
proport
case
high
caseload
sonograph
confi
dent
rule
pneumothorax
figur
total
diff
erent
combin
transduc
probe
orient
scan
mode
report
linear
transduc
sagitt
probeorient
bmode
mmode
scan
often
select
conclus
physician
use
lu
diagnosi
pneumothorax
modest
assess
diagnost
accuraci
gave
markedli
lower
score
report
clinic
trial
correl
frequenc
exposur
likelihood
lu
usag
confi
denc
diagnost
accuraci
warrant
research
natur
learn
curv
consider
variat
regard
technic
aspect
lu
refl
ect
ambigu
current
recommend
research
requir
establish
effi
cient
way
perform
lu
suspect
pneumothorax
eff
ort
need
made
promot
use
scenario
smoke
inhal
injuri
sii
progress
pulmonari
edema
pneumonia
acut
respiratori
distress
syndrom
sii
may
caus
bronchial
mucos
edema
hypothes
narrow
lumin
air
bronchu
due
bronchial
wall
edema
correl
respiratori
deterior
sii
patient
critic
care
volum
suppl
http
method
prospect
studi
patient
diagnosi
sii
accord
visual
bronchoscop
fi
nding
admiss
control
subject
thorac
highresolut
comput
tomographi
hrct
scan
obtain
within
hour
admiss
hospit
airway
wall
dimens
calcul
use
valid
method
imag
view
workstat
use
magnifi
cation
measur
overal
intern
l
diamet
bronchi
made
use
electron
calip
wall
thick
deriv
measur
l
lumin
area
ai
mm
total
airway
wall
area
ao
calcul
l
respect
use
formula
use
ratio
airway
wall
thick
total
diamet
td
ratio
percentag
lumin
area
la
ai
ao
ai
result
mean
age
patient
year
patient
men
mean
sd
diamet
bronchi
sii
patient
measur
mm
rang
mm
statist
signifi
cant
posit
associ
wall
thicken
express
td
ratio
lumin
narrow
express
la
develop
pneumonia
td
ratio
r
p
la
r
p
mechan
ventil
day
td
ratio
r
p
la
r
p
respect
statist
signifi
cant
associ
identifi
ed
td
ratio
la
initi
pf
ratio
infus
volum
initi
hour
icu
stay
day
outcom
mean
td
ratio
la
patient
sii
control
shown
use
hrct
scan
admiss
patient
sii
airway
wall
thicken
compar
normal
control
furthermor
airfl
ow
obstruct
due
bronchial
wall
edema
relat
develop
pneumonia
mechan
ventil
day
sii
patient
introduct
semiupright
posit
posit
ventil
patient
recommend
prevent
ventilatorassoci
pneumonia
vap
one
fi
rst
step
progress
earli
mobil
studi
ventil
intens
care
patient
semiupright
posit
compar
supin
posit
explor
whether
improv
oxygen
ventil
method
retrospect
studi
patient
mix
medic
surgic
neurolog
icu
studi
eff
ect
posit
peripher
oxygen
satur
spo
endtid
carbon
dioxid
etco
measur
bodi
posit
chang
total
bed
hillrom
result
supin
posit
obtain
half
hour
bodi
posit
chang
measur
taken
includ
spo
etco
conclus
demonstr
signifi
cant
increas
oxygen
satur
signifi
cant
decreas
endtid
co
head
bed
elev
mechan
ventil
believ
posit
therapi
intens
care
patient
import
semiupright
posit
easi
eff
ectiv
safe
treatment
icu
patient
posit
eff
ectiv
bundl
prevent
vap
fi
rst
step
progress
earli
mobil
also
eff
ectiv
oxygen
ventil
mechan
ventil
patient
clinic
benefi
headofb
elev
must
lead
standard
care
mechan
ventil
patient
sinc
semiupright
posit
standard
care
hospit
eff
ect
sit
armchair
mechan
ventil
patient
studi
enough
studi
group
patient
readi
wean
respiratori
pattern
mechan
work
breath
reclin
bed
sit
armchair
method
thirteen
patient
need
mechan
ventil
day
studi
volum
assistcontrol
mechan
ventil
spontan
breath
cpap
psv
posit
airway
esophag
pressur
fl
ow
regist
posterior
analysi
passiv
respiratori
mechan
measur
multipl
linear
regress
method
respiratori
drive
esophag
pressur
respiratori
eff
ort
use
pressur
time
product
ptp
result
control
mechan
ventil
respiratori
system
chest
wall
elast
signifi
cantli
higher
sit
compar
reclin
posit
er
vs
cmh
ol
vs
cmh
ol
respiratori
resist
similar
vs
cmh
olsecond
posit
loser
draw
pair
fi
rst
compar
mortal
diff
erenc
ventilatorfre
day
vfd
compar
outcom
endpoint
draw
result
activ
versu
placebo
group
compar
use
win
ratio
defi
ned
number
pair
activ
group
winner
divid
number
pair
result
draw
examin
sampl
size
power
characterist
win
ratio
endpoint
use
trial
simul
result
assum
mortal
rate
activ
arm
control
arm
power
twotail
test
mortal
would
requir
subject
per
arm
assumpt
diff
erenc
mean
vfd
favor
activ
arm
common
sd
subject
per
arm
provid
power
approxim
simul
win
ratio
result
pair
determin
mortal
simul
result
assum
result
within
pair
uncorrel
posit
correl
endpoint
within
pair
assum
power
win
ratio
endpoint
increas
conclus
win
ratio
method
clinic
meaning
straightforward
explain
method
could
provid
new
approach
power
superior
noninferior
trial
novel
antibiot
particular
method
allow
wellpow
phase
trial
potenti
decreas
requir
size
phase
trial
primari
object
assess
impact
failur
obtain
sputum
cultur
sc
among
patient
requir
intub
pneumonia
patient
admit
icu
sever
pneumonia
guidelin
recommend
obtain
lower
respiratori
tract
sampl
cultur
experi
suggest
rare
order
emerg
depart
ed
method
retrospect
review
chart
patient
admit
ed
diagnosi
pneumonia
requir
intub
fi
rst
hour
januari
novemb
patient
classifi
ed
sc
collect
collect
record
demograph
data
sc
result
antibiot
choic
deescal
ventilatorfre
day
day
mortal
icu
hospit
inferenti
statist
perform
use
spss
version
p
consid
signifi
cant
patient
review
intub
ed
sc
order
eight
ed
physician
sc
collect
diff
erenc
age
gender
sever
ill
measur
apach
score
two
group
icu
mortal
lower
sc
collect
group
vs
p
hospit
mortal
vs
p
antibiot
deescal
often
vs
p
patient
sc
collect
show
trend
toward
signifi
cantli
ventilatorfre
day
vs
p
conclus
sputum
cultur
rare
order
ed
physician
obtain
intub
patient
pneumonia
icu
hospit
mortal
higher
less
antibiot
deescal
trend
toward
fewer
ventilatorfre
day
eff
ort
improv
collect
sputum
cultur
patient
warrant
aim
determin
nonventilatori
factor
aff
ect
noninvas
mechan
ventil
nimv
success
patient
hypercapn
respiratori
failur
method
total
patient
includ
prospect
cohort
studi
follow
least
hour
icu
januari
novemb
diagnosi
hypercapn
respiratori
failur
patient
mmhg
decreas
paco
fi
rst
hour
accept
success
group
without
decreas
accept
unsuccess
group
among
patient
similar
nimv
applic
characterist
eff
ect
age
apach
ii
score
infect
bronchospasm
daili
respiratori
function
test
perform
portabl
spirometri
heart
failur
thyroid
dysfunct
physiolog
dead
space
ventil
vdvt
success
evalu
statist
analysi
test
mannwhitney
u
test
regress
analysi
use
introduct
averag
volumeassur
pressur
support
avap
develop
ensur
fi
xed
tidal
volum
along
conveni
advantag
pressur
support
ventil
studi
compar
avap
bipap
method
approv
obtain
hospit
ethic
committe
studi
thirtythre
patient
year
age
acut
respiratori
failur
result
either
intern
surgic
reason
includ
studi
studi
conduct
philip
v
ventil
includ
bipap
avap
mode
implement
protocol
noninvas
ventil
niv
includ
fi
rstli
bipap
applic
period
bi
without
interrupt
avap
applic
period
av
measur
basal
blood
ga
analysi
patient
inform
niv
would
practic
function
would
bipap
mode
ventil
paramet
adjust
follow
epap
cmh
ipap
cmh
patient
comfort
analyz
scale
rang
compat
mediumcompat
noncompat
bipap
ventil
level
arteri
blood
gase
ph
po
pco
spo
comfort
scale
hemodynam
data
record
minut
fi
rst
hour
second
hour
patient
monitor
hour
bipap
mode
mode
chang
avap
set
requir
rate
without
remov
mask
epap
set
adjust
follow
avap
cmh
pmin
max
cmh
tidal
volum
mlkg
bipap
mode
analyz
record
rate
arteri
blood
gase
comfort
scale
hemodynam
paramet
minut
fi
rst
hour
second
hour
case
agit
prevent
niv
patient
sedat
dexmedetomidin
result
analyz
patient
accord
bodi
mass
index
bmi
ph
pco
valu
patient
bmi
show
greater
improv
three
measur
avap
compar
bipap
p
patient
complianc
examin
number
patient
regard
comfort
bipap
period
fi
gure
avap
conclus
patient
comfort
higher
need
sedat
lower
avap
accord
result
obtain
studi
avap
posit
eff
ect
ph
ga
variat
patient
comfort
therefor
confi
dentli
use
clinic
practic
oxygen
index
outperform
pf
ratio
mortal
predict
k
davi
c
bourdeaux
peiri
gould
pf
ratio
wide
use
clinic
part
research
categoris
sever
respiratori
failur
howev
account
made
import
determin
oxygen
mean
airway
pressur
map
oxygen
index
oi
incorpor
map
suggest
accur
mean
determin
sever
respiratori
failur
addit
optim
time
assess
unclear
sought
answer
question
analys
larg
databas
patient
ventil
data
method
icu
bristol
royal
infi
rmari
use
electron
clinic
inform
system
ci
sinc
everi
hour
care
avail
analysi
result
ventil
patient
identifi
ed
pf
ratio
oi
calcul
worst
valu
determin
four
time
period
fi
rst
hour
ventil
logist
regress
analysi
use
creat
model
predict
unit
hospit
mortal
result
data
hour
care
patient
avail
analysi
exclud
nonventil
patient
transfer
ventil
anoth
icu
patient
provid
data
comparison
survivor
nonsurvivor
older
higher
oi
sofa
score
lower
pf
ratio
optim
time
calcul
oi
pf
ratio
mortal
predict
fi
rst
hour
ventil
model
use
worst
oi
better
predictor
icu
hospit
mortal
use
worst
pf
ratio
area
receiv
oper
curv
vs
conclus
analysi
suggest
oi
sensit
descriptor
sever
respiratori
failur
pf
ratio
calcul
perform
use
data
fi
rst
hour
ventil
introduct
wean
mechan
ventil
mv
compos
total
length
mv
besid
singl
reliabl
paramet
indic
patient
toler
extub
safe
rapid
shallow
breath
index
rsbi
rel
best
predict
paramet
initi
assess
readi
discontinu
mv
support
evalu
rsbi
valuabl
ttube
ventil
clinic
practic
alway
possibl
perform
assess
studi
aim
determin
best
mv
mode
pressur
combin
predict
success
rsbi
closest
valu
calcul
spontan
ventil
estim
patient
readi
wean
ttube
trial
patient
measur
spontan
ventil
perform
cosmoplu
novometrix
devic
capnographi
respiratori
monitoris
function
measur
perform
ventil
mean
age
studi
group
year
femal
mean
apach
ii
score
rsbi
diff
er
signifi
cantli
spontan
mode
combin
best
correl
spontan
mode
found
p
r
worst
combin
rsbi
calcul
combin
show
predict
valu
wean
success
respir
rate
f
higher
sbt
failur
group
sbt
success
group
measur
combin
threshold
valu
f
found
p
conclus
although
correl
rsbi
measur
ttube
rsbi
measur
diff
erent
mode
pressur
combin
especi
combin
threshold
valu
rsbi
detect
mv
predict
sbt
success
show
noninvas
neural
adjust
ventilatori
assist
nnava
improv
patientventil
interact
synchroni
recent
describ
new
set
nnava
abl
reduc
peak
electr
activ
diaphragm
eadipeak
dyspnea
assess
visual
analogu
scale
vasd
compar
npsv
nnava
patient
undergo
niv
helmet
improv
rate
pressur
therefor
design
physiolog
studi
evalu
compar
eff
ect
npsv
nnava
vasd
eadipeak
pressur
rate
arteri
blood
gase
abg
method
fourteen
patient
undergo
noninvas
ventil
acut
respiratori
failur
underw
three
random
trial
npsv
inspiratori
support
posit
endexpiratori
pressur
peep
cmh
fastest
rate
pressur
nnava
nava
level
achiev
compar
eadipeak
npsv
nava
level
cmh
maximum
inspiratori
airway
pressur
paw
set
valu
correspond
peep
inspiratori
support
npsv
oxygen
inspiratori
fraction
peep
remain
unmodifi
ed
throughout
studi
period
last
minut
trial
analyz
pawtim
product
initi
ms
onset
ventil
pressur
initi
ms
onset
eadi
swing
index
ideal
ptp
respect
trigger
area
ptpt
comput
abg
vasd
assess
end
trial
conclus
compar
npsv
nnava
mask
reduc
vasd
assur
optim
pressur
rate
trigger
perform
without
aff
ect
breath
pattern
neural
drive
abg
introduct
neural
adjust
ventilatori
assist
nava
far
use
minim
sedat
intens
care
patient
nava
appli
patient
oper
room
eff
ect
diff
erent
sedativesanesthet
electr
activ
diaphragm
edi
far
studi
aim
studi
compar
eff
ect
sevofl
uran
propofol
edi
signal
breath
pattern
sedat
anesthesia
also
combin
remifentanil
method
random
crossov
studi
compar
sevofl
uran
propofol
sedat
anesthesia
juvenil
pig
remifentanil
ad
period
anesthet
agent
administr
anim
ventil
nava
fi
xed
level
throughout
studi
respiratori
variabl
measur
last
minut
exposur
edi
signal
spontan
breath
preserv
anesthet
breath
variabl
express
coeffi
cient
variat
sdmean
tidal
volum
cvvt
high
drug
cvvt
greater
propofol
sevofl
uran
cvvt
vs
sedat
cvvt
vs
anesthesia
frequenc
sigh
higher
propofol
sedat
vs
sighshour
anesthesia
vs
sighshour
sevofl
uran
conclus
nava
appli
propofol
sevofl
uran
anesthesia
pig
wellpreserv
edi
spontan
breath
natur
variabl
maintain
nava
even
anesthesia
contrast
sevofl
uran
propofol
sedat
anesthesia
associ
high
frequenc
sigh
postsigh
apnea
probabl
due
central
induc
mechan
data
warrant
studi
nava
human
undergo
anesthesia
surgeri
neuromuscular
blockad
requir
singlecent
parallelgroup
trial
randomli
assign
adult
patient
present
signal
defi
cient
ga
exchang
pao
fio
peep
cmh
immedi
postop
period
either
intens
alveolar
recruit
standard
protocol
use
lowtid
volum
ventil
mlkgibw
hypothesi
aggress
alveolar
recruit
protocol
translat
better
lung
complianc
better
ga
exchang
fewer
pulmonari
complic
reduc
length
hospit
stay
compar
control
group
result
total
patient
enrol
studi
patient
standard
protocol
group
intens
alveolar
recruit
group
patient
intervent
group
present
higher
incid
pneumonia
patient
control
group
vs
p
length
hospit
stay
shorter
among
patient
receiv
intens
alveolar
recruit
among
receiv
standard
care
vs
day
p
diff
erenc
group
accord
extrapulmonari
complic
mortal
conclus
trial
intens
alveolar
recruit
protocol
associ
protect
mechan
ventil
strategi
reduc
pulmonari
complic
length
hospit
stay
patient
undergo
cardiac
surgeri
use
transthorac
endoscopi
continu
record
imag
subpleur
alveoli
recruit
manoeuvr
diff
erent
steadi
plateau
pressur
manoeuvr
method
investig
two
group
rat
anim
ventil
zeep
peep
mbar
fio
tidal
volum
mlkg
doubl
lowfl
ow
manoeuvr
design
consist
two
consecut
lowfl
ow
manoeuvr
peak
pressur
mbar
interrupt
plateau
phase
diff
erent
pressur
mbar
alveolar
size
peak
pressur
plateau
level
analyz
record
video
frame
frame
therefor
alveolar
outlin
alveoli
mark
manual
outlin
area
calcul
complianc
tidal
breath
manoeuvr
calcul
use
twopoint
complianc
group
analysi
alveolar
area
reveal
alveolar
size
second
peak
manoeuvr
diff
er
signifi
cantli
compar
fi
rst
peak
zeep
group
peep
group
plateau
phase
slight
increas
alveolar
size
higher
plateau
pressur
slope
linear
regress
plateau
mbar
ms
zeep
group
ms
peep
group
plateau
mbar
ms
zeep
group
ms
peep
group
manoeuvr
complianc
increas
zeep
group
peep
group
conclus
healthi
lung
recruit
alveoli
stay
stabl
size
wide
pressur
rang
recruit
manoeuvr
lead
increas
alveolar
size
increas
complianc
plateau
phase
alveolar
size
increas
depend
pressur
lead
assumpt
recruit
pressur
depend
also
time
depend
refer
introduct
lungprotect
mechan
ventil
requir
posit
endexpiratori
pressur
peep
tidal
volum
vt
chosen
regard
individu
state
lung
shape
intratid
compliancevolum
profi
le
might
refl
ect
state
lung
atelectat
open
overdistend
could
therefor
classifi
ed
shape
categori
translat
peep
suggest
intratid
resistancevolum
profi
le
might
refl
ect
intratid
open
collaps
lung
use
respiratori
data
anim
studi
suggest
classifi
cation
resist
shape
categori
base
slope
r
v
profi
le
method
fifteen
pig
lavageinduc
lung
damag
ventil
two
peep
level
mbar
three
tidal
volum
mlkg
bodyweight
complianc
c
v
resist
r
v
profi
le
individu
anim
ventil
set
calcul
respiratori
data
use
glidingslic
method
c
v
profi
le
associ
one
six
suggest
shape
categori
depend
mean
r
v
slope
anim
ventil
set
use
basi
classifi
cation
resist
shape
categori
resist
shape
categori
compar
complianc
shape
categori
individu
anim
test
whether
similar
peep
suggest
result
method
result
small
peep
vt
typic
associ
increas
c
v
decreas
c
v
correspond
larg
peep
vt
classifi
cation
c
v
profi
le
one
six
complianc
shape
categori
possibl
shape
r
v
profi
le
individu
anim
remark
similar
r
v
slope
typic
largest
peep
vt
set
derecruit
like
smallest
overdistens
like
base
classifi
cation
scheme
defi
ned
slope
mbar
categori
increas
peep
slope
mbar
categori
keep
peep
slope
mbar
categori
decreas
peep
comparison
resist
complianc
shape
categori
singl
anim
show
good
correl
conclus
resist
shape
categori
might
provid
addit
guidanc
peep
set
combin
complianc
resist
shape
categori
could
improv
lungprotect
ventil
introduct
protect
ventilatori
strategi
prevent
vili
patient
larger
nonaer
area
hyperinfl
ation
may
occur
tidal
ventil
even
protect
ventilatori
strategi
glide
sign
use
marker
pneumothorax
studi
quantifi
preoper
degre
pleural
adhes
thorac
surgeri
patient
studi
measur
variat
glide
g
static
complianc
introduct
bacteri
pneumonia
common
indic
mechan
ventil
icu
ventil
high
posit
endexpiratori
pressur
peep
low
tidal
volum
vt
recommend
patient
adult
respiratori
distress
syndrom
improv
clinic
outcom
compar
ventil
low
peep
mediumhigh
vt
howev
eff
ect
vt
peep
bacteri
growth
lung
tissu
known
studi
contrast
eff
ect
protect
ventil
protocol
standard
mediumhigh
vt
lower
peep
protocol
lung
bacteri
growth
lung
edema
format
lung
injuri
perform
porcin
model
intens
care
frequent
found
pathogen
pseudomona
aeruginosa
method
sixteen
pig
anesthet
random
mechan
ventil
two
diff
erent
ventil
set
hour
protv
peep
cmh
vt
mlkg
n
control
peep
cmh
vt
mlkg
n
hour
colonyform
unit
cfu
p
aeruginosa
instil
intratrach
end
experi
six
postmortem
lung
biopsi
predefi
ned
declivi
locat
taken
anim
cultur
weight
measur
result
p
aeruginosa
growth
lung
tissu
wet
dri
ratio
lower
protv
group
control
group
p
p
pao
fio
higher
protv
group
control
group
p
tabl
conclus
protect
ventil
low
vt
higher
peep
reduc
p
aeruginosa
growth
lung
tissu
lung
edema
format
lung
injuri
contrast
mediumhigh
vt
lower
peep
ventil
porcin
pneumonia
model
previous
oxygenationbas
method
shown
relat
ctmeasur
eff
ect
peep
lung
mechan
indic
lung
aerat
better
quantifi
ed
use
vq
mismatch
pulmonari
shunt
low
high
vq
mismatch
estim
vari
fio
measur
ventil
blood
ga
content
method
preliminari
result
six
ard
patient
ct
scan
taken
static
condit
peep
cmh
vq
estim
cmh
shunt
low
vq
alveolar
lung
capillari
po
diff
erenc
high
vq
alveolar
lung
capillari
pco
diff
erenc
nonaer
poor
aerat
normal
aerat
plu
hyperinfl
ation
calcul
hounsfi
eld
unit
aerat
vq
compar
pearson
result
peep
improv
vq
four
patient
shunt
reduc
nosmal
increas
two
deterior
larg
shunt
increas
systemat
chang
seen
figur
show
respons
peep
two
patient
chang
nonaer
region
shunt
correl
p
correl
found
poorli
aerat
region
p
hyperinfl
ate
region
p
conclus
preliminari
case
chang
shunt
nonaer
tissu
correl
well
howev
result
indic
poor
agreement
chang
low
high
vq
lung
morpholog
introduct
data
collect
third
intern
studi
mechan
ventil
compar
data
netherland
global
cohort
hypothes
tidal
volum
vt
smaller
appli
posit
endexpiratori
pressur
peep
higher
netherland
compar
global
cohort
also
compar
use
noninvas
ventil
niv
outcom
cohort
method
posthoc
analysi
prospect
observ
studi
patient
receiv
invas
mechan
ventil
conduct
figur
abstract
pcc
mean
g
cm
mean
cstat
diff
erent
peep
axi
pplat
conclus
accord
hypothesi
vt
smaller
appli
peep
higher
dutch
cohort
patient
cohort
receiv
larger
vt
recommend
prevent
ard
hypercapnia
main
criterion
use
niv
suggest
niv
could
use
often
netherland
lower
incid
delirium
worldwid
could
caus
diff
erenc
sedat
may
due
use
method
screen
introduct
analysi
dynam
volumedepend
complianc
provid
rational
basi
peep
titrat
mechan
ventil
due
volum
depend
complianc
respiratori
system
nonlinear
within
singl
breath
intratid
refl
ect
compliancevolum
curv
cv
curv
shape
cv
curv
determin
peep
level
mechan
stress
mechan
ventil
lung
expect
minim
lung
ventil
within
volum
rang
maxim
complianc
present
new
graphic
user
interfac
gui
support
clinician
titrat
peep
level
mean
shape
categori
analysi
cv
curv
method
decis
support
system
form
computerbas
gui
develop
test
use
respiratori
data
obtain
patient
univers
medic
center
freiburg
new
clinicianori
approach
provid
breathbybreath
visual
patient
individu
intratid
cv
curv
dynam
complianc
analyz
use
glidingslic
method
result
intratid
cv
curv
classifi
ed
one
six
shape
categori
accord
defi
nition
mol
colleagu
actual
shape
categori
cv
curv
indic
whether
peep
set
chang
whether
volum
rang
maxim
complianc
reach
gui
provid
breathbybreath
visual
intratid
cv
curv
intuit
individu
complianc
shape
categori
base
complianc
shape
categori
diff
erent
guidelin
peep
titrat
appli
object
ventil
patient
mechan
within
rang
maxim
complianc
conclus
newli
develop
gui
allow
breathbybreath
visual
intratid
cv
curv
high
reliabl
autom
classifi
cation
intratid
cv
curv
complianc
shape
categori
provid
rational
basi
patientindividu
peep
titrat
refer
cyclic
strain
lung
tissu
mechan
ventil
compar
spontan
breath
associ
larg
increas
mechan
load
due
larger
pressur
amplitud
higher
acceler
forc
addit
load
may
chang
tissu
mechan
may
lead
tissu
damag
although
experiment
mechanostimul
vitro
wide
use
method
analys
mechan
load
cell
tissu
vitro
experi
ventilationanalogu
stimul
miss
work
compar
fi
rst
time
chang
monolay
lung
cell
ventilationanalogu
stimul
spontaneousbreath
analogu
mechanostimul
aim
studi
show
timedepend
diff
erenc
induct
apoptosi
due
mechan
overload
fl
uoresc
microscop
observ
method
alveolar
epitheli
cell
grown
rgdcoat
highli
fl
exibl
polydimethyl
siloxan
membran
becom
approxim
confl
uent
cell
stain
hoechst
continu
observ
fl
uoresc
microscopi
cell
stimul
either
ventilationanalogu
spontaneousbreath
analogu
profi
le
set
frequenc
hz
surfac
increas
cell
monolay
stimul
time
period
hour
bioreactor
result
analysi
fl
uoresc
microscop
imag
show
fi
rst
evid
apoptosi
induct
minut
ventilationanalogu
stimul
contrast
apoptosi
induct
spontaneousbreath
analogu
stimul
occur
minut
conclus
observ
cell
stimul
continu
fl
uoresc
microscop
imag
allow
us
analys
timedepend
induct
apoptosi
aspect
diff
erent
stimuli
could
prove
hypothesi
ventilationanalogu
stimul
wors
cellular
viabil
spontaneousbreath
analogu
stimul
futur
direct
optic
track
cell
damag
allow
one
analys
stimul
profi
le
well
therebi
improv
stimul
profi
le
ultim
ventil
profi
le
well
measur
dynam
pulmonari
shunt
fraction
could
help
assess
degre
cylic
rd
howev
common
method
measur
pulmonari
shunt
allow
dynam
serial
measur
one
respiratori
cycl
studi
measur
serial
dynam
pulmonari
shunt
fraction
one
breath
cycl
investig
eff
ect
posit
endexpiratori
pressur
peep
cyclic
rd
artifi
cialli
ventil
pig
salin
washout
induc
acut
lung
injuri
method
pig
n
anesthet
ventil
tidal
volum
mlkg
two
level
peep
cmh
condit
hemodynam
respiratori
multipl
inert
ga
analysi
micropor
membran
inlet
mass
spectrometeri
mmimsmiget
oscillog
usa
measur
taken
salin
washout
retent
measur
fi
time
one
breath
cycl
taken
refl
ection
shunt
fraction
miget
sampl
acquisit
synchron
electr
imped
tomographi
observ
dynam
chang
pulmonari
shunt
fraction
express
chang
retent
within
breath
cycl
record
induct
ali
healthi
lung
decreas
sf
retent
end
inspir
return
baselin
level
expir
contrast
retent
increas
ali
inspir
decreas
expir
healthi
pig
ventil
increas
retent
end
inspir
return
baselin
expir
similar
chang
observ
pig
ali
ali
shunt
decreas
throughout
inspir
return
baselin
level
expir
conclus
serial
dynam
pulmonari
shunt
measur
mechan
ventil
show
distinct
variat
respiratori
cycl
healthi
injur
lung
increas
peep
cmh
alter
pattern
dynam
pulmonari
shunt
ali
thu
serial
assess
dynam
pulmonari
shunt
fraction
retent
mmimsmiget
could
prove
use
optim
mechan
ventil
healthi
injur
lung
quantifi
rv
function
echocardiographi
challeng
due
shape
posit
ste
rel
new
feasibl
sensit
angleindepend
method
describ
cardiac
deform
strain
particularli
use
analyz
rv
function
rv
free
wall
strain
rvfw
shown
pulmonari
hypertens
cohort
method
ten
pig
kg
anaesthet
fulli
mechan
ventil
mgkg
subject
stepwis
escal
level
peep
interv
cmh
rv
imag
obtain
use
intracardiac
echocardiographi
optim
framer
endocardi
defi
nition
analyz
offl
ine
fac
rvfw
use
veloc
vector
imag
siemen
result
escal
level
peep
strongli
associ
signifi
cant
reduct
mean
blood
pressur
r
p
fac
r
p
rvfw
r
p
pair
test
indic
signifi
cant
reduct
rvfw
step
increas
peep
fac
show
signifi
cant
deterior
cmh
peep
signifi
cant
hypotens
decreas
mmhg
occur
cmh
peep
rvfw
decreas
larger
extent
earlier
fac
mean
blood
pressur
increas
level
peep
conclus
rvfw
measur
ste
sensit
method
determin
rv
dysfunct
induc
peep
rvfw
display
stronger
associ
greater
deterior
earlier
reduct
fac
mean
blood
pressur
escal
level
peep
potenti
interest
implic
role
ste
manag
peep
level
critic
ill
patient
acut
lung
injuri
improv
oxygen
ventil
patient
cardiogen
shock
sever
progress
hypoxemia
method
cardiac
cardiac
surgic
patient
cardiogen
shock
aliard
admit
icu
enrol
januari
septemb
data
collect
admiss
patient
convent
mode
ventil
hour
switch
aprv
enrol
patient
hemodynam
monitor
pulmonari
arteri
cathet
frequent
echocardiographi
assess
retrospect
analysi
data
perform
result
complet
dataset
obtain
patient
cardiac
index
increas
p
serum
lactat
decreas
p
central
venou
satur
increas
p
peak
airway
pressur
decreas
p
increas
mean
airway
pressur
hypoxemia
improv
within
fi
rst
hour
alveolar
recruit
pao
fio
increas
p
less
use
vasopressor
sedat
neuromuscular
blockag
cours
aprv
applic
conclus
patient
seri
aprv
signifi
cantli
improv
oxygen
allow
spontan
breath
reduct
peak
airway
pressur
furthermor
strategi
improv
hemodynam
facilit
wean
mv
therefor
data
suggest
ventil
modal
favor
result
appear
eff
ectiv
altern
lung
recruit
patient
cardiogen
shock
acut
lung
injuri
cours
stay
cardiac
icu
develop
experiment
model
vili
ventil
piglet
strain
tvfrc
possibl
lung
inhomogen
act
stress
raiser
within
lung
parenchyma
local
multipli
pressur
healthi
lung
pleural
surfac
vessel
bronchi
detect
natur
lung
inhomogen
studi
develop
vili
ct
scan
determin
fi
rst
lung
lesion
develop
method
piglet
sedat
orotrach
intub
instrument
arteri
central
venou
cathet
urinari
cathet
whole
studi
perform
anim
ct
scan
facil
equip
icu
ct
scan
perform
everi
hour
respiratori
paramet
plateaupeak
pressur
chang
defi
ned
new
lesion
lung
region
appear
poorli
infl
atednot
infl
ate
lung
region
present
previou
ct
scan
imag
select
fi
rst
ct
scan
relev
number
new
lesion
appear
manual
delin
lesion
lesion
classifi
ed
closenot
close
pleural
surfac
result
six
piglet
studi
kg
ventil
tv
ml
mlkg
develop
vili
defi
ned
radiolog
infi
ltrate
present
pulmonari
fi
eld
ct
scan
plu
develop
lung
edema
fi
rst
ct
scan
lesion
appear
median
lesion
iq
rang
present
lesion
locat
near
pleura
nine
near
vesselsbronchi
see
figur
conclus
experiment
model
vili
fi
rst
lung
lesion
appear
pleural
surfac
mutipl
nonmutu
exclus
possibl
explan
possibl
pleural
surfac
act
stress
raiser
mechan
friction
lung
rib
high
tidal
volum
lead
parenchim
injuri
lung
skeleton
fanlik
structur
start
hilum
go
pleural
surfac
lead
increas
stressstrain
subpleur
region
introduct
mechan
ventil
energi
deliv
respiratori
system
rs
dissip
within
recov
expir
amount
unrecov
energi
repres
mechan
work
done
rs
ventil
may
relat
develop
ventilatoryinduc
lung
injuri
vili
unrecov
energi
measur
hysteresi
area
pressurevolum
pv
curv
static
dynam
condit
explor
energi
dissip
insid
rs
method
fi
piglet
weight
kg
gener
anesthesia
record
pv
curv
quantifi
dynam
dissip
energi
de
increas
tidal
volum
tv
increas
respiratori
rate
rr
record
pv
curv
tv
infl
ate
supersyring
ml
quantifi
static
de
also
quantifi
ed
airway
de
connect
postmortem
isol
tracheobronchi
tree
ventil
record
pv
curv
respiratori
set
previous
describ
introduct
ctscan
quantit
analysi
qct
repres
gold
standard
assess
lung
aerat
recruit
ard
patient
lung
ultrasound
lu
propos
bedsid
nonirradi
altern
assess
lung
recruit
identifi
patient
may
benefi
higher
peep
level
compar
two
method
assess
peepinduc
lung
aerat
chang
method
lu
wholelung
ct
scan
perform
ard
sedat
paralyz
mechan
ventil
patient
peep
cmh
lu
perform
consid
six
area
lung
comprehens
scan
intercost
space
area
assign
area
score
aerat
normal
lung
noncoalesc
bline
coalesc
bline
consolid
cumul
lu
score
luss
rang
two
lung
obtain
sum
area
individu
score
area
score
averag
pertain
lu
fi
nding
lu
recruit
upon
peep
increas
cmh
defi
ned
switch
least
three
area
well
aerat
area
score
lusbas
assess
lung
aerat
lung
recruit
compar
qct
fi
nding
correspond
nonaer
tissu
qct
luss
n
p
good
linear
correl
found
reduct
lu
consolid
area
area
score
versu
reduct
qct
nonaer
volum
r
reduct
lu
poorli
aerat
area
area
score
versu
reduct
qct
poorli
aerat
volum
r
chang
lu
least
three
area
well
aerat
lu
recruit
n
correspond
qct
increas
wellaer
lung
volum
g
versu
g
lu
nonrecruit
group
n
p
conclus
preliminari
data
suggest
lu
could
accur
tool
assess
lung
aerat
recruit
bedsid
avoid
risk
workload
relat
use
ct
scan
refer
introduct
grow
evid
suggest
long
total
lung
capac
overcom
dynam
tidal
volum
vt
injuri
static
posit
endexpiratori
pressur
peep
lung
deform
lung
behav
like
viscoelast
bodi
hysteresi
may
play
role
develop
ventilatorinduc
lung
injuri
aim
studi
investig
eff
ect
increas
vt
peep
lung
hysteresi
method
eight
healthi
piglet
measur
total
hysteresi
peak
inspiratori
pressur
ppeak
randomli
increas
vt
peep
peep
fi
xed
vt
extrapol
drop
airway
pressur
endinspiratori
paus
hysteresi
attribut
lung
parenchyma
comput
total
hysteresi
ppeak
vt
main
fi
nding
shown
figur
p
valu
refer
oneway
repeatedmeasur
analysi
varianc
conclus
lung
hysteresi
increas
vt
peep
studi
need
prospect
evalu
role
lung
hysteresi
pathogenesi
ventilatorinduc
lung
injuri
introduct
mechan
ventil
mv
aim
enhanc
blood
oxygen
remov
carbon
dioxid
howev
excess
hyperinfl
ation
mv
may
caus
lung
injuri
method
eighteen
cat
kg
anesthet
propofol
load
dose
mgkg
constant
rate
infus
mgkg
minut
neuromuscular
blockad
achiev
rocuronium
mgkgminut
lung
initi
mechan
ventil
fio
peak
inspiratori
pressur
ppeak
cmh
minut
ppeak
increas
cmh
increment
cmh
everi
minut
follow
ppeak
decreas
cmh
everi
minut
reach
ppeak
cmh
ventil
maintain
respiratori
rate
inspiratori
time
breathsminut
second
respect
ppeak
increment
appli
paus
comput
tomographi
ct
scan
thorax
area
radiograph
attenu
hounsfi
eld
unit
hu
classifi
ed
overinsuffl
ation
hu
normal
insuffl
ation
hu
atelectas
hu
split
lung
three
proport
gravit
zone
ii
iii
apex
base
three
zone
present
increas
overinsuffl
ate
area
decreas
area
normal
insuffl
ation
increas
ppeak
cmh
cmh
area
overinsuffl
ation
normal
insuffl
ation
zone
ii
iii
respect
cmh
area
overinsuffl
ation
normal
insuffl
ation
zone
ii
iii
respect
conclus
higher
proport
overli
distend
pulmonari
area
high
ppeak
may
increas
risk
lung
injuri
lowest
ppeak
cmh
show
less
potenti
lung
injuri
higher
area
normal
insuffl
ation
less
area
overinsuffl
ation
gravit
zone
introduct
activ
lymphocyt
apoptosi
reduc
endogen
nitric
oxid
predictor
advers
outcom
newborn
mechan
ventil
aim
improv
result
treatment
studi
eff
ect
inhal
nitric
oxid
immun
system
newborn
respiratori
diseas
mechan
ventil
method
permiss
ethic
committe
control
random
blind
clinic
trial
includ
newborn
respiratori
diseas
mechan
ventil
random
perform
method
envelop
group
n
patient
receiv
inhal
nitric
oxid
concentr
ppm
hour
control
level
methemoglobin
pulmonox
mini
messer
ii
therapeut
austria
group
ii
n
receiv
inhal
admiss
day
studi
subpopul
lymphocyt
oneparamet
immunophenotyp
use
reagent
immunotech
beckman
coulter
usa
fi
tzlabel
monoclon
antibodi
rel
content
lymphocyt
earli
late
apoptosi
use
annexin
v
label
fitk
propidium
iodid
pl
label
pe
saltag
usa
result
beckman
coulter
epic
xl
cytomet
usa
statist
power
studi
result
group
rel
group
ii
day
regist
increas
matur
monocyt
p
reduct
rel
content
lymphocyt
apoptosi
annexin
v
fitc
pi
annexin
v
fitc
pi
p
durat
mechan
ventil
day
p
patient
surviv
none
patient
show
clinic
laboratori
evid
advers
eff
ect
inhal
nitric
oxid
group
ii
seven
newborn
die
durat
mechan
ventil
survivor
day
conclus
inhal
nitric
oxid
activ
monocytemacrophag
immun
stabil
apoptosi
tlymphocyt
reduc
mortal
durat
mechan
ventil
newborn
respiratori
diseas
mechan
ventil
introduct
sepsisinduc
diaphragm
dysfunct
sidd
wide
describ
literatur
condit
aff
ect
diaphragm
muscl
character
contractil
loss
function
associ
high
mortal
assess
around
previou
studi
investig
pathogenesi
ventilatorinduc
diaphragmat
dysfunct
vidd
lipid
metabol
alter
microcirculatori
function
process
studi
design
investig
diaphragm
muscl
eff
ect
lpsinduc
endotoxemia
rabbit
undergo
two
diff
erent
mode
mechan
ventil
method
prospect
random
anim
studi
invas
monitor
mechan
ventil
new
zealand
white
rabbit
rabbit
random
control
n
control
mechan
ventil
cmv
n
pressur
support
ventil
psv
n
cmv
psv
lpsinduc
endotoxemia
cmvlp
psvlp
respect
n
endotoxemia
induc
lp
inject
cmvlp
psvlp
group
rabbit
anesthet
ventil
hour
except
control
minut
cathet
abl
detect
electr
activ
diaphragm
place
evalu
diaphragm
contractil
baselin
hour
hour
evalu
diaphragm
microcircul
assess
sidestream
darkfi
eld
videomicroscopi
mitochondria
membran
potenti
lipid
accumul
diaphragm
muscular
fi
ber
structur
result
endotoxem
anim
hour
diaphragm
contractil
fi
ber
structur
microcircul
mitochondri
membran
potenti
lipid
accumul
sever
compromis
cmv
psv
group
moreov
slight
signifi
cant
increas
lipid
accumul
observ
cmv
psv
group
comparison
control
p
conclus
endotoxem
rabbit
impair
microcircul
result
increas
lipid
accumul
disturb
mitochondria
membran
potenti
contractil
diaphragm
microvascular
alter
observ
ventil
nonendotoxem
anim
moreov
diaphragm
contractil
dysfunct
pronounc
endotoxem
anim
refer
conclus
studi
add
literatur
use
hfov
patient
manag
replic
exist
evid
respect
popul
age
incid
mortal
whilst
pf
ratio
improv
initi
hfov
patient
subsequ
long
critic
care
hospit
stay
uncertainti
regard
use
hfov
ard
may
valuabl
treatment
patient
ventil
strategi
employ
subsequ
consequ
patient
requir
evalu
aim
studi
eit
monitor
tool
tidal
ventil
tv
redistribut
follow
switch
patient
volumecontrol
ventil
vcv
airway
pressur
releas
ventil
aprv
patient
sever
ard
method
six
patient
sever
ard
pplat
cm
includ
studi
patient
ventil
ardsnet
strategi
subject
eit
analysi
region
tv
distribut
monitor
eit
system
pulmovista
medic
gmbh
germani
divid
lung
fi
eld
four
sames
region
interest
level
cellfre
dna
cfdna
increas
prognost
valu
sepsi
present
studi
eff
ect
tidal
volum
peep
arteri
transorgan
level
cfdna
investig
porcin
postop
sepsi
model
method
two
group
anaesthetis
pig
ventil
either
protect
ventil
vt
mlkg
peep
cmh
n
control
vt
mlkg
peep
cmh
n
hour
arteri
hepat
vein
portal
vein
jugular
bulb
catheter
continu
endotoxin
infus
hour
start
hour
laparotomi
simul
surgic
procedur
group
receiv
protect
ventil
show
lower
level
cfdna
arteri
blood
compar
control
p
transhepat
level
cfdna
higher
compar
transsplanchn
level
experi
p
eff
ect
attenu
group
receiv
protect
ventil
diff
erenc
group
detect
blood
sampl
jugular
bulb
conclus
experiment
postop
sepsi
protect
ventila
tion
suppress
arteri
level
cfdna
liver
seem
signifi
cant
contributor
system
cfdna
level
eff
ect
suppress
protect
ventil
introduct
hfov
promis
rescu
therapi
refractori
hypoxia
sever
ard
method
retrospect
compar
studi
retriev
data
patient
infl
uenzarel
sever
ard
treat
icu
octob
april
icu
one
hfov
machin
pandem
patient
divid
two
group
hfov
group
receiv
hfov
fi
rst
elig
convent
lung
protect
ventil
clpv
group
receiv
hfov
fi
rst
elig
due
nonavail
hfov
elig
criteria
rescu
therapi
hfov
pf
ratio
peep
need
cm
pplat
cm
clpv
select
omiss
bia
hfov
applic
hfov
appli
fi
rst
elig
patient
patient
demograph
data
laboratori
paramet
hemodynam
variabl
oxygen
ventil
set
record
clpv
fi
rst
hfov
elig
patient
total
patient
met
rescu
therapi
criteria
group
hfov
group
patient
clpv
group
patient
depend
upon
modal
ventil
receiv
satisfi
fi
rsttime
hfov
elig
criteria
group
compar
diff
erenc
fisher
test
qualit
variabl
anova
quantit
variabl
import
protect
lung
ventil
reduc
mortal
adult
respiratori
distress
syndrom
ard
patient
well
describ
howev
suboptim
complianc
recommend
tidal
volum
report
therefor
wish
assess
complianc
adher
protect
lung
ventil
patient
risk
develop
ard
method
retrospect
review
done
mechan
ventil
patient
icu
tallaght
hospit
period
februari
juli
hourli
tidal
volum
record
conclus
complianc
protect
lung
ventil
icu
suboptim
may
due
lack
educ
guidelin
unit
regard
protect
lung
ventil
moreov
accur
record
patient
height
determin
predict
bodi
weight
document
facilit
accur
tidal
volum
calcul
protect
lung
ventil
introduct
mechan
ventil
expir
occur
passiv
determin
recoil
forc
respiratori
system
experiment
studi
pig
could
fi
nd
linear
expiratori
fl
ow
via
flowcontrol
expir
flex
lung
protect
util
electr
imped
tomographi
eit
aim
investig
mechan
underli
lungprotect
eff
ect
flex
method
experi
approv
local
anim
welfar
committe
twelv
pig
oleic
acidinduc
lung
injuri
ventil
volumecontrol
mode
vcv
six
anim
expiratori
fl
ow
linear
via
flex
peep
set
achiev
similar
mean
airway
pressur
control
group
n
flex
group
n
use
eit
local
distribut
ventil
measur
alveolar
derecruit
nofl
ow
phase
late
expir
quantifi
ed
result
ventil
flex
nofl
ow
phase
late
expir
reduc
compar
passiv
expir
derecruit
nofl
ow
phase
clearli
reduc
flex
compar
vcv
furthermor
intratid
ventil
homogen
distribut
ventil
flex
compar
convent
passiv
expir
conclus
comparison
convent
vcv
passiv
expir
nofl
ow
phase
late
expir
reduc
time
lung
persist
lowest
pressur
level
peep
breath
reduc
lowpressur
time
associ
reduc
endtid
derecruit
lung
mechan
stabil
recruit
sustain
airway
pressur
throughout
expir
phase
distribut
ventil
homogen
mechan
alveolar
recruit
mainten
explain
lungprotect
eff
ect
flex
introduct
numer
paramet
suggest
predict
wean
mechan
ventil
howev
paramet
limit
success
predict
wean
outcom
aim
studi
assess
success
minut
peak
fl
ow
rate
spontan
peak
inspiratori
fl
ow
rate
spif
spontan
peak
expiratori
fl
ow
rate
spef
measur
spontan
breath
trial
sbt
predict
wean
outcom
figur
conclus
posit
fb
hour
preced
sbt
predict
wf
copd
individu
recogn
intervent
perform
order
acceler
wean
process
brain
natriuret
peptid
level
avail
rapid
shallow
breath
index
rsbi
consid
good
paramet
predict
mechan
ventil
liber
hypothes
rsbi
provid
benefi
clinic
readi
criteria
met
method
adult
acut
respiratori
requir
mv
hour
exclud
copd
assess
daili
liber
protocol
figur
rsbi
step
rsbi
record
blind
research
liber
process
continu
regardless
rsbi
result
primari
outcom
success
rate
mechan
ventil
liber
without
rsbi
result
analysi
case
clinic
characterist
present
tabl
statist
signifi
cant
diff
erenc
use
clinic
readi
use
clinic
readi
rsbi
vs
p
conclus
inclus
rsbi
standard
mechan
ventil
liber
protocol
patient
met
clinic
readi
criteria
signifi
cantli
increas
success
rate
mechan
ventil
liber
vap
confi
rmed
posit
microbiolog
approxim
onethird
patient
suspect
vap
impli
scope
improv
antibiot
stewardship
singlecentr
studi
bronchoalveolar
lavag
fl
uid
balf
infl
ammatori
mediat
particular
beta
neutrophil
proteas
demonstr
potenti
biomark
exclud
vap
aim
valid
fi
nding
multicentr
studi
method
conduct
prospect
multicentr
observ
studi
patient
clinic
suspect
vap
icu
across
uk
vap
confi
rmed
growth
potenti
pathogen
balf
colonyform
unitsml
matrix
human
neutrophil
elastas
hne
measur
balf
cytometr
bead
array
hne
measur
serum
patient
dichotomis
vap
conclus
studi
demonstr
eff
ectiv
exclud
vap
valid
multicentr
studi
perform
improv
addit
combin
could
form
rapid
diagnost
assay
exclud
vap
biomark
analysi
appear
potenti
improv
antibiot
stewardship
concept
formal
test
set
randomis
control
trial
introduct
ventilatorassoci
pneumonia
vap
frequent
occur
nosocomi
infect
icu
patient
associ
increas
morbid
prolong
durat
ventil
icu
stay
increas
cost
healthcar
shown
earli
diagnosi
vap
immedi
initi
appropri
antibiot
associ
reduc
morbid
mortal
aim
studi
evalu
potenti
abil
screen
test
base
clinic
pulmonari
infect
score
cpi
identifi
treat
patient
vap
method
fi
le
belong
patient
year
old
admit
icu
support
mechan
ventil
longer
hour
evalu
retrospect
demograph
data
patient
time
mechan
ventil
durat
icu
stay
result
surviv
death
record
cpi
calcul
hour
diagnosi
vap
patient
cpi
intub
evalu
vap
other
cpi
thought
vap
diagnosi
vap
bacteriolog
confi
rmed
cultur
endotrach
aspir
statist
evalu
done
accord
result
day
intub
result
day
intub
score
apach
ii
crp
level
also
record
day
durat
mechan
ventil
ratio
death
signifi
cantli
higher
patient
vap
cpi
level
patient
vap
signifi
cantli
higher
patient
vap
day
diagnosi
cpi
level
also
higher
patient
vap
day
diagnosi
day
paramet
includ
cpi
bodi
temperatur
leukocyt
number
tracheal
secret
pao
fio
level
presenc
infi
ltrate
chest
radiograph
signifi
cantli
higher
vap
patient
p
roc
curv
form
cpi
score
use
diagnosi
vap
cutoff
point
sensit
specifi
citi
diagnos
vap
conclus
end
studi
conclud
use
cpi
earli
diagnosi
treatment
vap
think
patient
cpi
vap
guid
factor
resolv
problem
associ
vap
icu
patient
method
retrospect
analysi
patient
malefemal
ratio
median
age
rang
underw
arterioven
venoven
intervent
lung
assist
ila
novalung
germani
support
bridg
primari
ltx
n
reltx
n
underli
diagnosi
bronchiol
obliteran
syndrom
iii
reltx
patient
n
cystic
fi
brosi
n
idiopath
pulmonari
fi
brosi
n
emphysema
n
adult
respiratori
distress
syndrom
n
hemosiderosi
n
chronic
obstruct
lung
diseas
n
respect
type
ila
arterioven
venoven
ila
activ
seven
patient
median
bridg
time
day
type
transplant
bilater
ltx
n
sizereduc
bilater
ltx
n
lobar
bilater
ltx
n
right
singl
ltx
contralater
pneumonectomi
n
respect
hypercapnia
eff
ectiv
correct
patient
within
fi
rst
hour
ila
therapi
paco
level
declin
mmhg
p
ila
initi
noninvas
ventil
three
patient
one
intub
prior
ltx
patient
n
place
ila
invas
mv
three
patient
extub
remain
ila
ltx
one
patient
wean
ila
remain
mv
ltx
one
patient
wean
ila
mv
prior
ltx
five
patient
switch
extracorpor
membran
oxygen
venoven
n
venoarteri
n
day
ila
support
one
patient
die
prior
ltx
due
septic
multiorgan
failur
smof
other
n
success
transplant
two
patient
die
icu
due
smof
remain
patient
surviv
hospit
discharg
aliv
median
followup
month
patient
lifethreaten
hypercapnia
bridg
ltx
ila
feasibl
result
favor
shortterm
longterm
outcom
primari
aim
studi
identifi
adult
intens
care
patient
whether
diff
erenc
acut
physiolog
respons
patient
sat
chair
compar
patient
place
chair
posit
use
electr
bed
secondari
aim
studi
observ
function
outcom
patient
method
studi
conduct
adult
tertiari
referr
icu
period
patient
met
predetermin
inclusionexclus
criteria
alloc
either
sit
chair
sit
electr
bed
heart
rate
respiratori
rate
tidal
volum
mean
arteri
pressur
obtain
patient
supin
bed
minut
hour
new
posit
arteri
blood
gase
obtain
hour
new
posit
function
outcom
measur
known
chelsea
critic
care
physic
assess
tool
cpax
also
taken
day
admiss
day
sit
day
discharg
intens
care
ward
level
data
analys
use
student
test
result
sixteen
subject
recruit
studi
signifi
cant
increas
pao
kpa
p
decreas
paco
kpa
p
chair
group
hour
sit
chair
compar
baselin
kpa
kpa
also
signifi
cant
increas
tidal
volum
chair
group
minut
sit
ml
compar
baselin
ml
diff
erenc
electr
bed
group
physiolog
paramet
chair
group
better
cpax
score
discharg
intens
care
chair
group
electr
bed
group
discharg
hospit
chair
group
electr
bed
group
advers
cardiovascular
respons
either
posit
conclus
sit
suitabl
critic
ill
patient
chair
safe
signifi
cantli
improv
arteri
blood
ga
measur
tidal
volum
compar
sit
patient
sit
posit
electr
bed
refer
introduct
sputum
essenti
protect
respiratori
tract
also
play
signifi
cant
role
pathophysiolog
lung
diseas
evid
critic
care
high
sputum
load
contribut
respiratori
failur
quantiti
sputum
produc
patient
impact
key
decis
wean
extub
discharg
undertook
survey
establish
whether
consensu
quantifi
sputum
intens
therapi
unit
itu
method
conduct
multidisciplinari
team
questionnair
tertiari
itu
staff
ask
quantifi
ed
sputum
load
intub
patient
also
ask
rate
statement
fi
vepoint
scale
pertain
sputum
characterist
result
analys
excel
result
one
hundr
member
staff
complet
sputum
product
intens
therapi
spit
questionnair
doctor
nurs
physiotherapist
sputum
load
deem
import
essenti
respond
make
decis
extub
decanul
quantifi
cation
sputum
inconsist
respond
count
frequenc
suction
measur
quantiti
sputum
suction
tube
wherea
use
anoth
method
eff
ectiv
cough
consist
colour
felt
import
featur
sputum
blood
stain
conclus
result
show
high
level
agreement
import
know
sputum
load
decis
extub
decanul
discharg
itu
contrast
littl
consensu
quantifi
sputum
load
ventil
patient
lack
standard
approach
may
contribut
uncertainti
clinic
decisionmak
process
develop
object
sputum
score
system
compon
identifi
ed
import
survey
suction
frequenc
sputum
consist
colour
includ
recognis
benefi
ts
standardis
bristol
stool
chart
facilit
commun
believ
achiev
sputum
load
ventil
patient
introduct
bilevel
noninvas
ventil
niv
establish
therapi
chronic
obstruct
pulmonari
diseas
copd
cardiogen
pulmonari
oedema
evid
use
acut
respiratori
condit
less
robust
report
icu
mortal
niv
treatment
pneumonia
rang
compar
exacerb
copd
aim
studi
outcom
patient
acut
respiratori
failur
mix
aetiolog
treat
niv
critic
care
unit
compar
fi
nding
alreadi
publish
method
data
collect
retrospect
patient
admit
critic
care
unit
acut
respiratori
failur
requir
niv
period
use
metavis
electron
patient
record
system
patient
primari
surgic
problem
receiv
continu
posit
airway
pressur
primari
intervent
exclud
record
primari
respiratori
diagnosi
caus
respiratori
failur
patient
demograph
serial
arteri
blood
ga
result
success
niv
defi
ned
british
thorac
societi
bt
mortal
statist
conclus
niv
use
treat
acut
respiratori
failur
due
wide
rang
aetiolog
unit
compar
mortal
rate
larg
publish
seri
success
respons
niv
fi
rst
hour
associ
reduct
mortal
compar
nonrespond
studi
eff
ect
nasal
high
fl
ow
nhf
postop
respiratori
failur
extub
gener
surgic
icu
recent
studi
report
nhf
improv
oxygen
reduc
respiratori
rate
howev
use
nhf
gener
surgic
icu
fulli
determin
method
prospect
observ
studi
conduct
gener
surgic
icu
investig
eff
ect
nhf
respiratori
paramet
patient
postop
respiratori
failur
patient
admit
icu
postop
respiratori
failur
defi
ned
oxygen
satur
measur
puls
oximetri
andor
respiratori
rate
beatsminut
receiv
l
minut
oxygen
facemask
elig
studi
pre
hour
nhf
treatment
collect
pao
paco
respiratori
rate
heart
rate
blood
pressur
introduct
use
extracorpor
life
support
ecl
trauma
casualti
limit
concern
regard
hemorrhag
particularli
presenc
traumat
brain
injuri
tbi
report
usag
ecmo
intervent
lung
assist
ila
salvag
therapi
trauma
patient
highfl
ow
techniqu
without
anticoagul
use
case
coagulopathi
sever
tbi
method
data
collect
adult
trauma
case
refer
one
center
ecmoila
treatment
due
sever
hypoxem
respiratori
failur
thirteen
consecut
case
report
type
assist
chosen
base
fl
owchart
type
studi
therapeut
level
evid
iv
analyz
patient
data
injuri
data
blood
gase
connect
method
assist
coagul
studi
complic
surviv
neurolog
outcom
result
thirteen
casualti
averag
injuri
sever
score
age
year
male
support
day
ecmo
n
day
ila
n
suff
ere
sever
chest
injuri
includ
one
cardiac
perfor
coagulopath
prior
initi
ecmoila
support
among
seven
patient
tbi
four
activ
intracrani
hemorrhag
patient
receiv
continu
anticoagul
fi
rst
hour
support
without
clot
system
diagnosi
thromboembol
event
complic
directli
relat
support
therapi
lethal
includ
hemorrhag
cannul
site
n
accident
remov
cannula
n
pressur
sore
n
death
occur
due
septic
n
cardiogen
shock
n
surviv
rate
ecmo
ila
respect
followup
survivor
detect
neurolog
deterior
conclus
ecmoila
therapi
use
rescu
therapi
adult
trauma
case
sever
hypoxem
respiratori
failur
even
presenc
coagulopathi
bleed
andor
brain
injuri
benefi
ts
oxygen
circulatori
support
must
weigh
individu
risk
hemorrhag
research
determin
whether
ecmo
therapi
also
confer
surviv
benefi
introduct
complement
protein
defi
cienci
associ
sever
recurr
pulmonari
infect
excess
complement
activ
play
role
pathogenesi
lung
injuri
hypothes
inhibit
complement
system
repetit
treatment
nebul
plasmaderiv
human
inhibitor
reduc
pulmonari
complement
activ
subsequ
attenu
lung
injuri
lung
infl
ammat
model
sever
streptococcu
pneumonia
pneumonia
method
thirtytwo
male
rat
intratrach
challeng
pneumonia
induc
pneumonia
rat
repeatedli
expos
nebul
salin
minut
induct
pneumonia
everi
hour
thereaft
rat
sacrifi
ced
hour
inocul
investig
earli
late
eff
ect
balf
lung
tissu
obtain
measur
level
complement
activ
balf
lung
injuri
total
protein
level
balf
infl
ammat
level
lung
tissu
result
pneumonia
character
bilater
macroscop
infi
ltrate
bacteri
outgrowth
lung
clinic
sign
ill
pneumonia
associ
pulmonari
complement
activ
rat
treat
nebul
function
fraction
detect
balf
howev
treatment
aff
ect
introduct
manag
acut
respiratori
diseas
must
avoid
ventilatorinduc
lung
injuri
along
rise
paco
respiratori
acidosi
eff
ort
made
fi
nd
devic
assist
protect
ventil
abl
remov
arteri
co
correct
acidosi
extracorpor
co
remov
devic
driven
wide
use
prismafl
platform
call
test
vivo
method
five
hypercapn
ventil
pig
equip
system
design
remov
co
bloodstream
decarboxyl
membran
mount
renal
replac
devic
without
hemofi
lter
experi
examin
potenti
blood
decarboxyl
gasexchang
membran
diff
erent
set
paramet
blood
fl
ow
rate
mlminut
sweep
ga
fl
ow
lminut
fio
statist
analysi
perform
student
test
extracorpor
devic
allow
effi
cient
co
remov
rate
fio
figur
figur
rang
ml
minut
effi
cienci
increas
blood
sweep
ga
fl
ow
carbia
ph
anim
signifi
cantli
modifi
ed
minut
introduct
referr
ecmo
demonstr
reduc
mortal
sever
hypox
respiratori
failur
number
patient
undergo
ecmo
still
small
servic
depend
time
referr
region
icu
evid
intensivist
view
role
ecmo
mix
purpos
studi
determin
whether
variat
geograph
distribut
patient
receiv
ecmo
method
nh
england
provid
home
primari
care
trust
pct
adult
patient
refer
ecmo
potenti
revers
respiratori
failur
referr
pct
index
popul
area
produc
referr
rate
per
peopl
result
see
figur
ecmo
servic
expand
rapidli
last
year
england
follow
public
evid
effi
caci
concern
regard
infl
uenza
pandem
referr
rate
ecmo
sever
hypox
respiratori
failur
vari
greatli
around
countri
per
popul
leicest
citi
referr
pct
possibl
explan
could
includ
distribut
swine
fl
u
around
countri
refer
doctor
belief
effi
caci
ecmo
local
access
highfrequ
oscil
ventil
possibl
reluct
teach
hospit
refer
specialist
centr
investig
account
variat
appear
indic
conclus
referr
rate
ecmo
vari
greatli
around
countri
refer
introduct
use
microcomput
tomographi
microct
assess
eff
ectiv
clean
closedsuct
system
css
remov
secret
endotrach
tube
ett
lumen
biofi
lm
grow
within
ett
soon
intub
increas
patient
risk
develop
ventilatorassoci
pneumonia
new
clean
devic
design
keep
ett
clean
secret
method
bench
test
inject
waterbas
gel
unus
ett
evalu
microct
scan
skyscan
bruker
belgium
eff
ectiv
measur
secret
six
critic
ill
patient
clean
css
airway
medix
close
suction
system
biovo
tel
aviv
use
three
time
day
keep
ett
clean
extub
measur
ett
secret
volum
microct
scan
length
cm
ett
tip
also
collect
ett
patient
treat
standard
css
control
evalu
ett
microbi
colon
volum
gel
measur
microct
strongli
correl
volum
inject
gel
p
r
extub
lower
amount
secret
measur
ett
treat
clean
css
compar
control
vs
mm
p
correspond
smaller
occup
crosssect
area
averag
vs
respect
p
microbi
colon
tend
reduc
ett
treat
clean
css
total
bacteri
charg
vs
log
cfuml
p
conclus
microct
scan
show
high
precis
accuraci
measur
volum
secret
bench
test
thu
use
evalu
eff
ectiv
action
devic
studi
reduc
ett
biofi
lm
accumul
small
nonrandom
popul
critic
ill
patient
use
ett
clean
devic
appear
eff
ectiv
reduc
volum
secret
present
ett
extub
refer
introduct
today
healthcar
environ
forc
provid
constantli
evalu
materi
use
fi
nd
less
expens
altern
recent
lowcost
endotrach
tube
ett
introduc
market
aim
studi
test
tube
portex
aircar
cardin
health
ett
compar
endotrach
tube
known
perform
hilo
covidi
pre
iso
standard
taperguard
covidi
post
iso
standard
method
use
requir
test
setup
accord
iso
standard
cuff
seal
perform
tube
test
versu
size
mm
kink
perform
done
routin
manner
critic
care
volum
suppl
http
result
leak
test
show
portex
aircar
ett
leak
signifi
cantli
compar
hilo
p
taperguard
p
ett
standard
deviat
leak
rate
aircar
larg
suggest
vari
seal
perform
tube
variou
lot
kink
test
show
diff
erenc
among
tube
conclus
although
tube
look
may
diff
erenc
perform
studi
demonstr
new
cheaper
ett
greater
cuff
leak
compar
two
tube
use
comparison
specul
whether
diff
erenc
found
studi
result
cost
cut
howev
great
variabl
seal
perform
ett
size
diff
erent
lot
would
indic
manufactur
control
may
less
stringent
although
demonstr
higher
incid
leak
result
advers
patient
outcom
one
surmis
possibl
exist
thu
select
endotrach
tube
base
purchas
price
alon
take
account
document
perform
standard
test
method
retrospect
review
perform
use
data
last
year
op
icu
univers
hospit
op
underw
pdt
select
bmi
kgm
op
need
prolong
mechan
ventil
total
op
identifi
ed
pdt
place
use
ciaglia
blue
rhino
cbr
introduc
kit
seven
pdt
uniperc
pdt
kit
pdt
perform
dedic
staff
includ
resid
valuat
clinic
anatom
physiopatholog
featur
op
us
scan
neck
came
procedur
begin
procedur
place
mm
id
orotrach
tube
tube
exchang
videofb
assist
alreadi
describ
mm
id
wirereinforc
silicon
tracheostomi
tube
rtt
adjust
fl
ang
chosen
instead
standard
pvc
silast
tt
stt
op
treat
cbr
anatom
particular
op
extern
traction
weight
tube
attach
tt
extralong
tt
ett
chosen
pretrach
tissu
thick
regulars
tt
op
bmi
kgm
treat
cbr
three
op
treat
cbr
need
chang
rtt
ett
tube
dislodg
subocclus
xray
videofb
diagnosi
uniperc
techniqu
chosen
op
bmi
kgm
result
major
complic
abort
procedur
ml
bleed
tt
misplac
death
observ
minor
complic
ml
bleed
ring
fractur
diffi
cult
insert
cbr
rtt
step
tip
rtt
introduc
uniperc
ett
placement
alway
easi
conclus
experi
data
support
previou
studi
shown
suggest
increas
risk
complic
op
know
stt
could
eff
ectiv
op
use
us
videofb
assist
rtt
adjust
fl
ang
allow
safe
eff
ectiv
adjust
anatom
op
particular
avoid
collect
risk
refer
introduct
highfl
ow
oxygen
therapi
hfot
deliv
nasal
cannula
improv
oxygen
compar
lowfl
ow
oxygen
devic
shown
nasal
hfot
gener
posit
airway
pressur
increas
linearli
ga
fl
ow
rate
data
use
hfot
deliv
tracheostomi
scarc
aim
present
random
control
crossov
trial
assess
eff
ect
hfot
deliv
tracheostomi
arteri
blood
gase
endotrach
pressur
critic
ill
patient
method
tracheostom
patient
underw
hfot
three
ga
fl
ow
rate
lminut
lminut
lminut
randomli
appli
period
end
period
arteri
blood
gase
respiratori
rate
endotrach
pressur
ptrach
measur
ptrach
record
last
minut
studi
period
maximum
expiratori
pressur
meptrach
mean
expiratori
pressur
measur
averag
respiratori
cycl
record
stabl
breath
fio
kept
constant
whole
studi
result
seventeen
tracheostom
patient
enrol
sap
ii
pao
mmhg
paco
mmhg
increas
ga
fl
ow
rate
lminut
lminut
associ
increas
pao
fio
improv
lminut
use
respect
p
trend
observ
pao
mmhg
mmhg
mmhg
respect
p
sao
respect
p
paco
mmhg
averag
respiratori
rate
breathsminut
averag
chang
diff
erent
ga
fl
ow
rate
meptrach
cmh
cmh
cmh
lminut
lminut
lminut
respect
p
mean
expiratori
pressur
cmh
cmh
cmh
l
minut
lminut
lminut
respect
p
increas
fl
ow
chang
pao
fio
correl
chang
expiratori
pressur
conclus
hfot
use
tracheostomi
increas
ga
fl
ow
rate
oxygen
increas
lminut
co
clearanc
respiratori
rate
vari
tracheal
expiratori
pressur
increas
fl
ow
chang
small
probabl
limit
clinic
relev
chang
oxygen
relat
variat
tracheal
expiratori
pressur
hfot
tracheostomi
diff
erent
eff
ect
nasal
interfac
use
nation
audit
project
conduct
royal
colleg
anaesthetist
review
major
airway
complic
uk
highlight
tracheostomi
tube
displac
signifi
cant
risk
critic
care
patient
prior
royal
london
hospit
icu
traco
twist
market
kapitex
primarili
use
default
choic
tracheostomi
tube
howev
period
signifi
cant
number
critic
incid
relat
tracheostomi
tube
displac
blockag
investig
incid
rootcaus
analysi
identifi
ed
inadequ
length
traco
twist
major
contribut
factor
consequ
also
increas
requir
use
adjust
fl
ang
tube
particularli
appar
obes
patient
object
develop
new
tracheostomi
tube
would
reduc
number
incid
relat
inadequ
length
addit
aim
maximis
inner
diamet
given
extern
diamet
thu
reduc
airway
resist
potenti
aid
wean
method
form
consult
committe
consist
consult
critic
care
consult
surgeon
consult
anaesthetist
specialist
interest
head
neck
anaesthesia
tracheostomi
care
collabor
kapitex
design
team
develop
new
tracheostomi
tube
address
perceiv
defi
cit
exist
devic
develop
prototyp
tracheostomi
tube
increas
length
given
intern
diamet
also
increas
mobil
fl
ang
order
reduc
pressur
area
assist
fi
xation
third
modifi
cation
ensur
maxim
intern
diamet
given
extern
diamet
pilot
use
patient
advers
event
observ
clinic
impress
increas
length
benefi
cial
patient
conclus
follow
success
pilot
studi
new
tracheostomi
tube
develop
market
kapitex
tube
name
traco
twist
plu
use
tube
year
sinc
perform
extens
retrospect
audit
tracheostomi
usag
eff
ect
introduct
novel
traco
twist
plu
complic
rate
reduc
term
displac
obstruct
refer
icu
patient
mv
defl
ate
cuff
patient
tracheostomi
provid
safe
comfort
use
bipap
air
leakag
upper
airway
enabl
speech
ad
speak
valv
second
step
qualiti
speech
cough
improv
abil
speak
provid
import
improv
commun
method
aim
studi
compar
wean
mv
gradual
decreas
level
support
cuff
defl
ate
ventil
use
bipap
passi
speak
valv
trial
spontan
breath
use
speak
valv
progress
longer
period
time
examin
diff
erenc
abil
speak
durat
wean
period
occurr
delirium
frequenc
tracheal
suction
perform
singlecentr
retrospect
prospect
observ
studi
mix
icu
year
data
collect
use
patient
data
manag
system
baselin
criteria
age
gender
apach
iv
score
icu
length
stay
durat
mv
placement
tracheostomi
result
ten
patient
includ
fi
bipap
group
fi
spontan
group
signifi
cant
diff
erenc
baselin
criteria
second
day
tracheostomi
three
fi
patient
bipap
group
abl
speak
compar
one
spontan
method
group
diff
erenc
speak
abil
remain
day
see
figur
fi
rst
time
speak
bipap
group
higher
peep
level
vs
cmh
higher
sofa
score
vs
compar
spontan
group
signifi
cant
diff
erenc
delirium
durat
wean
tracheal
suction
group
conclus
cuff
defl
ate
mv
icu
patient
enabl
speak
ventil
depend
techniqu
abil
speak
start
earlier
phase
wean
compar
wean
spontan
breath
trial
speak
valv
refer
vitro
evalu
show
dlet
lowest
k
dlet
cmh
olminut
vivo
evalu
pt
perform
convent
ett
fob
dlet
fi
patient
group
age
vs
sap
ii
vs
gc
vs
ga
exchang
procedur
diff
er
group
valu
ph
pao
paco
measur
procedur
ettfob
versu
dlet
versu
p
versu
p
versu
p
versu
p
conclus
dlet
result
adequ
airway
patenc
minim
obstruct
due
lower
channel
exclus
dedic
patient
ventil
ga
exchang
pt
dlet
remain
stabl
without
variat
oxygen
carbon
dioxid
level
although
set
mechan
ventil
introduct
respiratori
wean
icu
lengthi
expens
process
may
facilit
use
tracheostomi
discharg
patient
tracheostomi
gener
ward
improv
icu
bed
avail
rais
potenti
patient
safeti
issu
demonstr
increas
mortal
compar
patient
decannul
discharg
icu
investig
often
icu
uk
discharg
patient
tracheostomi
ward
ward
whether
system
place
ensur
adequ
safeti
discharg
method
telephon
icu
uk
nurs
staff
answer
seri
question
regard
discharg
patient
tracheostomi
ward
followup
obtain
inform
icu
total
unit
use
tracheostomi
respiratori
wean
total
routin
discharg
patient
ward
tracheostomi
never
occasion
five
discharg
high
depend
unit
respiratori
ward
specialist
ward
ward
eightyfi
unit
discharg
patient
tracheostomi
cuff
discharg
cuff
cuffl
ess
cuff
usual
total
hospit
routin
followup
tracheostomi
patient
critic
care
outreach
servic
critic
care
outreach
avail
hour
day
hospit
conclus
vast
major
icu
uk
perform
tracheostomi
respiratori
wean
mani
routin
discharg
patient
ward
prior
decannul
routin
followup
usual
avail
cover
may
avail
day
patient
may
go
specialist
ward
train
nurs
alway
case
patient
often
discharg
ward
tracheostomi
cuff
rais
major
safeti
issu
tracheostomi
tube
block
nurs
train
emerg
twentyfour
hour
day
critic
care
outreach
cover
may
improv
patient
safeti
research
product
guidelin
need
facilit
safe
discharg
patient
tracheostomi
icu
ward
introduct
percutan
dilat
tracheostomi
pdt
standard
airway
access
critic
ill
patient
requir
prolong
mechan
ventil
howev
patient
sever
coagulopathi
thrombocytopenia
might
increas
risk
periprocedur
bleed
method
retrospect
review
record
patient
underw
pdt
use
ciaglia
techniqu
bronchoscop
guidanc
cardiothorac
icu
januari
februari
patient
stratifi
ed
two
group
coagulopathi
group
coagulopathythrombocytopenia
defi
ned
intern
normal
ratio
partial
thromboplastin
time
second
andor
platelet
count
l
group
result
total
patient
male
mean
age
year
underw
pdt
identifi
ed
patient
sever
coagulopathi
group
procedurerel
death
major
procedurerel
complic
includ
sever
bleed
requir
transfus
andor
surgeri
two
patient
group
one
lacer
brachiocephal
trunk
one
venou
bleed
two
bleed
thyroid
vessel
injuri
membran
wall
trachea
two
patient
group
well
pneumothorax
devic
failur
group
incid
moder
periprocedur
bleed
compar
two
group
n
vs
n
p
ns
conclus
periprocedur
bleed
complic
pdt
rare
even
patient
sever
coagulopathi
thu
pdt
safe
perform
patient
introduct
percutan
tracheostomi
becom
establish
procedur
airway
manag
critic
ill
patient
repeat
pdt
consid
rel
contraind
result
distort
anatomi
method
retrospect
review
repeat
bedsid
percutan
dilat
tracheostomi
ciaglia
techniqu
direct
bronchoscop
guidanc
perform
cardiothorac
critic
care
unit
januari
februari
conduct
result
total
patient
undergo
pdt
identifi
ed
patient
repeat
pdt
patient
previou
tracheostomi
date
back
day
year
mean
day
mean
age
year
patient
femal
mean
time
intub
pdt
day
death
associ
pdt
one
major
procedurerel
complic
one
patient
suff
ere
periprocedur
lacer
brachiocephal
trunk
emerg
surgeri
surgic
tracheotomi
st
patient
recov
complet
patient
convers
st
loss
airway
paratrach
insert
accident
tracheal
extub
observ
pneumothorax
pneumomediastinum
hypotens
hypoxemia
arrhythmia
record
mild
bleed
observ
patient
moder
signifi
cant
bleed
observ
one
patient
tracheal
ring
fractur
occur
six
patient
fourteen
patient
could
wean
success
respir
tracheostomi
could
remov
thirteen
patient
transfer
anoth
icu
tracheostomi
place
function
cosmet
outcom
pdt
excel
conclus
repeat
pdt
safe
procedur
experienc
hand
gener
consid
contraind
howev
special
attent
paid
anatom
situat
increas
risk
vascular
complic
tracheostomi
ancient
techniqu
recent
develop
percutan
techniqu
percutan
tracheostomi
pct
shown
safer
reduc
infect
cost
complic
surgic
techniqu
ventilatorassoci
pneumonia
vap
seriou
complic
result
use
endotrach
tube
ett
tracheostomi
chang
design
tube
addit
subglott
suction
port
shown
improv
vap
rate
mechan
ventil
patient
larg
metaanalysi
review
show
subglott
drainag
reduc
number
day
mechan
ventil
requir
reduc
number
day
stay
icu
method
contact
icu
uk
telephon
spoke
nurseincharg
ascertain
normal
practic
regard
pct
subglott
suction
use
contact
total
gener
icu
receiv
respons
averag
number
bed
per
icu
unit
respond
ninetyeight
per
cent
icu
question
use
pct
three
unit
averag
bed
number
per
unit
icu
use
pct
fi
bed
per
unit
averag
proport
icu
employ
subglott
suction
port
ett
averag
bed
per
unit
whilst
proport
icu
employ
subglott
suction
port
also
bed
per
unit
averag
regard
pct
subglott
suction
port
icu
utilis
tube
whilst
group
icu
use
subglott
suction
port
tracheostomi
tube
averag
bed
per
unit
group
icu
use
subglott
suction
port
tracheostomi
tube
averag
bed
per
unit
conclus
signifi
cant
diff
erenc
practis
exist
pct
subglott
suction
port
tube
size
icu
group
variabl
larger
unit
like
use
pct
smaller
unit
regard
subglott
suction
port
ett
tracheostomi
tube
size
icu
necessarili
dictat
use
propos
icu
review
polici
use
pct
subglott
suctionassist
tube
help
improv
surgic
complic
cost
vap
rate
icu
stay
critic
care
volum
suppl
http
introduct
tracheostomi
perform
uk
per
year
nation
audit
project
identifi
ed
signifi
cant
morbid
mortal
associ
tracheostomi
care
nation
tracheostomi
safeti
project
ntsp
manual
highlight
need
local
polici
appropri
care
environ
immedi
avail
emerg
equip
train
staff
local
train
programm
bedhead
sign
emerg
algorithm
tracheostomi
patient
follow
guidelin
ask
adult
tracheostomi
patient
manag
post
discharg
intens
carehigh
depend
unit
icuhdu
throughout
uk
method
novemb
adult
icuhdu
throughout
uk
contact
take
part
telephon
survey
data
collect
tracheostomi
wean
posticuhdu
care
safeti
guidelin
emerg
protocol
train
clinician
nurs
result
adult
icuhdu
contact
took
part
survey
tracheostomi
wean
protocol
initi
wean
whilst
patient
mechan
ventil
use
speak
valv
wean
process
also
allow
tracheostomi
patient
oral
nutrit
intak
decis
involv
speech
languag
therapi
post
icu
hdu
unit
discharg
specialis
ward
nonspecialis
ward
dedic
stepdown
unit
step
tracheostomi
patient
critic
care
outreach
team
review
patient
hospit
survey
furthermor
hospit
consult
lead
tracheostomi
ward
round
tracheostomi
multidisciplinari
team
mdt
also
within
hospit
tracheostomi
safeti
guidelin
emerg
tracheostomi
manag
protocol
ward
tracheostomi
bedhead
inform
sign
emerg
bedsid
tracheostomi
equip
tracheostomi
train
programm
mdt
approach
decannul
conclus
wide
variat
posticuhdu
manag
tracheostomi
patient
throughout
uk
although
well
establish
uk
nation
guidelin
manag
tracheostomi
patient
outsid
icuhdu
environ
lack
full
implement
ntsp
recommend
increas
risk
tracheostomyrel
morbid
mortal
introduct
ventilatorassoci
pneumonia
vap
common
nosocomi
infect
among
ventil
patient
associ
increas
mortal
morbid
oral
chlorhexidin
use
decontamin
airway
critic
ill
patient
studi
suggest
risk
reduct
vap
chlorhexidin
react
soap
toothpast
form
inact
insolubl
salt
minimum
delay
minut
tooth
brush
subsequ
applic
chlorhexidin
therefor
recommend
method
telephon
questionnair
conduct
icu
uk
assess
current
oral
decontamin
procedur
regard
chlorhexidin
use
time
tooth
brush
toothpast
result
sixtyfi
per
cent
icu
uk
respond
survey
n
ninetyseven
per
cent
n
use
chlorhexidin
n
use
part
ventil
care
bundl
fortysix
per
cent
n
use
gel
n
use
mouthwash
n
use
prepar
frequenc
chlorhexidin
applic
vari
icu
appli
seven
appli
variabl
time
ninetyseven
per
cent
n
brush
patient
teeth
n
use
toothpast
n
use
chlorhexidin
gel
n
use
ninetyseven
per
cent
n
icu
use
chlorhexidin
also
brush
patient
teeth
toothpast
fortyeight
per
cent
n
administ
chlorhexidin
within
minut
toothpast
applic
tabl
conclus
chlorhexidin
use
soon
applic
toothpast
icu
uk
result
attenu
eff
ect
may
remov
benefi
cial
risk
reduct
vap
awar
interact
emphasis
introduct
aim
assess
eff
ect
continu
drainag
subglott
secret
prevent
ventilatorassoci
pneumonia
vap
patient
requir
prolong
mechan
ventil
hour
icu
prospect
random
control
studi
method
studi
perform
document
ethic
committe
written
inform
consent
rel
patient
april
februari
icu
fiftyfour
patient
whose
mechan
ventil
requir
expect
longer
hour
includ
studi
patient
randomli
divid
two
group
form
group
use
convent
intub
tube
group
c
group
use
intub
tube
allow
aspir
subglott
secret
group
group
continu
subglott
aspir
occur
constant
pressur
special
devic
group
cuff
pressur
maintain
constant
pressur
use
digit
cuff
pressur
devic
result
group
c
vap
develop
patient
group
vap
develop
fi
patient
group
compar
accord
develop
vap
introduct
subglott
secret
drainag
ssd
shown
reduc
incid
ventilatorassoci
pneumonia
vap
review
current
uk
practic
practic
surround
implement
ssd
use
survey
method
construct
survey
question
use
surveymonkey
circul
via
email
link
linkmen
uk
intens
care
societi
respons
receiv
august
novemb
respons
major
doctor
rest
nurs
respond
work
district
gener
hospit
teach
hospit
rest
specialist
unit
overal
respond
work
unit
use
ssd
respons
type
patient
receiv
ssd
summaris
tabl
one
hundr
per
cent
unit
use
intermitt
ssd
seventyon
per
cent
respond
report
ssd
tube
store
icu
report
avail
acut
area
rest
hospit
wide
twentyeight
per
cent
respond
indic
unit
polici
reintub
patient
facilit
ssd
unit
ventil
care
bundl
regularli
measur
cuff
pressur
overal
survey
thought
ssd
benefi
cial
prevent
vap
conclus
despit
specifi
c
recommend
uk
depart
health
onehalf
respond
work
icu
ssd
adopt
studi
show
benefi
patient
expect
ventil
greater
hour
unit
use
ssd
intub
patient
reintub
rate
facilit
ssd
also
reason
high
despit
lack
evid
support
practic
vast
major
hospit
ssd
endotrach
tube
store
icu
need
reintub
may
result
lack
avail
appropri
tube
point
fi
rst
intub
introduct
emulsifi
ed
perfl
uorocarbon
pfc
synthet
hydrocarbon
carri
time
oxygen
human
plasma
properti
may
advantag
applic
requir
preserv
tissu
viabil
oxygendepriv
state
make
potenti
candid
combat
civilian
prehospit
resuscit
hypothesi
intraven
dose
pfc
increas
vital
organ
tissu
oxygen
improv
surviv
reduc
prevent
develop
ventilatorassoci
ard
report
data
second
part
ard
multiphas
swine
studi
investig
benefi
ts
pfc
treat
hemorrhag
shock
prevent
ard
method
anesthet
yorkshir
swine
random
n
group
receiv
bolu
pfc
either
minut
pfcb
pfca
induct
ard
noth
control
non
ard
induc
via
intraven
oleic
acid
infus
time
minut
anim
monitor
physiolog
hematolog
paramet
euthan
minut
full
necropsi
histopatholog
analysi
perform
result
surviv
non
group
pfca
group
pfcb
group
mean
arteri
pressur
map
mean
pulmonari
arteri
pressur
mpap
signifi
cantli
increas
infus
pfc
ard
pfcb
group
cardiac
output
co
signifi
cantli
reduc
pfca
group
observ
map
mpap
increas
co
decreas
ard
induct
pfc
infus
chang
signifi
cant
comparison
non
group
oxygen
deliveri
consumpt
pfca
group
signifi
cantli
increas
histopatholog
analysi
current
perform
interim
analysi
show
trend
reduc
alveolar
damag
pfca
anim
conclus
administr
pfc
induct
ard
detriment
give
pfc
ard
improv
oxygen
deliveri
increas
oxygen
consumpt
although
surviv
group
lower
non
control
group
vs
signifi
cant
reduct
alveolar
damag
observ
might
improv
longterm
outcom
ard
base
data
continu
fi
nal
phase
project
evalu
capac
pfc
prevent
ard
combin
hs
introduct
venoven
extracorpor
membran
oxygen
vv
ecmo
treatment
option
acut
respiratori
distress
syndrom
ard
minim
ventilatorinduc
lung
injuri
includ
lifethreaten
pneumothorax
purpos
studi
investig
safeti
effi
caci
vv
ecmo
prevent
pneumothorax
ard
patient
complic
emphysematouscyst
chang
lung
method
retrospect
analyz
data
ard
patient
complic
emphysematouscyst
chang
lung
admit
icu
divid
subject
two
group
patient
treat
vv
ecmo
ecmo
group
treat
convent
ventil
manag
nonecmo
group
correl
age
sex
underli
diseas
pao
fio
ratio
admiss
durat
icu
stay
surviv
incid
pneumothorax
evalu
critic
care
volum
suppl
http
result
fortyon
patient
includ
studi
ecmo
nonecmo
group
patient
respect
signifi
cant
diff
erenc
ecmo
nonecmo
group
regard
age
sex
underli
diseas
pao
fio
ratio
durat
icu
stay
surviv
ecmo
group
mean
durat
ecmo
use
day
bleed
due
anticoagul
observ
fi
patient
mean
airway
pressur
ecmo
group
signifi
cantli
lower
nonecmo
group
cmh
cmh
respect
p
incid
pneumothorax
also
signifi
cantli
lower
ecmo
group
nonecmo
group
respect
p
kaplanmei
analysi
proport
pneumothoraxfre
patient
signifi
cantli
higher
ecmo
group
p
multivari
analysi
convent
ventil
manag
presenc
interstiti
pneumonia
durat
intub
independ
risk
factor
pneumothorax
hazard
ratio
hr
p
hr
p
hr
p
respect
conclus
although
surviv
rate
statist
diff
erent
use
ecmo
ard
patient
complic
emphysemat
cystic
chang
lung
markedli
reduc
incid
pneumothorax
underli
molecular
mechan
associ
age
higher
suscept
develop
ard
poorli
understood
pulmonari
reninangiotensin
system
ra
lungprotect
angiotensinconvert
enzym
ace
ang
receptor
axi
lunginjuri
aceang
iiang
ii
receptor
axi
implic
pathogenesi
ard
chang
age
hypothes
injuri
ventil
agedepend
eff
ect
pulmonari
ra
lpschalleng
rat
associ
increas
lung
injuri
method
infant
month
juvenil
month
adult
month
older
month
wistar
rat
challeng
intratrach
lp
injuri
ventil
use
tidal
volum
mlkg
hour
lung
injuri
assess
wettodri
ratio
chang
pf
ratio
level
infl
ammatori
mediat
measur
bronchoalveolar
lavag
fl
uid
mrna
express
key
gene
pulmonari
ra
determin
lung
homogen
result
lpschalleng
ventil
older
rat
show
higher
mortal
larger
chang
wettodri
ratio
larger
declin
pf
ratio
compar
age
group
increas
neutrophil
infl
ux
infl
ammatori
mediat
age
depend
higher
level
increas
age
compar
control
ventil
lpschalleng
rat
show
decreas
mrna
express
ace
ma
receptor
age
group
except
infant
rel
decreas
mrna
express
ma
receptor
extens
older
rat
therebi
shift
balanc
toward
lung
injuri
axi
age
group
conclus
eff
ect
injuri
ventil
lung
injuri
age
depend
model
lpschalleng
rat
associ
pronounc
imbal
pulmonari
ra
expens
lungprotect
axi
increas
age
cytokin
howev
exact
role
thelper
cell
th
ali
model
remain
unknown
hypothes
might
th
imbal
within
lung
earli
phase
lpsinduc
ali
studi
assess
role
lung
th
polar
respons
ali
mice
method
mice
randomli
divid
two
group
control
group
ali
group
ali
anim
receiv
mgkg
lp
lung
wet
weightbodi
weight
lwbw
record
assess
lung
injuri
patholog
chang
examin
optic
microscop
mrna
express
level
tbet
determin
quantit
realtim
revers
transcriptasepolymeras
chain
reaction
meanwhil
level
lung
homogen
assess
enzymelink
immunosorb
assay
increas
lwbw
induc
ali
mice
histolog
widespread
alveolar
wall
thicken
caus
edema
sever
hemorrhag
interstitium
alveolu
mark
diff
use
interstiti
infi
ltration
infl
ammatori
cell
observ
ali
group
meanwhil
level
lung
tissu
signifi
cantli
enhanc
lpsinduc
ali
mice
mrna
express
tbet
upregul
ali
mice
hour
hour
rel
normal
mice
p
vs
con
signifi
cant
diff
erenc
express
among
group
hour
hour
meanwhil
level
lung
tissu
signifi
cantli
enhanc
hour
hour
lpsinduc
ali
mice
addit
level
lung
tissu
signifi
cantli
enhanc
hour
lpsinduc
ali
mice
express
tbet
mrna
mrna
strong
correl
concentr
howev
signifi
cant
correl
concentr
addit
signifi
cant
correl
level
lpsinduc
ali
hour
hour
conclus
ali
provok
polar
respons
may
particip
earli
infl
ammatori
respons
ali
introduct
dendrit
cell
dc
may
play
import
role
acut
lung
injuri
ali
crucial
costimulatori
molecul
express
surfac
dc
howev
littl
known
express
purpos
studi
observ
express
circul
lung
splenic
dendrit
cell
dc
ali
mice
method
twelv
mice
randomli
divid
two
group
control
group
ali
group
blood
lung
spleen
harvest
hour
lp
pb
administr
level
dc
assess
fl
ow
cytometri
fcm
level
lung
measur
enzymelink
immunosorb
assay
lung
wet
weight
bodi
weight
lwbw
record
assess
lung
injuri
meanwhil
patholog
chang
examin
optic
microscop
result
lpsali
result
signifi
cant
increas
lung
wd
ratio
histolog
widespread
alveolar
wall
thicken
caus
edema
sever
hemorrhag
interstitium
alveolu
mark
diff
use
interstiti
infi
ltration
infl
ammatori
cell
observ
ali
group
meanwhil
level
lung
tissu
signifi
cantli
enhanc
lpsinduc
ali
mice
fcm
analysi
show
level
circul
dc
control
group
express
lung
dc
express
splenic
dc
signifi
cantli
higher
circul
dc
lung
dc
p
ali
mous
level
peripher
blood
dc
level
lung
dc
signifi
cantli
higher
peripher
blood
dc
p
level
splenic
dc
signifi
cantli
higher
level
peripher
blood
lung
dc
p
level
lung
splenic
dc
ali
mice
signifi
cantli
higher
lung
splenic
dc
control
mice
p
vs
con
conclus
dynam
characterist
express
dc
popul
normal
ali
mice
elev
express
dc
seem
play
import
role
pathogenesi
ali
acknowledg
support
research
project
cpsfg
jspsfg
refer
introduct
two
recent
rct
oscar
oscil
show
highfrequ
oscillatori
ventil
hfov
posit
impact
mortal
present
experi
year
method
adult
ard
patient
receiv
hfov
includ
demograph
ill
sever
outcom
collect
retrospect
result
total
patient
includ
male
mean
age
year
rrt
use
admiss
vasoact
agent
use
neuromuscular
blockad
infus
rate
pre
hfov
respect
mortal
total
less
hour
convent
ventil
cv
pre
hfov
mortal
group
patient
hour
cv
pre
hfov
mortal
see
tabl
conclus
mortal
rate
higher
recent
trial
patient
repres
critic
unwel
group
lower
pf
ratio
pre
hfov
high
vasoact
rrt
use
hfov
may
still
role
treatment
sick
patient
treatment
refractori
convent
ventil
introduct
losartan
antagonist
angiotensin
ii
ang
ii
type
receptor
potenti
therapeut
drug
acut
lung
injuri
ali
recent
report
suggest
losartan
inhibit
thelper
th
immun
respons
ultim
attenu
infl
ammat
sever
angiotensin
iimedi
infl
ammatori
diseas
howev
possibl
protect
mechan
losartan
ali
remain
poorli
understood
studi
assess
eff
ect
losartan
lung
th
polar
respons
ali
method
mice
randomli
divid
three
group
control
group
ali
group
ali
losartan
group
ali
anim
receiv
mgkg
lp
ali
losartan
anim
receiv
mgkg
lp
mgkg
losartan
minut
intratrach
inject
lp
patholog
chang
examin
optic
microscop
mrna
express
level
tbet
determin
quantit
realtim
revers
transcriptasepolymeras
chain
reaction
increas
lwbw
induc
lp
partli
prevent
pretreat
losartan
histolog
losartan
eff
ectiv
attenu
lpsinduc
lung
hemorrhag
leukocyt
cell
infi
ltration
interstitium
alveolu
meanwhil
level
lung
tissu
signifi
cantli
enhanc
lpsinduc
ali
mice
pretreat
ali
mice
losartan
level
lung
markedli
decreas
mrna
express
tbet
upregul
ali
mice
hour
hour
rel
normal
mice
p
vs
con
signifi
cant
diff
erenc
express
among
group
hour
hour
note
pretreat
ali
mice
losartan
result
signifi
cantli
reduc
mrna
express
tbet
hour
hour
mrna
express
hour
p
vs
ali
meanwhil
level
lung
tissu
signifi
cantli
enhanc
hour
hour
lpsinduc
ali
mice
addit
lung
tissu
hour
hour
decreas
signifi
cantli
losartanpretr
mice
compar
ali
mice
pretreat
ali
mice
losartan
level
lung
chang
conclus
ang
iiinduc
polar
respons
could
upregul
infl
ammatori
respons
induc
lung
injuri
losartan
may
promis
substanc
clinic
use
lpsinduc
ali
increas
preval
infect
multiresist
organ
mdr
increas
last
decad
implic
overal
level
therapeut
success
also
select
pressur
exert
use
broadspectrum
antibiot
defeat
increasingli
resist
agent
therebi
creat
viciou
cycl
aim
studi
describ
risk
factor
associ
infect
mdr
organ
among
septic
patient
method
retrospect
cohort
studi
includ
adult
patient
microbiolog
document
sepsi
admit
emerg
room
tertiari
care
univers
hospit
juli
june
result
studi
period
patient
admit
emerg
room
sever
sepsi
microbiolog
document
includ
studi
mean
sd
age
categor
variabl
compar
use
fisher
test
odd
ratio
or
confi
denc
interv
ci
calcul
evalu
strength
associ
continu
variabl
compar
use
student
test
wilcoxon
test
appropri
multivari
analysi
perform
use
multipl
logist
regress
variabl
p
bivari
analys
consid
inclus
multivari
model
introduct
clostridium
diffi
cile
infect
becom
common
worldwid
critic
ill
patient
particularli
high
risk
diseas
due
multipl
risk
factor
popul
accur
diagnosi
essenti
patient
manag
infect
control
epidemiolog
varieti
method
detect
presenc
toxigen
c
diffi
cile
stool
aim
studi
evalu
incid
c
diffi
cile
infect
icu
laboratori
result
c
diffi
cile
toxin
detect
perform
method
avail
institut
present
method
last
year
stool
specimen
receiv
microbiolog
depart
patient
hospit
multidisciplinari
icu
tertiarycar
hospit
evalu
specimen
order
physician
presenc
clinic
featur
compat
c
diffi
cileassoci
infect
specimen
subject
diagnost
test
c
diffi
cile
infect
includ
toxin
enzym
immunoassay
c
diffi
cile
toxin
b
detect
duo
toxin
b
vedalab
franc
glutam
dehydrogenas
gdh
cell
wall
antigen
detect
c
diff
quik
chek
usa
result
studi
period
stool
specimen
evalu
result
obtain
twostag
immunoassay
test
shown
figur
infect
patient
treat
metronidazol
vancomycin
follow
cours
therapi
infect
patient
recurr
relaps
crude
mortal
rate
conclus
gdh
antigen
posit
stool
specimen
receiv
icu
patient
suspect
c
diffi
cileassoci
infect
major
specimen
produc
c
diffi
cile
toxin
b
wherea
toxin
b
produc
toxin
remain
thirtyseven
arteri
line
return
growth
seven
cultur
grew
organ
like
contamin
four
cultur
grew
signifi
cant
organ
yield
two
case
document
clinic
sign
catheterrel
local
infect
crli
arteri
line
punctur
site
one
case
crli
primari
sourc
infect
felt
remot
arteri
line
second
repres
local
infect
organ
typic
skin
commens
four
cultur
like
repres
invas
pathogen
three
clinic
suspicion
primari
sourc
site
remot
arteri
line
two
case
confi
rmed
grow
organ
altern
site
like
sourc
infect
conclus
result
suggest
crli
rate
arteri
line
low
per
arteri
lineday
howev
signifi
cant
bacteri
colonis
rate
arteri
line
sampl
three
arteri
line
grew
organ
could
repres
import
potenti
sourc
ongo
bacteraemia
evid
suggest
risk
infect
colonis
arteri
line
may
similar
central
line
prospect
work
need
assess
impact
cathet
care
bundl
colonis
infect
rate
arteri
line
icu
introduct
central
venou
cathet
cvc
essenti
deliveri
medic
fl
uid
icu
patient
howev
carri
substanti
infect
risk
evid
collabor
cohort
studi
suggest
bundl
intervent
provid
sustain
decreas
infect
method
sinc
decemb
data
collect
daili
number
patient
one
cvc
posit
blood
cultur
review
monthli
predefi
ned
criteria
judg
whether
genuin
bacteraem
episod
thu
classifi
ed
laboratoryconfi
rmed
bloodstream
infect
monthli
rate
crbsi
per
dwellday
calcul
data
sinc
juli
number
intervent
aim
reduc
crbsi
introduc
icu
result
data
present
cvc
dwellday
month
tabl
present
data
three
full
year
one
part
year
januari
novemb
despit
increas
bedday
per
year
sustain
reduct
infect
rate
reduct
dwellday
conclus
crbsi
rate
dwellday
fi
rst
year
similar
postintervent
rate
pronovost
studi
subsequ
rate
reduc
suggest
outperform
secular
trend
proport
dwellday
bedday
reduc
may
suggest
reduct
durat
andor
quantiti
cvc
placement
predict
mortal
patient
candidemia
highli
advers
aim
studi
identifi
risk
factor
develop
candidemia
postop
patient
method
juli
june
postop
patient
n
admit
multival
icu
hospit
enrol
studi
record
age
sex
length
stay
icu
apach
ii
score
upon
admiss
icu
adjust
mortal
score
underli
condit
recent
oper
invas
therapeut
procedur
prior
usag
antimicrobi
agent
initi
bivari
statist
comparison
conduct
use
test
categor
data
student
test
wilcoxon
test
continu
data
rel
risk
rr
confi
denc
interv
ci
calcul
statist
signifi
canc
set
p
identifi
patient
characterist
associ
candidemia
use
multivari
logist
regress
multivari
analysi
also
includ
independ
risk
factor
report
recent
medic
literatur
result
logist
regress
analysi
report
adjust
odd
ratio
ci
age
birth
weight
place
birth
nicu
babi
born
show
place
hospitalis
signifi
cant
eff
ect
eco
infect
risk
highest
level
resist
among
eco
isol
observ
ampicillin
amoxicillinclavulan
acid
eco
isol
show
diff
erent
pulsotyp
domin
epidem
clone
detect
cluster
analysi
base
pfge
isol
show
uniqu
type
less
similar
suggest
genotyp
variabl
popul
isol
ident
pulsotyp
usual
deriv
patient
case
isol
isol
diff
erent
patient
nicu
period
time
case
seven
isol
locat
nicu
site
isol
appear
correl
cluster
analysi
conclus
unfortun
present
data
indic
antibiot
prophylaxi
presenc
symptom
chorioamnion
prom
help
reduc
risk
eco
infect
group
examin
infant
addit
multivari
analysi
demonstr
one
signifi
cant
risk
factor
eco
infect
among
infant
birth
weight
g
impact
nicu
epidemiolog
eco
infect
clearli
indic
observ
case
infect
connect
horizont
transmiss
thu
proof
link
observ
eco
infect
possibl
neglig
hand
hygien
excess
congest
nicu
confi
rmed
fact
epidem
clone
observ
introduct
healthcareassoci
infect
hai
icu
patient
relat
intub
mechan
ventil
central
venou
urinari
cathet
incid
hai
high
antibiot
strategi
suff
er
resist
common
class
antibacteri
agent
method
complex
program
includ
staff
teach
basic
approach
hand
hygien
microbiolog
passport
icu
depart
detect
sourc
pathogen
pollut
treatment
area
icu
implement
lugansk
region
clinic
hospit
incid
hai
studi
polytrauma
patient
implement
program
implement
result
implement
infect
control
program
incid
respiratori
tract
infect
polytrauma
patient
stay
icu
patient
urinari
infect
occur
patient
surgic
site
infect
found
patient
combin
infect
detect
patient
incid
multipledrugresist
bacteri
coloni
contrast
recent
data
obtain
implement
program
infect
control
show
respiratori
infect
occur
patient
catheterrel
urinari
tract
infect
detect
surgic
site
infect
detect
polytrauma
patient
hand
incid
multipledrugresist
bacteri
coloni
increas
signifi
cantli
p
type
hai
chang
nonsignifi
cantli
conclus
era
total
antibacteri
resist
educ
strategi
organ
approach
exampl
infect
control
antibiot
suscept
hand
hygien
forth
becom
potent
eff
ectiv
pharmacolog
innov
polytrauma
patient
one
sever
categori
suff
ere
hai
demand
high
level
complianc
infect
control
approach
side
doctor
well
staff
visitor
icu
refer
introduct
use
contact
precaut
recommend
reduc
transmiss
pathogen
howev
littl
research
regard
relationship
rate
patient
cultureposit
fi
nding
acinetobact
baumannii
consumpt
hand
disinfect
object
studi
therefor
evalu
trend
nosocomi
bacteri
detect
includ
baumannii
use
hand
disinfect
icu
method
singlecent
retrospect
observ
studi
carri
result
cultur
sputum
urin
blood
forth
use
examin
trend
detect
microbiolog
icu
patient
cultureposit
fi
nding
multidrugresist
baumannii
identifi
ed
studi
rate
patient
cultureposit
fi
nding
multidrugresist
pseudomona
aeruginosa
vs
per
patientday
p
p
aeruginosa
vs
per
patientday
p
signifi
cantli
diff
erent
earli
period
group
late
period
group
rate
patient
cultureposit
fi
nding
mrsa
vs
per
patientday
p
baumannii
vs
per
patientday
p
signifi
cantli
higher
late
period
group
earli
period
group
observ
studi
report
associ
wors
clinic
outcom
eff
ect
antifung
therapi
patient
remain
unclear
design
pilot
studi
assess
feasibl
larger
trial
evalu
infl
ammatori
profi
le
clinic
outcom
patient
conduct
doubleblind
placebocontrol
multicent
pilot
random
trial
antifung
therapi
critic
ill
patient
clinic
suspicion
ventilatorassoci
pneumonia
posit
airway
secret
specimen
candida
spp
also
includ
observ
group
without
candida
spp
airway
secret
measur
recruit
rate
infl
ammatori
profi
le
time
clinic
outcom
recruit
patient
random
trial
patient
observ
studi
recruit
halt
end
studi
diffi
culti
recruit
patient
marker
infl
ammat
clinic
outcom
compar
placebo
antifung
treatment
group
baselin
overtim
baselin
level
higher
vap
candida
compar
observ
group
mean
sd
interindividu
variabl
pk
paramet
ascrib
exponenti
model
accord
equat
exp
nj
estim
pharmacokinet
paramet
jth
patient
typic
popul
pk
paramet
valu
ka
clf
vf
n
random
variabl
normal
distribut
zero
mean
varianc
residu
variabl
estim
use
addit
additiveproport
error
model
cij
cj
cij
cj
cij
cj
observedpredict
concentr
jth
patient
time
respect
error
random
variabl
normal
distribut
zero
mean
varianc
bayesian
estim
obtain
pharmacokinet
paramet
cmax
tmax
hour
calcul
result
cmax
pza
recommend
concentr
mgl
rif
cmax
recommend
level
mgl
cmax
inh
recommend
level
mgl
see
tabl
conclus
larg
interindividu
pharmacokinet
variabl
concentr
recommend
level
rif
iso
need
monitor
drug
reevalu
dose
introduct
staphylococcu
epidermidi
se
often
isol
speci
coagulaseneg
staphylococci
recogn
one
main
caus
icu
infect
studi
aim
studi
resist
profi
le
se
clinic
isol
lastlin
antibiot
vancomycin
va
teicoplanin
tec
linezolid
lz
daptomycin
da
treat
cn
infect
period
method
januari
decemb
examin
nondupl
se
isol
recov
blood
cultur
patient
hospit
surgic
icu
hospit
speci
identifi
cation
suscept
test
perform
use
autom
vitek
ii
system
biomerieux
addit
use
etest
method
biomerieux
abibiodisk
order
confi
rm
isol
resist
tec
lz
found
vitek
ii
system
estim
mic
level
da
va
muellerhinton
agar
adjust
contain
physiolog
level
free
calcium
ion
use
test
da
suscept
isol
mic
mgl
consid
resist
tec
lz
mic
mgl
mic
mgl
suscept
da
va
respect
result
percentag
resist
rate
examin
se
isol
shown
tabl
methicillin
resist
observ
overal
preval
approxim
resist
isol
tec
lz
also
resist
methicillin
mic
valu
va
lower
mgl
tabl
conclus
examin
se
isol
present
scatter
resist
tec
show
remark
continu
increas
resist
lz
fi
nding
enforc
necess
take
appropri
measur
icu
environ
clinic
practic
limit
dissemin
amplifi
cation
resist
da
va
possess
excel
vitro
activ
se
isol
could
good
altern
solut
treat
icu
infect
caus
speci
introduct
patienttopati
transmiss
enabl
vancomycinresist
enterococci
vre
outbreak
outbreak
manag
expens
time
consum
therefor
possibl
vre
erad
desir
sinc
vancomycin
scarc
absorb
gastrointestin
tract
treatment
vancomycin
per
os
may
result
high
gastrointestin
concentr
mani
time
minimum
inhibit
concentr
mic
purpos
studi
measur
vivo
gastrointestin
concentr
vancomycin
patient
treat
standard
dose
oral
investig
vitro
whether
vancomycin
abl
kill
vre
concentr
time
mic
method
faecal
vancomycin
concentr
measur
eight
patient
suff
ere
clostridium
diffi
cile
infect
treat
mg
vancomycin
oral
per
day
vitro
dilut
seri
vancomycin
rang
creat
ml
vancomycin
solut
ad
ml
standard
inoculum
one
vancomycinsuscept
enterococcu
isol
vse
mic
ml
two
vre
isol
mic
studi
day
incub
growth
defi
ned
macroscop
visibl
turbid
test
surviv
bacteria
inocula
cultur
sheep
blood
agar
plate
read
incub
etest
measur
mic
perform
relev
sampl
vitro
experi
perform
twice
result
faecal
vancomycin
concentr
patient
treat
oral
vancomycin
averag
vse
growth
day
detect
vancomycin
wherea
vre
growth
detect
mic
vre
speci
grow
vancomycin
increas
vse
vre
surviv
bacteria
detect
high
concentr
vancomycin
mic
survivor
increas
conclus
oral
treatment
vancomycin
result
extrem
high
faecal
concentr
high
concentr
vre
bacteria
kill
vitro
howev
minor
vre
abl
surviv
vancomycin
thu
seem
unsuit
erad
howev
high
concentr
vancomycin
dramat
reduc
bacteri
vre
load
therefor
oral
treatment
vancomycin
may
help
termin
vre
outbreak
dramat
reduct
bacteri
load
colonis
patient
minimis
risk
patienttopati
transmiss
introduct
optim
durat
antibiot
treatment
critic
ill
patient
remain
subject
debat
multidisciplinari
icu
short
cours
antibiot
monotherapi
day
gener
use
critic
care
volum
suppl
http
strategi
treat
bacteraemia
unless
specifi
calli
indic
otherwis
exampl
endocard
osteomyel
aim
determin
impact
strategi
antibiot
resist
pattern
patient
outcom
compar
similar
exercis
conduct
method
conduct
retrospect
studi
patient
bacteraemia
fungaemia
communityacquir
hospitalacquir
icuacquir
treat
univers
hospit
icu
period
decemb
may
compar
data
blood
cultureposit
patient
admit
februari
juli
inform
collect
bacteraemia
episod
caus
pathogen
antimicrobi
resist
pattern
antibiot
use
durat
patient
outcom
notabl
icu
admit
mani
immunosuppress
patient
exampl
haemoncolog
result
tabl
present
demograph
incid
bacteraemia
antimicrobi
resist
remain
low
cohort
multiresist
gramneg
organ
fungaemia
episod
mark
decreas
methicillinresist
staphylococcu
aureu
mrsa
figur
number
relaps
breakthrough
bacteraemia
remain
low
conclus
strategi
shortcours
antibiot
monotherapi
associ
low
breakthrough
relaps
rate
low
rate
antibiot
resist
communityacquir
bacteraemia
hospitalacquir
bacteraemia
icuacquir
bacteraemia
introduct
administr
time
appropri
antibiot
therapi
wellknown
prognost
factor
among
sever
sepsi
patient
purpos
studi
describ
magnitud
impact
earli
appropri
empir
antibiot
therapi
hospit
mortal
conclus
contrarili
describ
previous
earli
appropri
empir
antibiot
therapi
associ
better
prognosi
probabl
explan
higher
complianc
found
current
recommend
reinforc
need
period
audit
feedback
team
refer
introduct
candida
spp
increasingli
isol
critic
ill
clinic
signifi
canc
hereof
hard
establish
candida
spp
colon
suggest
risk
factor
ventilatorassoci
pneumonia
vap
effi
caci
safeti
inhal
amphotericin
b
ab
unknown
hypothesi
inhal
ab
deoxychol
safe
eff
ectiv
treatment
candida
spp
colon
respiratori
tract
therebi
prevent
vap
prolong
need
mechan
ventil
result
administr
adjunct
system
antibiot
associ
decreas
system
infl
ammat
acut
respiratori
insuffi
cienci
sign
day
treatment
onset
vs
day
group
p
decreas
microbi
titer
cfuml
detect
group
day
critic
care
volum
suppl
http
reliabl
patient
group
p
noteworthi
group
patient
vitro
resist
tobramycin
clinic
eff
ectiv
probabl
due
local
superconcentr
treatment
associ
increas
sensit
microb
antibiot
prior
resist
patient
probabl
due
eff
ect
biolay
deescal
antibiot
therapi
possibl
group
day
patient
treatment
made
possibl
wean
patient
day
treatment
cessat
vs
day
group
p
hear
loss
tinnitu
detect
three
patient
group
case
bronchospasm
mortal
n
group
n
group
p
relat
progress
np
conclus
administr
adjunct
system
antibiot
effi
cient
treatment
np
caus
multiresist
gramneg
bacteria
sepsi
introduct
appropri
antibiot
prophylaxi
play
crucial
role
prevent
sternal
wound
infect
cardiac
surgeri
institut
high
preval
methicillinresist
staphylococci
speci
vancomycin
prophylaxi
recommend
either
monotherapi
adjuv
agent
studi
assess
sternal
wound
infect
rate
introduct
vancomycin
prophylaxi
protocol
method
twentysix
total
consecut
cardiac
surgic
patient
juli
decemb
develop
sternal
wound
infect
group
patient
receiv
standard
empir
antibiot
prophylaxi
januari
juli
patient
underw
cardiac
surgeri
group
b
group
appli
restrict
antibiot
protocol
consid
resist
pattern
result
microbiolog
test
group
also
evalu
result
mic
suscept
test
fi
antibiot
oxacillin
linezolid
daptomycin
teicoplanin
vancomycin
new
protocol
fi
rst
vancomycin
dose
given
hour
sternal
incis
follow
three
addit
dose
hour
durat
thirtythre
yield
signifi
cant
result
nine
deem
clinic
use
total
cultur
taken
fi
rst
hour
icu
posit
six
use
fiftythre
taken
next
hour
two
posit
two
use
fortyfour
cultur
taken
follow
hour
two
posit
one
use
total
cultur
taken
subsequ
icu
posit
three
deem
use
blood
cultur
taken
hour
post
icu
one
posit
deem
use
yield
conclus
result
demonstr
overal
low
clinic
util
blood
cultur
specifi
calli
util
icu
cultur
signifi
cantli
lower
pre
icu
vs
p
yield
posit
blood
cultur
clinic
util
also
decreas
icu
stay
may
refl
ect
appropri
empir
antibiot
lower
bacteraemia
burden
later
ill
given
low
clinic
yield
lack
establish
sensit
specifi
c
trigger
suggest
work
icu
set
maximis
util
whilst
minimis
harm
refer
introduct
surviv
sepsi
campaign
ssc
develop
guidelin
promot
evidencebas
manag
patient
sever
sepsi
improv
bundl
complianc
demonstr
time
complianc
remain
sepsi
studi
acut
critic
care
environ
littl
research
focus
manag
level
ward
initi
audit
patient
sepsi
refer
gstt
critic
care
outreach
team
reveal
low
overal
complianc
ssc
bundl
novel
qualiti
improv
campaign
institut
aim
improv
bundl
complianc
method
retrospect
cohort
studi
univers
hospit
perform
patient
level
ward
sever
sepsi
regist
adult
critic
care
respons
team
ccrt
databas
novemb
identifi
ed
cohort
physiolog
observ
track
trigger
score
complianc
bundl
element
measur
lactat
blood
cultur
antibiot
fl
uid
challeng
earli
antibiot
antimicrobi
stewardship
mortal
record
follow
qualiti
improv
project
initi
central
electron
sepsi
order
set
contain
appropri
investig
stepbystep
manag
guid
use
level
ward
viral
print
social
media
campaign
also
undertaken
complianc
ssc
earli
care
bundl
reexamin
two
cohort
patient
juli
patient
refer
ccrt
cohort
b
also
patient
electron
order
set
activ
cohort
c
mean
age
patient
studi
n
year
fiftythre
per
cent
patient
male
thirtyon
per
cent
septic
shock
time
sepsi
identifi
cation
overal
ssc
bundl
complianc
cohort
cohort
b
cohort
c
improv
bundl
paramet
also
seen
includ
blood
cultur
antibiot
administr
fl
uid
administr
septic
shock
cohort
cohort
b
cohort
c
respect
conclus
baselin
complianc
ssc
bundl
level
ward
low
electron
sepsi
order
set
associ
mark
improv
novel
qualiti
improv
methodolog
may
import
achiev
optim
complianc
evidencebas
guidelin
electron
sepsi
order
set
recommend
refer
introduct
lung
cardiac
oper
caus
signifi
cant
chang
fl
uid
balanc
thu
high
incid
develop
postop
acut
kidney
injuri
aki
renal
resist
index
rri
calcul
pattern
renal
arteri
fl
ow
indic
renal
arteri
fl
ow
research
work
aim
evalu
effi
cienci
rri
earli
predict
postop
kidney
injuri
major
lung
cardiac
oper
method
twentytwo
patient
undergon
lung
cardiac
surgeri
includ
studi
kidney
local
ultrasonographi
best
region
blood
fl
ow
detect
use
color
doppler
arteri
waveform
region
obtain
optim
doppler
measur
taken
three
diff
erent
region
averag
rri
calcul
preoper
postop
fi
rst
hour
respect
result
signifi
cant
correl
establish
rri
postop
creatinin
level
p
rri
valu
reach
highest
point
postop
fi
rst
day
wherea
creatinin
level
reach
highest
level
postop
third
day
although
correl
postop
creatinin
level
durat
stay
hospit
signifi
cant
relationship
detect
durat
stay
icu
creatinin
level
p
case
divid
two
group
rri
less
n
larger
n
signifi
cant
diff
erenc
present
regard
age
creatinin
level
conclus
rri
use
evalu
renal
arteri
fl
ow
directli
relat
increas
renal
vascular
resist
case
aki
use
rri
predict
aki
shown
clinic
follow
renal
allograft
experiment
acut
tubular
necrosi
model
also
septic
patient
assert
rri
better
marker
cystatin
c
one
popular
marker
recent
time
predict
develop
aki
result
show
rri
could
simpl
noninvas
use
techniqu
earli
diagnosi
aki
patient
undergo
major
oper
lung
cardiac
surgeri
assess
eff
ect
fl
uid
balanc
fb
acut
kidney
injuri
aki
classifi
cationprognosi
cardiac
surgic
patient
compar
patient
classifi
ed
aki
adjust
creatinin
use
classifi
aki
fb
fluid
accumul
associ
neg
outcom
includ
develop
aki
critic
ill
patient
cardiac
surgic
patient
commonli
receiv
larg
volum
fl
uid
postop
could
risk
harm
eff
ect
fl
uid
accumul
furthermor
fl
uid
accumul
may
infl
uenc
serum
creatinin
concentr
mask
aki
method
perform
retrospect
analysi
prospect
collect
data
cardiac
surgic
patient
admit
st
vincent
hospit
icu
melbourn
australia
juli
june
aki
network
creatinin
criteria
use
classifi
aki
usual
method
use
fbadjust
creatinin
fb
hour
assumpt
total
bodi
water
weight
involv
fb
total
iv
input
minu
total
urin
output
chest
drain
loss
calcul
hour
post
surgeri
patient
icu
period
result
patient
classifi
ed
aki
increas
n
adjust
creatinin
fb
patient
categoris
four
group
base
presenc
absenc
aki
adjust
fb
group
aki
adjust
fb
group
b
aki
beforeaki
group
c
aki
beforeno
aki
group
aki
group
b
n
inhospit
mortal
rate
similar
patient
group
n
vs
p
greater
group
n
vs
p
group
b
also
icu
mortal
rate
similar
patient
group
vs
p
signifi
cantli
greater
group
vs
p
need
renal
replac
therapi
rrt
group
b
also
high
patient
group
vs
p
signifi
cantli
greater
group
vs
p
thu
hospit
icu
mortal
use
rrt
patient
classifi
ed
aki
adjust
fb
similar
patient
aki
adjust
fb
notabl
higher
patient
without
aki
conclus
lack
adjust
fb
post
cardiac
surgeri
may
mask
presenc
aki
associ
increas
risk
death
rrt
could
hinder
optim
treatment
refer
introduct
acut
kidney
injuri
aki
complic
icu
admiss
associ
signifi
cantli
increas
mortal
length
stay
cost
across
broad
spectrum
condit
method
perform
singlecentr
retrospect
analysi
aki
diagnosi
patient
icu
admiss
day
surviv
hospit
discharg
examin
relationship
hospit
length
stay
aki
diagnosi
demograph
clinic
characterist
multivari
coxhazard
analysi
result
identifi
ed
case
incid
aki
aki
associ
older
age
greater
initi
ill
sever
longer
icu
hospit
length
stay
univari
analysi
tabl
coxhazard
analysi
aki
categori
icu
length
stay
signifi
cantli
associ
lower
probabl
discharg
time
figur
associ
hazard
ratio
hospit
discharg
introduct
acut
kidney
injuri
aki
signifi
cant
complic
follow
cardiac
surgeri
associ
increas
morbid
hospit
stay
mortal
although
estim
incid
aki
follow
cardiac
surgeri
studi
identifi
ed
incid
aki
follow
cardiac
surgeri
defi
ned
kidney
diseas
improv
global
outcom
kdigo
group
conduct
prospect
observ
studi
institut
identifi
incid
stage
aki
accord
kdigo
defi
nition
also
aim
identifi
factor
predispos
adult
patient
develop
aki
post
cardiac
surgeri
method
prospect
analysi
perform
adult
patient
admit
icu
postcardiac
surgeri
septemb
octob
data
periop
risk
factor
renal
biochem
marker
collect
sixth
postop
day
express
mean
sd
result
order
logist
regress
use
analys
data
thirtythre
per
cent
cardiac
surgeri
patient
institut
develop
aki
factor
poor
left
ventricular
lv
function
low
preoper
haematocrit
low
preoper
glomerular
fi
ltration
rate
gfr
signifi
cant
risk
factor
p
p
p
respect
develop
postop
aki
follow
cardiac
surgeri
see
tabl
result
suggest
focu
lv
function
gfr
predictor
develop
aki
follow
cardiac
surgeri
strategi
increas
preoper
haematocrit
investig
reduc
incid
sever
postop
aki
refer
introduct
critic
ill
patient
care
icu
often
requir
radiolog
investig
use
iodin
contrast
agent
contrastinduc
nephropathi
cin
form
acut
kidney
injuri
aki
complic
follow
use
contrast
although
cin
thoroughli
studi
popul
exampl
undergo
coronari
angiographi
investig
larg
number
icu
patient
infl
ammatori
condit
aim
describ
immun
phenotyp
human
aki
method
enrol
patient
aki
grade
iiiii
defi
ned
kdigo
criteria
system
infl
ammatori
respons
syndrom
sir
without
sepsi
sir
without
aki
aki
iiiii
without
sir
healthi
control
popul
use
baselin
comparison
serial
blood
sampl
taken
day
cell
separ
use
percol
gradient
phenotyp
use
fl
ow
cytometri
result
day
sampl
identifi
ed
statist
signifi
cant
diff
erenc
sir
aki
aki
sir
healthi
control
amongst
cytotox
cell
regulatori
cell
cytokin
secret
nontregulatori
cell
tabl
percentag
neutrophil
signifi
cantli
increas
across
three
group
rel
control
littl
variat
aki
sir
aki
sir
patient
introduct
approxim
acut
kidney
injuri
aki
associ
sepsi
neutrophil
gelatinaseassoci
lipocalin
ngal
cystatin
c
two
wide
use
biomark
aki
howev
two
marker
also
aff
ect
system
infl
ammatori
respons
diagnost
valu
sepsisinduc
aki
disput
unlik
clinic
aki
anim
model
use
explor
singl
etiolog
purpos
studi
examin
relationship
infl
ammatori
mediat
biomark
aki
sepsi
model
rat
method
sepsi
induc
cecal
ligat
punctur
clp
adult
sd
rat
observ
aki
surviv
blood
urin
sampl
collect
baselin
hour
clp
aki
sever
assess
rifl
criteria
creatinin
associ
plasma
plasma
ngal
plasma
cystatin
c
urin
ngal
urin
cystatin
c
analyz
area
receiveroper
characterist
curv
auc
use
evalu
diagnost
capabl
sever
aki
riflei
riflef
aki
includ
rifler
diff
erent
biomark
chang
plasma
ngal
plasma
cystatin
c
urin
ngal
urin
cystatin
c
time
similar
chang
plasma
howev
plasma
ngal
level
close
correl
level
plasma
r
p
analysi
plasma
cystatin
c
urin
ngal
urin
cystatin
c
hour
sever
aki
show
auc
respect
p
auc
plasma
ngal
p
signifi
cant
diff
erenc
plasma
ngal
hour
sever
aki
aki
vs
uml
p
conclus
anim
model
clp
sepsi
plasma
ngal
level
aff
ect
system
infl
ammatori
respons
discrimin
aki
urin
ngal
plasma
cystatin
c
urin
cystatin
c
abl
diff
erenti
sever
aki
aki
clp
sepsi
refer
serum
creatinin
howev
serum
creatinin
insensit
nonspecifi
c
biomark
studi
design
investig
whether
correl
exist
urinari
oxygen
tension
uot
earli
marker
aki
aim
evalu
whether
uot
could
provid
warn
sign
insuffi
cient
renal
oxygen
suppli
lead
postop
aki
method
fourteen
subject
undergo
cardiac
surgeri
cpb
includ
prospect
clinic
pilot
studi
uot
measur
periop
patient
oper
room
cpb
icu
biomark
aki
blood
urin
measur
preoper
postop
hour
initi
cpb
includ
serum
creatinin
earli
urinari
biomark
kidney
injuri
neutrophil
gelatinaseassoci
lipocalin
ngal
cystatin
c
student
test
mannwhitney
test
use
compar
continu
variabl
signifi
cant
decreas
uot
start
cpb
mmhg
lowest
uot
cpb
mmhg
p
divid
subject
two
group
accord
acut
kidney
injuri
network
akin
classifi
cation
signifi
cant
diff
erenc
found
mean
uot
group
patient
normal
kidney
function
n
group
akin
stage
n
signifi
cant
diff
erenc
two
group
found
hour
p
initi
cpb
ngal
signifi
cant
increas
biomark
concentr
compar
preoper
valu
observ
group
akin
stage
diff
erent
postop
time
point
hour
p
hour
p
hour
p
hour
p
contrari
signifi
cant
increas
urinari
ngal
level
measur
group
normal
kidney
function
conclus
pilot
studi
abl
demonstr
associ
periop
measur
uot
marker
postop
aki
addit
laboratori
clinic
studi
necessari
defi
ne
relationship
uot
new
biomark
aki
refer
introduct
acut
kidney
injuri
aki
surgic
critic
ill
patient
independ
risk
factor
earli
mortal
two
novel
urin
biomark
insulinlik
growth
factorbind
protein
tissu
inhibitor
may
help
detect
clinic
silent
episod
aki
golden
hour
prior
irrevers
damag
kidney
evalu
earli
predict
valu
biomark
aki
moder
sever
aki
earli
requir
renal
replac
therapi
rrt
icu
mortal
cutoff
valu
method
four
six
hour
admiss
surgic
icu
urin
biomark
prospect
evalu
patient
present
exposur
suscept
aki
accord
kdigo
recommend
incid
sever
aki
kdigo
requir
rrt
assess
hour
admiss
addit
icu
mortal
variabl
norepinephrin
dose
mean
arteri
pressur
hemoglobin
level
cumul
fl
uid
balanc
urin
product
note
time
biomark
evalu
hour
fi
rst
hour
admiss
predict
valu
biomark
better
earli
predict
clinic
paramet
urin
output
within
fi
rst
hour
admiss
icu
recent
report
multicent
studi
sapphir
biomark
combin
tissu
inhibitor
insulinlik
growth
factor
bind
protein
valid
risk
stratifi
cation
moder
sever
acut
kidney
injuri
aki
kdigo
stage
method
subsequ
select
two
clinic
cutoff
valu
combin
sapphir
dataset
one
high
sensit
specifi
citi
one
high
specifi
citi
sensit
develop
aki
kdigo
stage
within
hour
studi
enrol
examin
time
chang
rel
chang
creatinin
use
sign
test
result
result
avail
patient
develop
aki
stage
median
result
signifi
cantli
greater
cutoff
valu
hour
hour
aki
p
figur
convers
median
serum
creatinin
diff
erent
baselin
prior
develop
aki
conclus
biomark
combin
identifi
es
patient
ultim
develop
moder
sever
aki
hour
earlier
serum
creatinin
refer
introduct
comput
tomographi
contrast
medium
common
diagnost
tool
emerg
critic
medicin
contrastinduc
nephropathi
cin
one
lead
caus
hospitalacquir
acut
kidney
injuri
focu
renal
tubul
protect
may
hope
improv
eff
ectiv
current
strategi
method
use
human
renal
proxim
tubul
cell
evalu
therapeut
potenti
resveratrol
polyphenol
phytoalexin
anim
model
singl
high
dose
epo
shown
amelior
reperfus
injuri
ischemia
howev
recent
human
studi
shown
confl
ict
result
aim
studi
eff
ect
singl
high
dose
epo
preoper
renal
function
coronari
arteri
bypass
graft
cabg
patient
preoper
impair
renal
function
method
singlecentr
random
doubleblind
placebocontrol
studi
includ
patient
schedul
cabg
preexist
renal
impair
estim
glomerular
fi
ltration
rate
base
pcystatin
c
mlminut
mlminut
patient
either
receiv
singl
high
dose
epo
iukg
placebo
preoper
primari
endpoint
renal
protect
evalu
pcystatin
c
third
postop
day
compar
preoper
valu
incid
acut
kidney
injuri
renal
biomark
chang
among
secondari
endpoint
result
signifi
cant
diff
erenc
third
postop
day
pcystatin
c
level
mgl
studi
group
mgl
control
group
p
signifi
cant
diff
erenc
renal
biomark
measur
group
pngal
pcreatinin
purea
estim
glomerular
fi
ltration
rate
diff
erenc
outcom
variabl
group
conclus
intraven
administr
singl
high
dose
iu
kg
epo
renal
protect
eff
ect
patient
reduc
kidney
function
undergo
coronari
arteri
bypass
surgeri
introduct
aim
studi
quantifi
impact
use
egfr
instead
measur
creatinin
clearanc
clcr
evalu
recoveri
acut
kidney
injuri
aki
introduct
acut
kidney
injuri
aki
seriou
complic
follow
lung
transplant
ltx
aim
describ
incid
outcom
associ
aki
follow
ltx
fl
uid
accumul
percentag
total
urin
chest
drain
loss
subtract
total
iv
intak
l
weight
kg
calcul
hour
post
surgeri
patient
icu
period
acut
kidney
injuri
network
akin
creatinin
criteria
use
classifi
aki
use
creatinin
adjust
fl
uid
balanc
result
renal
replac
therapi
perform
patient
group
fl
uid
accumul
percentag
associ
increas
odd
aki
ci
increas
odd
requir
renal
replac
therapi
percent
increas
fl
uid
accumul
lkg
cardiac
surgeri
adjust
variabl
includ
apach
score
cardiac
failur
type
surgeri
inotrop
use
multivari
analysi
conclus
rel
homogen
patient
group
undergo
cardiac
surgeri
postop
percent
fl
uid
accumul
hour
associ
aki
need
renal
replac
therapi
whether
residu
confound
due
indic
fl
uid
use
unmeasur
risk
factor
requir
investig
control
trial
introduct
renal
replac
therapi
critic
care
associ
increas
mortal
known
patient
rrt
confer
benefi
recov
function
remain
dialysi
independ
longterm
basi
conclus
report
incid
aki
critic
care
rang
highest
rate
seen
sepsi
utilis
crrt
aki
higher
centr
describ
potenti
due
close
collabor
critic
care
nephrolog
rel
lenient
icu
admiss
criteria
increas
mortal
seen
age
apach
ii
score
delay
initi
rrt
prospect
analysi
requir
look
determin
biomark
aki
risk
factor
mortal
dynam
monitor
haemodynam
respond
requir
hour
percentag
creatinin
decreas
severityofil
score
urin
output
result
current
rct
await
may
provid
inform
mode
clearanc
fl
ow
rate
earli
versu
standard
initi
rrt
accur
prognos
patient
outcom
elderli
year
uk
popul
increas
along
increas
utilis
critic
care
resourc
use
chronolog
age
bar
treatment
uneth
yet
discrep
opinion
remain
disinclin
elderli
advoc
intensivist
acut
kidney
injuri
requir
dialysi
frequent
complic
critic
ill
associ
high
morbid
mortal
increas
risk
seen
age
due
high
preval
risk
factor
chronic
kidney
diseas
elderli
method
elderli
patient
admit
tertiari
referr
itu
includ
decemb
novemb
retrospect
cohort
analysi
outcom
receiv
rrt
review
result
admiss
itu
classifi
ed
elderli
mean
apach
ii
score
rrt
utilis
n
elderli
patient
mean
apach
ii
score
fortyfi
per
cent
aki
due
sepsi
due
emerg
surgeri
itu
elderli
patient
mortal
receiv
rrt
itu
hospit
discharg
respect
recoveri
renal
function
seen
patient
itu
discharg
surviv
hospit
discharg
two
patient
requir
ongo
ihd
commun
conclus
current
predict
estim
elderli
uk
popul
almost
doubl
biggest
uptak
accept
chronic
rrt
elderli
diff
erenc
shown
healthrel
qualiti
life
gener
dialysi
popul
experi
suggest
rrt
role
critic
ill
elderli
patient
surviv
hospit
discharg
challeng
identifi
like
benefi
cohort
multipl
comorbid
avail
resourc
rise
demand
critic
care
age
popul
increas
expect
tabl
median
interquartil
rang
introduct
aim
studi
analyz
function
alter
may
infl
uenc
fi
nal
result
use
citrat
versu
heparin
anticoagul
critic
ill
patient
method
perform
retrospect
analyt
studi
includ
patient
exclus
submit
citrat
heparin
year
includ
demograph
data
sap
ii
sofa
rifl
score
mortal
rate
function
analysi
consid
time
begin
durat
loss
dose
loss
creatinin
clearanc
analyz
dialitrauma
consid
variat
potassium
total
ioniz
calcium
magnesium
sodium
phosphoru
ph
lactat
bicarbon
platelet
albumin
creatinin
urea
data
present
averag
standard
deviat
access
infl
uenc
dose
clearanc
loss
mortal
use
logist
regress
test
studi
includ
patient
citrat
group
versu
heparin
group
found
statist
signifi
cant
diff
erenc
age
p
sap
ii
p
sofa
p
time
begin
techniqu
p
versu
patient
r
rifl
versu
rifl
versu
f
rifl
durat
techniqu
p
length
stay
although
notic
greater
loss
dose
absolut
creatinin
clearanc
citrat
group
statist
signifi
canc
p
p
mortal
found
citrat
heparin
group
respect
diff
erenc
statist
signifi
canc
relat
dialitrauma
emerg
k
p
ca
p
na
p
platelet
p
ph
p
bicarbon
p
conclus
may
say
function
diff
erenc
must
taken
account
despit
statist
signifi
canc
sampl
loss
dose
creatinin
clearanc
show
direct
relat
mortal
refer
mean
aortic
crossclamp
minut
rang
measur
myg
procalcitonin
pct
creatinin
scr
icu
admiss
serum
myg
higher
mgdl
patient
treat
anticoagul
within
hour
icu
admiss
hour
dose
mlhour
biochem
assay
obtain
hour
icu
discharg
result
pretreat
myg
median
valu
ngml
signifi
cantli
reduc
averag
cvvhd
see
figur
remain
low
icu
discharg
median
valu
ngml
scr
remain
stabl
averag
time
valu
equal
mgdl
cvvhd
pct
also
decreas
time
reduct
rate
equal
mgdl
mgdl
end
cvvhd
final
six
patient
surviv
day
conclus
small
experi
confi
rm
serum
myg
like
increas
postcardiac
surgic
highrisk
patient
suggest
benefi
cial
eff
ect
crrt
treatment
membran
citrat
serum
myg
potenti
prevent
aki
larger
assess
advis
confi
rmation
refer
introduct
rhabdomyolysi
character
breakdown
striat
muscl
due
great
number
caus
acut
kidney
injuri
aki
common
complic
consequ
high
concentr
circul
myoglobin
mb
aki
degre
vari
often
requir
dialysi
condit
drastic
worsen
icu
stay
prognosi
sinc
mb
overconcentr
repres
caus
aki
one
therapi
aim
remov
prevent
kidney
damag
allow
faster
renal
recoveri
intermitt
hemodialysi
highvolum
cvvhf
poorli
eff
ectiv
remov
mb
smallprotein
leakag
membran
seem
promis
set
aim
studi
therefor
measur
effi
caci
mb
remov
new
high
cutoff
membran
freseniu
cutoff
valu
kda
continu
renal
replac
therapi
crrt
icu
set
method
report
result
treatment
seven
patient
four
malethre
femal
diff
erent
caus
rhabdomyolysi
trauma
sepsi
limb
ischemia
five
patient
classic
dialysi
indic
persist
anuria
two
patient
treatment
prophylact
start
crrt
deliv
cvvhd
mode
dialyz
locoregion
trisodiumcitr
anticoagul
mb
plasma
level
assess
hour
remov
rate
total
bodi
dialyz
clearanc
estim
kinet
model
previous
describ
clinic
data
also
collect
global
renal
patient
surviv
report
result
median
mb
valu
crrt
start
ngml
rang
ngml
crrt
deliv
averag
blood
fl
ow
rate
mlminut
dialys
fl
ow
rate
mlhour
oper
condit
allow
one
stop
treatment
averag
hour
median
hour
mb
reduct
rang
overal
median
mb
remov
per
treatment
mg
rang
mg
mainli
due
fi
rst
hour
treatment
mg
rang
mg
two
patient
residu
renal
function
one
case
measur
account
mg
mb
remov
entir
treatment
six
patient
surviv
recov
renal
function
dialysi
need
present
followup
one
patient
die
icu
stay
conclus
data
measur
high
perform
membran
mb
remov
confi
rm
theoret
model
indic
crrt
high
cutoff
membran
achiev
major
mb
remov
within
hour
great
superior
comparison
avail
techniqu
refer
introduct
remov
middl
molecular
weight
substanc
includ
cytokin
albuminbound
toxin
could
eff
ectiv
patient
acut
liver
failur
alf
develop
new
system
plasma
fi
ltration
dialysi
plasma
diafi
ltration
pdf
assess
effi
caci
multicent
analysi
method
subgroup
analysi
observ
studi
conduct
icu
six
hospit
pdf
simpl
plasma
exchang
perform
use
select
membran
plasma
separ
evaxclio
kawasumi
chemic
inc
tokyo
japan
siev
coeffi
cient
albumin
dialys
fl
ow
outsid
hollow
fi
ber
fl
ow
rate
blood
dialys
substitut
addit
substitut
mlminut
mlhour
mlhour
accord
rate
water
elimin
ml
hour
respect
substitut
addit
fl
uid
line
ad
ml
mlhour
fresh
frozen
plasma
follow
ml
albumin
consid
loss
albumin
diff
usion
anticoagul
nafamostat
mesil
torii
pharmaceut
co
ltd
tokyo
japan
use
rate
mghour
result
multicent
studi
underway
octob
august
perform
pdf
patient
alf
sever
sepsi
post
oper
fulmin
hepat
alcohol
hepat
graft
versu
host
diseas
other
serum
total
bilirubin
plasma
ptinr
model
endstag
liver
diseas
meld
score
pdf
procedur
mgdl
averag
sd
respect
pdf
perform
session
per
patient
overal
surviv
rate
accord
sever
meld
score
stratifi
ed
patient
three
categori
defi
ned
meld
score
number
patient
score
score
score
introduct
acut
liver
failur
alf
critic
ill
high
mortal
plasma
diafi
ltration
pdf
blood
purifi
cation
therapi
simpl
plasma
exchang
perform
use
select
membran
plasma
separ
dialys
fl
ow
outsid
hollow
fi
ber
sever
studi
demonstr
pdf
therapi
use
blood
purifi
cation
therapi
patient
alf
pdf
therapi
often
diffi
cult
employ
alf
patient
complic
multipl
organ
failur
especi
unstabl
hemodynam
furthermor
like
reoccur
immedi
pdf
therapi
develop
continu
pdf
cpdf
new
concept
pdf
therapi
assess
effi
caci
safeti
alf
patient
compar
convent
plasma
exchang
pe
plu
continu
hemodiafi
ltration
chdf
therapi
studi
method
ten
alf
patient
gender
malefemal
age
employ
cpdf
therapi
primari
outcom
alter
liver
function
measur
model
endstag
liver
diseas
meld
score
total
bilirubin
prothrombin
time
intern
normal
ratio
ptinr
day
cpdf
therapi
secondari
outcom
includ
sequenti
organ
failur
assess
sofa
score
day
cpdf
therapi
surviv
rate
day
therapi
result
meld
score
p
total
bilirubin
mgdl
p
ptinr
p
sofa
score
p
improv
day
cpdf
therapi
nine
patient
aliv
one
patient
die
due
acut
pancreat
complic
alf
effi
caci
cpdf
therapi
maintain
liver
function
renal
function
inferior
pe
plu
chdf
therapi
paramet
renal
function
creatinin
valu
also
improv
day
cpdf
therapi
circul
paramet
mean
arteri
pressur
heart
rate
maintain
without
inotrop
vasopressor
support
cpdf
treatment
period
oxygen
index
pao
fio
measur
pulmonari
function
tend
increas
treatment
could
employ
treatment
without
advers
event
infect
unstabl
hemodynam
conclus
present
studi
cpdf
therapi
safe
support
liver
function
gener
improv
condit
critic
ill
patient
alf
introduct
demonstr
blood
purifi
cation
therapi
perform
mean
venoven
hemodialysi
high
cutoff
membran
hcocvvhd
may
modul
host
infl
ammatori
respons
septic
patient
acut
kidney
injuri
aki
potenti
limit
organ
dysfunct
improv
hemodynam
respiratori
function
describ
hcocvvhd
treatment
sepsi
florenc
studi
sift
design
evalu
chang
infl
ammatori
biomark
tissu
oxygenationperfus
index
septic
icu
patient
aki
hcocvvhd
method
patient
microbiolog
confi
rmed
sever
sepsi
septic
shock
aki
rifl
criteria
f
treat
hcocvvhd
start
within
hour
diagnosi
prospect
includ
studi
cumul
vasopressor
index
cvi
creactiv
protein
level
crp
serum
lactat
concentr
lac
central
venou
oxygen
satur
scvo
measur
hour
hour
hcocvvhd
initi
data
express
median
rang
mannwhitney
u
test
appli
detect
diff
erenc
cvi
crp
lac
scvo
three
time
point
statist
signifi
canc
p
result
icu
total
patient
six
cardiac
surgeri
four
abdomin
surgeri
six
medic
met
inclus
criteria
enrol
studi
signifi
cant
reduct
crp
level
observ
time
mgdl
mgdl
p
scvo
signifi
cantli
increas
p
final
serum
lactat
decreas
mmoll
mmoll
p
convers
cvi
signifi
cantli
reduc
time
vs
p
conclus
preliminari
data
show
patient
sepsisrel
aki
may
benefi
earli
treatment
hcocvvhd
modul
proinfl
ammatori
antiinfl
ammatori
mediat
previous
demonstr
may
improv
microcircul
tissu
perfus
cellular
oxygen
although
promis
result
must
confi
rmed
end
studi
larger
observ
final
subgroup
analysi
absolut
mandatori
order
explor
diff
erent
behavior
tissu
perfus
index
diff
erent
popul
patient
introduct
littl
inform
avail
regard
ciprofl
oxacin
pharmacokinet
pharmacodynam
sepsi
patient
receiv
sustain
loweffi
cienci
dialysi
sled
studi
determin
pharmacokinet
simul
pharmacodynam
ciprofl
oxacin
icu
patient
sled
method
studi
prospect
evalu
ciprofl
oxacin
pharmacokinet
patient
sepsi
year
age
urin
output
mlday
receiv
sled
least
hour
follow
inform
consent
plasma
sampl
collect
baselin
hour
ciprofl
oxacin
mg
dose
iv
sled
postsl
therapi
time
dialys
sampl
collect
interv
sled
pharmacokinet
paramet
determin
use
winnonlin
compar
two
period
simul
pharmacodynam
paramet
determin
pseudomona
aeruginosa
use
mic
result
total
seven
patient
four
male
three
femal
age
apach
ii
enrol
ciprofl
oxacin
clear
rel
rapidli
halflif
hour
ke
sled
compar
hour
postsl
p
simul
pharmacodynam
demonstr
inadequ
coverag
p
aeruginosa
sled
cmaxmic
ratio
aucmic
conclus
ciprofl
oxacin
rapidli
clear
sled
similar
clearanc
normal
renal
function
may
result
adequ
pharmacodynam
coverag
pathogen
introduct
antibiot
dose
patient
acut
renal
failur
receiv
continu
renal
replac
therapi
crrt
clinic
challeng
aim
studi
investig
pharmacokinet
meropenem
crrt
method
prospect
multicent
studi
conduct
seven
hospit
fifteen
critic
ill
patient
undergo
either
continu
venoven
hemofi
ltration
cvvhf
hemodiafi
ltration
cvvhdf
includ
serum
ultrafi
ltrate
uf
level
determin
liquid
chromatographi
blood
sampl
drawn
hour
start
crrt
pm
pm
pm
follow
day
crrt
clearanc
cl
total
amount
uf
muf
percentag
dose
extract
crrt
ef
auc
nghourml
calcul
result
nine
patient
treat
cvvhdf
six
cvvhf
g
administ
everi
h
iv
infus
minut
data
mean
sd
concern
dialys
fl
ow
rate
df
mlhour
blood
fl
ow
rate
mlminut
averag
uf
rate
ml
kghour
crrt
techniqu
shown
tabl
pharmacokinet
introduct
acut
kidney
injuri
aki
critic
ill
independ
risk
factor
advers
outcom
previous
suggest
highvolum
haemofi
ltration
hvhf
may
confer
mortal
benefi
lead
reduct
organ
failur
compar
standard
ultrafi
ltration
rate
uf
confi
rmed
recent
investig
also
determin
whether
ideal
introduct
sepsisinduc
immunosuppress
long
consid
factor
late
mortal
sepsi
patient
littl
known
immun
immunocompet
cell
eff
ect
polymyxin
bimmobil
fi
ber
hemoperfus
therapi
pmxdhp
sepsisinduc
immunosuppress
present
studi
design
evalu
eff
ect
pmxdhp
recoveri
sepsisrel
immunodefi
cienci
method
patient
septic
shock
treat
pmxdhp
enrol
studi
studi
number
peripher
lymphocyt
cell
especi
regulatori
cell
treg
serum
cytokin
level
examin
evalu
eff
ect
pmxdhp
septic
shock
patient
peripher
blood
mononuclear
cell
pbmc
patient
examin
evalu
infl
ammatori
cytokin
product
pmxdhp
obtain
pbmc
stimul
interleukin
il
antibodi
lipopolysaccharid
hour
tumor
necrosi
factor
alpha
interferongamma
product
cultur
supernat
measur
use
enzymelink
immunosorb
assay
studi
whole
blood
patient
sepsi
incub
polymyxin
bimmobil
fi
lter
cut
small
size
small
anim
hour
pmx
group
treat
polymyxin
b
hour
plb
group
treat
sepsi
group
product
pbmc
compar
among
three
group
result
studi
number
cell
lower
percentag
treg
cell
higher
septic
shock
patient
compar
without
shock
signifi
cant
increas
number
cell
signifi
cant
decreas
percentag
treg
tcell
popul
signifi
cant
decreas
serum
level
observ
hour
pmxdhp
septic
shock
patient
surviv
compar
product
pbmc
signifi
cantli
lower
patient
sepsi
healthi
volunt
product
pbmc
signifi
cantli
increas
pmxdhp
therapi
studi
product
pbmc
patient
sepsi
increas
signifi
cantli
pmx
plb
group
compar
sepsi
group
conclus
pmxdhp
directli
decreas
number
percentag
treg
peripher
blood
circul
cell
patient
septic
shock
pmxdhp
improv
product
natur
killer
nk
nkt
cell
patient
septic
shock
therefor
pmxdhp
could
improv
sepsisrel
immunosuppress
actigraph
devic
sleep
watch
shown
equival
accuraci
polysomnographi
previous
use
critic
ill
show
sleep
disrupt
object
assess
patient
longterm
sleep
qualiti
use
actigraph
devic
method
studi
patient
select
multidisciplinari
icu
thirteen
patient
year
old
stay
longer
day
icu
acut
brain
injuri
follow
month
post
hospit
discharg
actigraph
devic
given
patient
take
home
worn
hour
previous
valid
algorithm
use
analyz
sleep
wake
cycl
addit
patient
complet
pittsburgh
sleep
qualiti
index
pqsi
measur
subject
sleep
qualiti
result
sixtytwo
percent
patient
month
post
hospit
discharg
report
poor
sleep
qualiti
per
psqi
actigraph
result
show
patient
averag
total
sleep
time
hour
sleep
effi
cienci
mean
time
fall
asleep
minut
patient
averag
awaken
per
night
awak
averag
minut
awaken
associ
found
patient
perceiv
sleep
qualiti
total
sleep
sleep
effi
cienci
sleep
disrupt
patient
sever
ill
measur
apach
ii
score
statist
associ
lower
total
sleep
time
p
reduc
sleep
effi
cienci
p
higher
number
sleep
disrupt
p
number
day
ventil
icu
hospit
length
stay
statist
associ
actigraph
sleep
paramet
conclus
survivor
critic
ill
high
level
sleep
dysfunct
measur
actigraphi
patient
sever
ill
critic
ill
appear
increas
level
longterm
sleep
dysfunct
experienc
discord
object
subject
measur
sleep
qualiti
shown
previous
object
measur
sleep
qualiti
need
larger
number
patient
confi
rm
fi
nding
use
label
augment
sedat
delirium
treatment
knowledg
public
evalu
effi
caci
safeti
clonidin
ventil
critic
ill
adult
survey
german
icu
show
clonidin
use
sedat
unit
undertook
enquiri
investig
label
use
clonidin
dutch
icu
critic
care
volum
suppl
http
lifethreaten
complic
audit
done
highlight
lipid
profi
le
electrocardiogram
ecg
rare
monitor
recommend
regular
monitor
paramet
propofol
sedat
use
day
propofolspar
agent
consid
patient
risk
develop
pri
method
patient
requir
propofol
sedat
day
prospect
monitor
frequenc
perform
lipid
profi
le
ecg
frequenc
coadministr
propofolspar
agent
provid
rate
sedat
satisfact
cough
abil
perform
intend
procedur
use
mm
visual
analog
scale
end
procedur
blind
bi
unsatisfi
ed
satisfi
ed
patient
survey
hour
hour
regard
overal
sedat
symptom
procedur
recal
unpleas
recal
recal
group
diff
erenc
consid
statist
signifi
cant
p
result
twentysix
procedur
monitor
cs
six
endobronchi
ultrasound
procedur
ds
diff
erenc
respect
age
gender
mean
dose
midazolam
fentanyl
mg
respect
bi
valu
lower
predefi
ned
point
procedur
ds
case
versu
cs
physician
satisfi
ed
sedat
lack
cough
ds
signifi
cant
diff
erenc
patient
satisfact
two
group
regard
overal
sedat
procedurerel
symptom
willing
repeat
bronchoscopi
patient
recal
lower
nadir
bi
score
vs
p
score
procedur
end
vs
p
compar
recal
diff
erenc
dose
midazolam
fentanyl
cs
case
despit
statist
signifi
cant
diff
erenc
patient
recal
bi
score
junior
fellow
score
greater
satisfact
sedat
less
bother
cough
often
felt
abl
perform
intend
procedur
compar
senior
fellow
conclus
deep
sedat
result
greater
physician
satisfact
procedur
condit
well
lower
bi
score
signifi
cant
diff
erenc
patient
satisfact
compar
consciou
sedat
patient
recal
procedur
lower
bi
score
nadir
end
procedur
bi
may
novel
tool
monitor
procedur
depth
allow
proceduralist
better
monitor
narrow
window
adequ
sedat
danger
oversed
withdraw
assess
evalu
children
wean
analges
sed
patient
diagnos
withdraw
syndrom
score
compar
subject
ever
score
lower
score
assess
risk
factor
outcom
withdraw
syndrom
two
group
fact
identifi
ed
least
epidur
hematoma
occur
far
follow
countri
belgium
n
brazil
n
franc
n
germani
n
india
n
itali
n
japan
n
korea
n
malaysia
n
norway
n
russia
n
sweden
n
uk
n
usa
n
even
public
health
point
view
benefi
ts
seem
encourag
use
epidur
analgesia
cardiac
surgeri
possibl
reduct
periop
mortal
topic
merit
investig
decis
insert
epidur
cathet
discuss
patient
consid
local
experi
legal
disput
case
medic
complic
introduct
establish
earli
enter
nutrit
critic
ill
patient
improv
overal
outcom
mortal
unit
feed
protocol
establish
base
espen
recommend
implement
last
year
purpos
studi
evalu
complianc
septic
patient
nutrit
approach
feed
protocol
method
prospect
studi
done
mix
icu
period
month
eightythre
patient
year
includ
studi
patient
depend
mechan
ventil
met
ccm
criteria
sepsi
upon
admiss
icu
apach
ii
score
sofa
score
weight
bmi
nutrit
statu
calcul
patient
initi
enter
feed
base
establish
feed
protocol
within
hour
admiss
feed
statu
patient
record
start
day
day
day
factor
aff
ect
feed
process
progress
also
record
result
patient
mean
age
lo
icu
day
base
bmi
patient
malnourish
upon
admiss
apach
ii
sofa
mortal
rate
enter
nutrit
start
earli
patient
day
patient
met
calor
goal
day
patient
achiev
calor
goal
discontinu
enter
feed
mainli
due
procedur
wherea
late
start
andor
decreas
hourli
intak
due
gi
complic
gi
intoler
excess
diarrhoea
hemodynam
instabl
associ
complianc
feed
protocol
lo
nutrit
statu
sever
diseas
progress
conclus
although
initi
earli
enter
feed
seem
adequ
good
number
septic
patient
still
far
signifi
cant
percentag
patient
even
wors
calor
goal
achiev
better
suboptim
associ
howev
nutrit
statu
complianc
feed
protocol
therefor
mandatori
follow
daili
nutrit
therapi
septic
patient
reli
feed
protocol
conclus
level
vitamin
c
markedli
decreas
replac
vitamin
c
consid
homeless
visit
emerg
depart
alcohol
ingest
introduct
phosphat
essenti
cell
bone
function
critic
ill
hypophosphatemia
common
practic
often
correct
even
mild
derang
supplement
signifi
cant
cost
risk
includ
hypotens
hypocalcaemia
investig
whether
chang
frequenc
routin
serum
phosphat
test
eff
ect
detect
incid
abnorm
plasma
level
prescript
phosphat
method
servic
improv
project
use
observ
anonym
data
collect
data
serum
phosphat
level
itu
two
period
introduct
new
test
regim
phase
conclus
reduc
test
daili
three
time
weekli
associ
signifi
cant
chang
mean
phosphat
level
detect
abnorm
highlow
phosphat
level
daili
test
howev
associ
higher
rate
phosphat
prescript
known
signifi
cant
diurnal
variat
serum
phosphat
specul
mild
hypophosphataemia
selfcorrect
without
intervent
treat
mild
hypophosphatemia
may
therefor
indic
introduct
direct
ionselect
electrod
without
dilut
eff
ectiv
method
determin
concentr
ioniz
fraction
sodium
test
hypothesi
diff
erenc
indirect
direct
sodium
assay
would
relat
plasma
albumin
concentr
total
protein
concentr
method
retrospect
observ
studi
conduct
plasma
sodium
concentr
pair
venou
arteri
sampl
patient
admit
icu
respect
analyz
arteri
blood
ga
abg
analyz
direct
ionselect
electrod
central
laboratori
autoanalyz
indirect
ionselect
electrod
pair
test
perform
compar
central
laboratori
abg
measur
correl
regress
analysi
perform
total
protein
concentr
albumin
diff
erenc
central
laboratori
abg
assay
sodium
central
laboratori
sodium
measur
averag
mmoll
icu
assay
limit
agreement
mmoll
greater
p
blandaltman
analysi
central
laboratori
result
minu
icu
sodium
measur
limit
agreement
mmoll
correl
assay
diff
erenc
total
protein
concentr
albumin
respect
r
p
r
p
diff
erenc
plasma
sodium
concentr
assay
increas
plasma
concentr
albumin
total
protein
concentr
decreas
respect
r
r
conclus
diff
erenc
indirect
direct
sodium
assay
found
statist
relat
plasma
albumin
concentr
total
protein
concentr
although
relationship
found
weak
total
protein
concentr
monitor
measur
sodium
indirect
ionselect
electrod
refer
introduct
waterelectrolyt
disturb
one
common
complic
acut
brain
injuri
variou
origin
threaten
life
patient
requir
time
correct
work
studi
structur
waterelectrolyt
complic
patient
neurolog
intens
care
acut
brain
injuri
method
analyz
case
waterelectrolyt
disturb
develop
patient
treat
depart
intens
care
russian
polenov
neurosurg
institut
patient
year
old
total
patient
oper
brain
tumor
basalsupratentori
local
eight
sever
brain
trauma
hemorrhag
type
stroke
one
herp
enceph
exclud
studi
patient
heart
renal
failur
receiv
diuret
measur
bp
hr
cvp
hourli
daili
urin
output
level
k
na
plasma
brain
natriuret
peptid
bnp
one
four
time
day
level
k
na
urin
singl
daili
serv
patient
receiv
dexamethason
dose
mgday
antiedema
therapi
thu
level
acth
cortisol
investig
underli
ultradian
rhythm
discret
puls
result
feedforward
feedback
interact
cortisol
acth
puls
critic
normal
function
pulsatil
constant
infus
yield
diff
erent
transcript
respons
patient
optim
nonpulsatil
glucocorticoid
replac
twice
agerel
mortal
gener
popul
characteris
ultradian
rhythm
pituitaryadren
interact
patient
undergo
coronari
arteri
bypass
graft
cabg
method
twenti
male
patient
present
elect
cabg
onpump
pump
recruit
blood
sampl
taken
hour
placement
fi
rst
venou
access
cortisol
sampl
everi
minut
acth
sampl
everi
hour
cortisol
bind
globulin
cbg
sampl
baselin
end
oper
end
period
result
cortisol
acth
pulsatil
throughout
periop
period
cortisolacth
interact
persist
figur
sensit
interact
calcul
ratio
cortisol
acth
puls
amplitud
chang
hour
post
surgeri
adren
sensit
acth
increas
conclus
cortisol
acth
remain
pulsatil
cardiac
surgeri
pituitaryadren
interact
persist
although
sensit
adren
gland
chang
throughout
periop
period
studi
show
endogen
glucocorticoid
level
reach
high
oscil
level
follow
cardiac
surgeri
invalid
interpret
point
measur
adren
function
diagnos
adren
insuffi
cienci
also
demonstr
constant
infus
hydrocortison
unphysiolog
introduct
mani
critic
ill
patient
treat
insulin
stay
icu
intens
monitor
blood
glucos
level
prerequisit
effi
cient
safe
insulin
titrat
patient
current
continu
glucos
measur
techniqu
reli
subcutan
glucos
measur
measur
blood
hypothes
chang
volatil
organ
compound
voc
concentr
exhal
breath
refl
ect
chang
blood
glucos
level
chang
voc
concentr
analyz
continu
use
socal
electron
nose
enos
aim
investig
exhal
breath
analysi
predict
chang
glucos
level
intub
icu
patient
method
exhal
breath
analyz
intub
icu
patient
monitor
subcutan
cgm
devic
enos
result
compar
subcutan
glucos
measur
linear
regress
model
built
includ
subjectspecifi
c
model
wholesampl
model
model
valid
use
tempor
valid
train
model
fi
rst
measur
prospect
test
last
measur
perform
model
measur
use
r
valu
clark
error
grid
ceg
rateerror
grid
analysi
rega
result
chang
voc
concentr
associ
chang
subcutan
glucos
level
r
perform
mean
valu
subjectspecifi
c
model
mean
valu
model
whole
sampl
howev
extern
valid
model
predict
perform
drop
mean
r
subjectspecifi
c
model
model
whole
sampl
point
accuraci
ceg
mostli
good
zone
b
trend
accuraci
visual
rega
low
conclus
exhal
breath
predict
glucos
level
seem
promis
howev
perform
current
model
low
use
daili
practic
introduct
regardless
ongo
debat
optimum
target
rang
glycaemia
control
gc
remain
import
therapeut
goal
critic
ill
patient
dozen
diff
erent
insulin
protocol
icu
develop
diff
erent
complex
eff
ectiv
blood
glucos
bg
variabl
safeti
although
comparison
exist
protocol
diffi
cult
due
signifi
cant
diff
erenc
process
outcom
measur
computer
clinic
decis
support
system
gener
achiev
better
gc
consist
lower
hypoglycaemia
rate
achiev
paperbas
protocol
enhanc
model
predict
control
empc
algorithm
develop
clinicip
group
eff
ectiv
clinic
proven
protocol
success
test
multipl
institut
medic
surgic
patient
diff
erent
nutrit
protocol
empc
model
behaviour
glucos
insulin
icu
patient
variabl
sampl
interv
base
accuraci
bg
predict
integr
bbraun
space
glucosecontrol
sgc
system
allow
direct
data
commun
pump
space
control
incorpor
empc
algorithm
although
sgc
alreadi
clinic
use
dozen
icu
worldwid
publish
experi
use
primari
object
multicentr
european
nonintervent
studi
evalu
perform
effi
cienci
sgc
routin
condit
adult
icu
patient
requir
bg
control
primari
endpoint
percentag
time
within
target
rang
secondari
outcom
measur
frequenc
hypoglycaem
episod
bg
measur
interv
patient
trial
assign
target
rang
mmoll
nutrit
manag
enter
parenter
carri
discret
centr
result
seventeen
centr
nine
european
countri
includ
total
patient
studi
total
bg
valu
enter
sgc
number
recommend
render
mean
timeintarget
mean
propos
next
measur
time
hour
four
episod
hypoglycaemia
mmoll
occur
measur
conclus
sgc
safe
effi
cient
system
control
bg
icu
patient
introduct
glycem
control
icu
shown
reduc
morbid
mortal
length
stay
howev
current
method
blood
glucos
bg
monitor
invas
intermitt
laborintens
continu
glucos
monitor
cgm
potenti
improv
safetyeffi
caci
bg
control
perform
noninvas
transderm
cgm
system
symphoni
cgm
echo
therapeut
philadelphia
pa
usa
evalu
postsurg
icu
patient
method
adult
surgic
patient
plan
icu
admiss
hour
four
medic
center
consent
follow
admiss
icu
skin
upper
arm
clean
mm
diamet
site
prepar
control
microabras
use
symphoni
cgm
system
transderm
cgm
sensor
contain
glucos
oxidas
appli
follow
warmup
period
calibr
perform
blood
sampl
obtain
radial
arteri
cathet
approxim
everi
hour
centrifug
plasma
glucos
measur
use
ysi
stat
plu
glucos
analyz
refer
bg
maximum
refer
bg
sampl
collect
patient
sampl
collect
frequent
everi
minut
trend
analysi
cgm
prospect
calibr
everi
hour
treatment
decis
base
bg
alon
safeti
assess
visual
inspect
site
use
dermatolog
scale
follow
sensor
remov
studi
defi
ned
evalu
cgm
session
hour
result
thirtytwo
subject
complet
studi
addit
subject
consid
evalu
due
earli
discharg
icu
failur
earli
remov
radial
arteri
cathet
administr
intraven
acetaminophen
studi
cohort
femal
diabet
cardiac
surgeri
mean
age
year
overal
mean
absolut
rel
diff
erenc
cgm
refer
bg
continu
glucos
errorgrid
analysi
assess
point
trend
accuraci
show
read
zone
clinic
accur
b
zone
benign
error
glucos
valu
rang
mgdl
devic
studyrel
advers
event
report
conclus
symphoni
cgm
system
demonstr
clinic
relev
accuraci
excel
safeti
varieti
patient
icu
environ
futur
studi
need
determin
whether
symphoni
cgm
use
direct
therapi
improv
bg
control
patient
popul
introduct
aim
studi
determin
impact
preadmiss
fi
rst
blood
glucos
bg
measur
uk
icu
mortal
method
intens
care
nation
audit
research
centr
casemix
programm
databas
adult
admiss
gener
neurosci
cardiothorac
critic
care
unit
use
analysi
within
databas
highest
lowest
blood
glucos
bg
valu
measur
fi
rst
hour
admiss
record
bg
control
valu
defi
ned
bg
mmoll
bg
level
defi
ned
low
mmoll
mgdl
low
mmoll
mgdl
high
mmoll
mgdl
high
mmoll
mgdl
result
increas
incid
mortal
patient
least
one
bg
measur
mmoll
mgdl
compar
without
tabl
link
bg
level
lo
surviv
patient
longest
hospit
stay
critic
care
total
hospit
experienc
bg
level
mmoll
mgdl
conclus
strong
associ
bg
level
admiss
mortal
lo
outcom
although
possibl
make
link
causat
dataset
present
result
largest
singl
dataset
critic
care
unit
patient
introduct
ongo
discuss
optim
rang
glycem
control
hospit
intens
care
recent
public
mackenzi
colleagu
krinsley
suggest
mean
bg
consid
also
glucos
variabl
complex
may
equal
import
increas
need
continu
system
provid
earli
warn
hypoglycemia
eff
ectiv
measur
variabl
glysur
ltd
develop
intravascular
glucos
monitor
system
simplifi
applic
hospit
protocol
tight
glycem
control
tgc
point
care
experi
origin
researchbas
instrument
incorpor
combin
preproduct
monitor
critic
care
volum
suppl
http
autocalibr
unit
complet
trial
use
devic
present
data
collect
studi
method
studi
use
glysur
steril
singleus
sensor
cvc
devic
allow
fl
uoresc
opticalbas
sensor
place
patient
right
intern
jugular
vein
screen
data
blind
bedsid
staff
data
monitor
later
compar
sampl
measur
yellow
spring
ysi
glucos
analyz
data
accuraci
measur
use
mean
absolut
rel
diff
erenc
mard
error
calcul
tool
devic
met
primari
safeti
eff
ectiv
endpoint
trial
sampl
valu
record
monitor
base
calibr
correl
sampl
taken
ysi
mard
studi
analysi
show
data
fell
within
zone
clark
error
grid
rest
fall
within
b
zone
conclus
result
demonstr
good
correl
accept
standard
blood
glucos
determin
icu
practic
earli
detect
glycem
excurs
provid
carer
opportun
earli
intervent
thu
achiev
elus
target
tgc
around
chosen
target
rang
refer
first
clinic
studi
data
therapeut
use
novel
continu
introduct
aim
studi
determin
safeti
effi
caci
treat
patient
use
novel
intraven
continu
glucos
monitor
cgm
system
edward
lifesci
practic
benefi
control
blood
glucos
critic
ill
remain
contenti
larg
lack
tool
adequ
measur
therefor
manag
level
real
time
system
abl
provid
instant
constantli
calibr
accur
valu
major
bonu
icu
care
report
fi
rst
clinic
use
novel
cgm
system
directli
use
manag
postop
glycaemia
method
consecut
consent
adult
patient
undergo
cardiac
surgeri
involv
cardiopulmonari
bypass
requir
postop
insulin
patient
enrol
studi
target
enrol
blood
glucos
measur
via
dedic
peripher
intraven
cathet
valu
report
everi
minut
primari
outcom
number
data
point
target
glycaem
control
rang
mmoll
use
dynam
insulin
protocol
secondari
endpoint
includ
mean
glucos
level
time
rang
number
hypoglycaem
hyperglycaem
episod
result
fi
rst
patient
mean
age
year
male
undergon
valv
surgeri
without
cabg
major
histori
diabet
cgm
sensor
typic
sight
forearm
hand
resit
occas
median
monitor
time
icu
hour
mean
glycaem
valu
mmoll
perform
notabl
improv
experi
also
highlight
even
previous
valid
dynam
algorithm
need
refi
ned
maximis
benefi
ggm
overal
evid
fi
rst
appli
clinic
use
novel
cgm
show
proper
safe
tight
glycaem
control
achiev
investig
requir
demonstr
reduct
morbid
mortal
use
cgm
plan
embark
studi
address
impact
corticosteroid
administr
septic
shock
glycem
variabl
l
mirea
r
ungureanu
pavelescu
ic
grintescu
c
dumitrach
mirea
grintescu
introduct
purpos
studi
assess
relat
glycem
control
sever
sepsi
cohort
patient
vasopressordepend
septic
shock
treat
corticosteroid
prospect
control
studi
patient
septic
shock
random
three
studi
group
group
n
mgday
hydrocortison
hemisuccin
four
daili
dose
group
b
n
dose
hydrocortison
hemisuccin
continu
administr
group
c
n
hydrocortison
hemisuccin
patient
diabet
mellitu
exclud
durat
hydrocortison
treatment
maximum
day
target
blood
glucos
bg
level
mgdl
bg
valu
analyz
calcul
mean
daili
valu
standard
deviat
sd
bg
valu
index
glycem
variabl
insulin
dose
local
ethic
committe
approv
studi
result
diff
erenc
three
group
begin
studi
regard
demograph
data
clinic
characterist
includ
bg
valu
bg
level
strongli
correl
sever
septic
shock
estim
apach
ii
score
r
p
simplifi
ed
acut
physiolog
score
ii
r
p
pearson
correl
risk
death
signifi
cantli
increas
sd
bg
mgdl
vs
p
total
deceas
patient
group
regist
sd
bg
mgdl
versu
group
b
group
c
p
total
patient
group
need
insulin
therapi
versu
group
b
group
c
dose
uiday
group
uiday
group
b
uiday
group
c
p
conclus
bg
variabl
highli
associ
mortal
compar
bg
mean
daili
valu
insulin
dose
sd
level
mgdl
associ
signifi
cantli
higher
mortal
rate
rel
sd
level
mgdl
introduct
tubercul
mening
tbm
least
common
extrapulmonari
manifest
tuberculosi
although
uk
incid
tbm
rel
low
carri
high
mortal
morbid
neurolog
deterior
continu
import
reason
icu
admiss
littl
known
outcom
tbm
patient
requir
icu
admiss
aim
evalu
patient
demograph
tbm
clinic
data
necess
organ
support
whether
associ
outcom
method
retrospect
studi
tertiari
centr
patient
tbm
admit
icu
data
retriev
demograph
microbiolog
radiolog
pharmacolog
fi
nding
type
level
organ
support
apach
ii
sofa
score
calcul
patient
stratifi
ed
two
group
csf
pcrve
csf
pcrve
result
eight
patient
six
male
two
femal
evalu
total
mean
age
year
reduct
gc
main
reason
icu
admiss
patient
receiv
antitbm
drug
steroid
two
csf
pcrve
patient
primari
drug
resist
isoniazid
also
longer
mean
delay
time
onset
antitbm
treatment
csf
pcrve
patient
day
higher
apach
ii
sofa
score
admiss
mean
associ
posit
csf
pcr
result
increas
requir
mechan
ventil
tracheostomi
inotrop
neurosurg
intervent
predominantli
csf
drainag
enter
feed
signifi
cant
group
mortal
longterm
neurolog
morbid
substanti
higher
pcrve
patient
contrast
major
cultureneg
patient
surviv
experienc
good
recoveri
followup
overal
mortal
conclus
second
document
case
analysi
tbm
icu
admiss
adult
patient
find
show
poor
outcom
associ
posit
csf
pcr
result
factor
link
poor
outcom
includ
delay
initi
antitbm
treatment
neurosurg
intervent
increas
requir
multiorgan
support
earlier
drug
suscept
test
would
prefer
particularli
patient
posit
csf
pcr
cultur
given
potenti
sever
tbm
high
index
clinic
suspicion
remain
critic
toward
optim
outcom
refer
introduct
aim
evalu
role
intrathec
lactat
earli
predictor
spinal
cord
injuri
thoracoabdomin
aortic
aneurysmectomi
fortyfour
consecut
patient
schedul
undergo
thoracoabdomin
aortic
aneurysmectomi
two
patient
type
b
dissect
aneurysm
patient
suff
ere
degen
aneurysm
method
surgeri
sampl
cerebrospin
fl
uid
arteri
blood
simultan
withdrawn
evalu
lactat
concentr
sampl
collect
fi
fi
xed
time
surgeri
begin
intervent
minut
aortic
crossclamp
unclamp
end
surgeri
hour
end
surgeri
result
mean
lactat
level
cerebrospin
fl
uid
rose
consist
begin
intervent
steadili
surgeri
mmoll
mmoll
mmoll
mmoll
mmoll
seven
patient
develop
spinal
cord
injuri
two
delay
injuri
occur
hour
end
surgeri
remain
fi
earli
onset
group
fi
patient
preoper
cerebrospin
fl
uid
lactat
level
signifi
cantli
p
higher
patient
preoper
vs
mmoll
conclus
preoper
cerebrospin
lactat
concentr
elev
patient
develop
earlyonset
spinal
cord
injuri
thoracoabdomin
aortic
aneurysmectomi
may
allow
better
stratifi
cation
patient
suggest
aggress
strategi
spinal
cord
function
preserv
possibl
guarante
better
outcom
year
north
america
occur
cervic
level
cervic
spinal
cord
injuri
csi
particular
risk
mechan
ventil
mv
pulmonari
complic
increas
length
hospit
stay
small
cohort
studi
look
predictor
mv
knowledg
studi
address
factor
associ
prolong
mv
purpos
studi
compar
known
clinic
predictor
mv
determin
predictor
prolong
mv
method
conduct
retrospect
chart
review
consecut
csi
admit
januari
march
record
data
relat
injuri
durat
mv
respiratori
complic
icu
hospit
length
stay
patient
outcom
review
literatur
identifi
ed
known
predictor
asia
level
iss
level
injuri
forth
univari
multivari
logist
regress
use
identifi
predictor
mv
prolong
mv
patient
male
mean
age
year
hospit
mortal
main
caus
injuri
motor
vehicl
accid
fall
injuri
level
repres
popul
complet
loss
motor
function
asia
level
b
found
patient
mean
median
iss
score
total
patient
requir
mv
patient
requir
prolong
mv
multivari
analysi
four
predictor
mv
identifi
ed
pneumonia
iss
score
age
level
two
predictor
prolong
mv
asia
score
b
pneumonia
conclus
studi
iss
cervic
level
age
associ
mv
need
prolong
mv
wherea
pneumonia
independ
risk
factor
potenti
prevent
risk
factor
specifi
c
strategi
appli
improv
patient
outcom
compar
microcircul
braindead
diagnos
patient
healthi
volunt
howev
presenc
conjunctiv
fl
ow
case
gener
cerebr
fl
ow
complet
absent
make
diffi
cult
use
conjunctiv
fl
ow
substitut
brain
fl
ow
previous
develop
model
predict
increas
icp
minut
advanc
use
dynam
characterist
routin
monitor
minutebyminut
icp
mean
arteri
blood
pressur
map
signal
model
develop
use
data
brainit
databas
present
extern
valid
result
model
recent
cohort
adult
tbi
patient
avertit
project
method
retrospect
analysi
physiolog
data
collect
minut
resolut
adult
patient
avertit
project
total
episod
icp
mmhg
last
least
minut
identifi
ed
cohort
fourhour
time
seri
icp
map
anteced
episod
minut
analyz
addit
time
seri
preced
elev
icp
episod
use
valid
result
tabl
summar
main
fi
nding
perform
model
origin
studi
reproduc
fi
rst
column
model
retain
ident
perform
criteria
cohort
recent
tbi
patient
avertit
databas
conclus
obtain
extern
valid
result
previous
unseen
cohort
adult
tbi
patient
confi
rm
robust
model
accur
predict
futur
increas
icp
event
minut
advanc
gener
applic
model
probabl
due
spars
use
two
routin
monitor
signal
input
name
icp
map
result
larg
step
forward
work
toward
earli
warn
system
elev
icp
use
worldwid
patient
aneurysm
subarachnoid
hemorrhag
sah
hypervolem
therapi
may
result
fl
uid
overload
may
associ
advers
clinic
outcom
hypothes
goaldirect
transpulmonari
thermodilut
tpt
monitor
protocol
aim
normovolemia
may
result
decreas
fl
uid
intak
sustain
adequ
volum
statu
poorgrad
sah
patient
method
follow
introduct
hemodynam
protocol
consecut
patient
sah
includ
use
tpt
picco
pulsion
cardiac
output
co
global
enddiastol
volum
index
gedvi
extravascular
lung
water
index
evlwi
determin
fluid
administr
target
fl
uid
unrespons
indic
start
protocol
hypotens
spite
fl
uid
pulmonari
edema
cardiac
stun
daili
fl
uid
balanc
l
cerebr
ischemia
dci
progress
symptom
data
collect
fl
uid
intak
output
day
day
start
tpt
assess
cours
fl
uid
input
output
hemodynam
paramet
start
protocol
gener
estim
equat
result
mean
age
median
glasgow
coma
scale
admiss
iqr
tpt
start
median
day
icu
admiss
iqr
dci
develop
inhospit
death
rate
compar
day
preced
protocol
day
tpt
day
associ
decreas
fl
uid
intak
compar
day
refer
day
l
p
day
l
p
day
l
p
increas
critic
care
volum
suppl
http
fl
uid
output
day
l
p
compar
day
consequ
strong
decreas
fl
uid
balanc
day
l
p
day
l
p
day
l
p
decreas
fl
uid
intak
fl
uid
balanc
result
decreas
co
gedvi
evlwi
day
compar
day
mean
pcci
lminutem
mean
gedvi
mlm
mean
evlwi
mlkg
conclus
data
suggest
poorgrad
sah
patient
goaldirect
fl
uid
manag
tpt
feasibl
decreas
intak
increas
diuresi
without
advers
eff
ect
cardiac
output
preload
paramet
futur
research
assess
eff
ect
protocol
clinic
outcom
refer
receptor
advanc
glycat
end
product
rage
multiligand
receptor
immunoglobulin
superfamili
implic
multipl
neuron
infl
ammatori
stress
process
present
studi
investig
chang
rage
immunoreact
protein
level
gerbil
hippocampu
region
minut
transient
global
cerebr
ischemia
method
ischem
hippocampu
stain
cresyl
violet
cv
neun
neuronspecifi
c
solubl
nuclear
antigen
antibodi
flurojad
b
marker
neuron
degener
result
five
day
ischemiareperfus
delay
neuron
death
occur
stratum
pyramidal
sp
region
rage
immunoreact
detect
region
region
sham
group
rage
immunoreact
detect
region
day
post
ischemia
rage
immunoreact
newli
express
astrocyt
neuron
addit
level
rage
protein
highest
day
post
ischemia
brief
rage
immunoreact
protein
level
distinct
increas
astrocyt
ischem
region
day
transient
cerebr
ischemia
conclus
result
indic
increas
rage
express
astrocyt
post
ischemia
may
relat
ischemiainduc
activ
astrocyt
ischem
region
introduct
purpos
studi
investig
relationship
continu
monitor
region
cerebr
blood
fl
ow
cbf
microdialysi
valu
sever
subarachnoid
hemorrhag
traumat
brain
injuri
patient
method
advanc
multimod
neuromonitor
includ
measur
cbf
qflow
hemedex
brain
lactat
pyruv
lactat
pyruv
ratio
glycerol
glucos
valu
use
microdialysi
microdialysi
perform
patient
sever
subarachnoid
hemorrhag
n
traumat
brain
injuri
n
thirteen
patient
success
discharg
icu
eight
surviv
addit
record
paramet
includ
pbro
licox
gm
icp
cpp
mabp
cvp
local
brain
temperatur
bodi
core
temperatur
pco
blood
glucos
among
other
cerebr
monitor
probe
insert
via
bolt
icp
pbro
microdialysi
addit
burr
hole
cbf
probe
posit
penumbra
locat
verifi
ed
brain
ct
pbro
arm
studi
signifi
canc
still
underway
announc
later
thirteen
patient
success
discharg
icu
eight
surviv
fi
nal
data
current
statist
evalu
complet
time
present
howev
indic
link
brain
glucos
level
cbf
valu
clear
cbfpbro
correl
second
part
studi
evalu
may
due
fl
uctuat
brain
glucos
brain
ischemia
hyperemia
hypermetabol
hypometabol
far
abl
establish
correl
cbf
lactatepyruv
ratio
persist
low
cbf
valu
conclus
fi
nal
report
studi
human
patient
sever
subarachnoid
hemorrhag
traumat
brain
injuri
result
indic
correl
vari
signifi
canc
pool
data
still
statist
analysi
hope
outcom
studi
abl
answer
question
regard
pathophysiolog
sever
brain
injuri
guid
us
titrat
therapi
need
individu
patient
introduct
sever
report
indic
potenti
use
monitor
brain
metabol
paramet
correl
system
want
establish
diff
erenc
correl
pco
lactat
serum
sodium
creactiv
protein
crp
arteri
jugular
venou
bulb
blood
method
observ
studi
januari
octob
includ
neurocrit
patient
ncp
multimod
neuromonitor
mmn
daili
sampl
arteri
blood
venou
jugular
bulb
blood
obtain
measur
pco
lactat
serum
sodium
crp
result
ncp
six
mmn
fi
men
mean
age
year
diagnost
two
tbi
two
sah
one
stroke
one
lupu
enceph
apach
ii
glasgow
coma
scale
admiss
pco
mmhg
arteri
versu
jugular
r
p
lactat
mgdl
arteri
versu
jugular
r
p
sodium
meqdl
arteri
versu
r
p
crp
mgdl
arteri
versu
r
p
correl
trend
curv
shown
figur
conclus
suitabl
correl
observ
arterialjugular
bulb
diff
erent
variabl
signifi
cant
diff
erenc
crp
pco
valu
persist
higher
jugular
particularli
crp
studi
requir
defi
ne
interpret
potenti
use
result
wernick
area
activ
observ
nine
patient
eight
patient
tbi
one
hypoxia
subsequ
examin
last
month
seven
patient
activ
wernick
area
show
conscious
expans
minim
conscious
state
conscious
expans
seen
two
patient
two
patient
activ
wernick
area
show
sign
conscious
two
patient
reveal
signifi
cant
activ
broca
area
conclus
accord
fi
rst
result
studi
one
conclud
behind
outwardli
similar
clinic
symptom
patient
vs
lie
divers
due
organ
brain
function
group
patient
fmri
enabl
one
reveal
fi
rst
sign
cognit
activ
reveal
linguist
valu
speech
address
patient
detect
routin
neurolog
examin
introduct
patient
declar
brain
dead
bd
physician
determin
perman
loss
brain
function
unfortun
criteria
defi
ning
bd
vari
across
diff
erent
countri
therefor
decid
survey
bd
diagnost
modal
europ
order
describ
diff
erenc
method
multiplechoic
questionnair
develop
onlin
platform
direct
link
sent
nation
repres
european
societi
intens
care
medicin
neurointens
care
section
member
thirtythre
countri
contact
answer
review
case
discrep
miss
data
particip
contact
clarifi
cation
descript
statist
appli
result
twentyeight
particip
return
questionnair
everi
countri
either
specifi
c
law
guidelin
issu
scientifi
c
societi
clinic
examin
essenti
diagnosi
requir
countri
coma
apnea
absenc
corneal
cough
refl
exe
alway
necessari
blood
pressur
electrolyt
check
mandatori
prerequisit
apnea
test
legal
defi
ned
countri
eightytwo
percent
countri
requir
achiev
target
paco
level
netherland
law
state
target
apnea
durat
number
physician
median
rang
number
clinic
examin
median
minimum
observ
time
median
hour
variabl
requisit
diff
erent
countri
nation
addit
test
requir
hypothermia
anox
injuri
inabl
complet
clinic
examin
toxic
drug
level
inconclus
apnea
test
legal
indic
perform
addit
test
cerebr
blood
fl
ow
investig
mandatori
countri
either
option
use
select
case
convent
angiographi
still
prefer
method
follow
transcrani
doppler
angioct
ct
perfus
angiomr
eeg
alway
option
record
russia
croatia
evalu
eeg
cerebr
blood
fl
ow
conclus
still
area
uncertainti
dispar
brain
death
diagnosi
european
countri
predispos
misdiagnosi
confus
clinician
famili
measur
promot
uniform
brain
death
procedur
clinic
practic
therefor
desir
introduct
icuacquir
weak
frequent
complic
critic
ill
unclear
whether
marker
mediat
poor
outcom
aim
determin
acut
longterm
outcom
cost
icuacquir
weak
among
longstay
day
icu
patient
assess
impact
recoveri
weak
icu
discharg
method
data
prospect
collect
rct
clinic
trialsgov
impact
weak
mrc
sum
outcom
cost
analyz
propens
scorematch
baselin
characterist
ill
sever
risk
factor
exposur
prior
assess
among
weak
patient
impact
persist
weak
icu
discharg
risk
death
year
examin
multivari
cox
proportionalhazard
analysi
result
total
longstay
assess
icu
patient
weak
weak
patient
match
notweak
patient
compar
match
notweak
patient
weak
patient
lower
likelihood
time
live
wean
mechan
ventil
hr
p
live
icu
hr
p
hospit
discharg
hr
p
inhospit
costspati
p
mortal
vs
p
also
higher
weak
patient
matchabl
notweak
patient
even
wors
prognosi
higher
cost
time
within
fi
rst
year
follow
icu
admiss
compar
patient
recov
weak
adjust
potenti
confound
persist
weak
mrc
sum
critic
care
volum
suppl
http
icu
discharg
higher
likelihood
death
hr
ci
p
likelihood
late
death
even
higher
patient
sever
degre
persist
weak
mrc
sum
hr
ci
p
conclus
patient
icuacquir
weak
wors
acut
morbid
outcom
consum
resourc
reveal
higher
mortal
year
patient
without
weak
persist
weak
icu
discharg
increas
late
mortal
introduct
cerebr
nearinfrar
spectroscopi
nir
repres
excit
prospect
noninvas
monitor
cerebr
tissu
oxygen
traumat
brain
injuri
tbi
earlier
attempt
clinic
applic
cerebr
nir
demonstr
work
need
basic
layout
probe
portion
devic
consist
light
sourc
light
detector
arrang
calcul
distanc
confi
gurat
order
observ
target
tissu
aim
determin
commerci
avail
nir
probe
repres
sensit
layout
sourcesdetector
greatest
sensit
observ
tissu
oxygen
optim
depth
tbi
method
optim
depth
grey
matter
target
tissu
greywhit
matter
junction
ascertain
review
seri
brain
ct
scan
patient
sustain
tbi
set
averag
measur
deriv
identifi
target
depth
grey
matter
strip
point
probe
placement
current
fi
commerci
avail
cerebr
nir
system
tabl
present
varieti
confi
gurat
ere
devic
sourc
detector
layout
model
simul
use
comput
light
model
softwar
develop
univers
birmingham
novel
approach
model
system
make
extrapol
assumpt
base
subtract
critic
care
volum
suppl
http
result
review
trauma
seri
ct
brain
imag
averag
depth
grey
matter
deriv
mm
rang
mm
sd
surfac
figur
spectrum
sensit
fi
probe
model
figur
appar
foresight
ca
medic
ct
usa
probe
current
er
greatest
sensit
deriv
target
depth
conclus
base
comput
model
work
foresight
nir
devic
ca
medic
sourc
detector
layout
provid
greatest
sensit
depth
purpos
cortic
profound
impact
tbi
felt
individu
suff
er
injuri
also
caregiv
societi
whole
studi
observ
longterm
outcom
patient
sever
traumat
brain
injuri
admit
intens
care
method
studi
includ
patient
n
sever
head
trauma
gc
admit
icu
emerg
depart
tertiari
referr
center
careggi
teach
hospit
florenc
itali
patient
undergo
clinic
assess
year
routin
postintens
followup
object
index
abil
function
injuri
glasgow
outcom
scale
go
use
neurolog
evalu
determin
outcom
patient
go
perform
two
diff
erent
mode
elig
patient
year
discharg
icu
contact
telephon
nurs
intens
care
staff
invit
make
visit
surgeri
followup
intensivist
evalu
patient
determin
go
patient
still
hospit
month
rehabilit
depart
go
assess
perform
doctor
structur
notifi
ed
telephon
icu
hospit
mortal
respect
n
n
mortal
year
n
result
neurolog
followup
year
go
n
go
n
go
n
go
n
conclus
accord
studi
data
confi
rm
sever
traumat
brain
injuri
associ
high
mortal
year
onehalf
survivor
diff
erent
level
disabl
introduct
recent
studi
shown
vitamin
defi
cienci
may
aff
ect
neg
clinic
cours
traumat
brain
injuri
tbi
problem
becom
import
respect
older
patient
consid
preval
vitamin
defi
cienci
data
third
nation
health
nutrit
examin
survey
document
caucasian
aff
ect
defi
cienci
patient
tbi
age
theoret
risk
unfavor
outcom
object
preliminari
studi
determin
whether
low
level
vitamin
admiss
icu
hour
could
neg
aff
ect
neurolog
recoveri
patient
tbi
method
retrospect
analyz
data
patient
aff
ect
tbi
sever
moder
moder
isol
associ
extracrani
lesion
sampl
vitamin
carri
within
hour
icu
admiss
regist
gc
moment
present
gc
discharg
gc
diff
erenc
gc
diff
compar
level
vitamin
patient
die
icu
assign
gc
see
tabl
result
data
accord
studi
confi
rm
presenc
defi
cienci
vitamin
tabl
howev
demonstr
statist
signifi
canc
correl
univari
regress
r
p
vitamin
level
outcom
icu
correl
stratifi
patient
age
tbi
class
injuri
sever
score
bmi
conclus
vitamin
defi
cienci
realli
preval
tbi
case
seem
aff
ect
neurolog
recoveri
icu
discharg
howev
preliminari
result
expos
sever
critic
need
confi
rmed
prospect
studi
introduct
sever
traumat
brain
injuri
tbi
major
caus
death
peopl
year
old
gastrointestin
dysfunct
common
complic
due
mucos
ischemia
motil
disord
disrupt
gut
barrier
sever
consequ
malnutrit
weight
loss
high
risk
infect
therefor
maintain
intestin
barrier
function
systemat
engin
project
select
new
probiot
due
capac
bind
neutral
toxin
interfer
pathogen
adher
immunomodulatori
properti
mop
infect
could
improv
recoveri
critic
ill
patient
aim
assess
eff
ect
new
probiot
earli
enter
regimen
clinic
outcom
sever
tbi
patient
term
vap
incid
toler
enter
nutrit
durat
mechan
ventil
mortal
rate
method
prospect
random
studi
patient
year
old
alloc
receiv
day
either
earli
enter
diet
plu
new
probiot
bioent
lactobacillu
bulgaricu
trillion
cfucp
activ
charcoal
everi
hour
group
formula
without
probiot
group
b
diet
isocalor
isonitrogen
diff
erenc
group
gender
age
nutrit
statu
assess
vap
incid
durat
mechan
ventil
toler
enter
nutrit
length
icu
stay
durat
diarrhea
episod
mortal
rate
anova
test
test
carri
p
consid
signifi
cant
result
infect
rate
higher
group
b
durat
mechan
ventil
shorter
group
patient
group
receiv
total
calor
need
enter
rout
versu
group
b
signifi
cant
diff
erenc
number
diarrhea
episod
icu
length
stay
signifi
cantli
lower
group
signifi
cant
diff
erenc
mortal
rate
group
see
figur
conclus
earli
administr
new
probiot
sever
tbi
patient
could
benefi
cial
eff
ect
term
reduct
gi
dysfunct
vap
incid
length
icu
stay
note
spearman
rho
p
impact
apach
ii
found
identifi
slightli
diff
erent
group
patient
eventu
surviv
figur
conclus
impact
apach
ii
model
show
equal
perform
mortal
predict
moder
strong
posit
correl
major
discrep
model
found
thu
featur
impact
apach
ii
model
valuabl
optim
outcom
predict
patient
tbi
treat
icu
refer
demograph
profi
le
sever
tbi
local
context
implic
manag
sever
tbi
particularli
utilis
critic
care
resourc
result
total
patient
admit
tbi
studi
period
patient
sustain
sever
tbi
major
sever
tbi
patient
male
bimod
preponder
sever
tbi
case
young
adult
age
older
peopl
age
motor
vehicl
accid
fall
main
mechan
injuri
invas
monitor
frequent
employ
patient
sever
tbi
arteri
blood
pressur
monitor
patient
central
venou
pressur
monitor
patient
intracrani
pressur
monitor
patient
incid
use
tier
therapi
sedat
mild
hyperventil
osmotherapi
mannitol
cerebrospin
fl
uid
drainag
barbitur
coma
decompress
craniectomi
control
icp
converg
intern
practic
conclus
young
adult
older
peopl
involv
mainli
motor
vehicl
accid
fall
respect
among
highrisk
group
sever
tbi
manag
patient
goe
beyond
icu
involv
limit
social
support
emot
motiv
commun
reintegr
patient
tbi
among
highrisk
group
larg
prevent
public
awar
prevent
programm
go
way
reduc
incid
tbi
amongst
highrisk
group
result
studi
patient
age
year
apach
ii
point
glasgow
coma
scale
admiss
point
cranial
tomographi
admiss
diff
use
injuri
type
diff
use
injuri
type
ii
diff
use
injuri
type
iii
diff
use
injuri
type
iv
evacu
mass
lesion
nonevacu
mass
lesion
hospit
mortal
patient
die
year
miss
die
year
miss
regard
work
activ
year
patient
evalu
diffi
culti
work
diffi
culti
work
work
parttim
chang
job
requir
minimum
eff
ort
patient
work
year
patient
evalu
diffi
culti
work
diffi
culti
work
work
parttim
chang
job
requir
minimum
eff
ort
patient
work
evolut
year
mcnemar
test
statist
signifi
cant
p
total
patient
similar
situat
one
deterior
patient
evalu
work
activ
improv
conclus
year
admiss
icu
tbi
patient
diffi
culti
work
year
number
patient
work
increas
although
approxim
surviv
patient
work
introduct
antiseizur
prophylaxi
recommend
prevent
earli
posttraumat
seizur
pt
guidelin
manag
sever
traumat
brain
injuri
tbi
brain
trauma
foundat
phenytoin
recommend
reduc
incid
earli
pt
prophylaxi
earli
enter
nutrit
recent
shown
theoret
advantag
prevent
bacteri
transloc
maintain
normal
turnov
gut
mucosa
commonli
use
tbi
patient
hypothesi
enter
administr
antiepilept
agent
also
use
earli
pt
method
retrospect
observ
studi
includ
adult
patient
admit
tertiari
academ
medicosurg
icu
due
tbi
septemb
august
patient
epilepsi
past
histori
exclud
clinic
data
collect
electr
medic
archiv
baselin
characterist
collect
age
gender
diagnosi
antiepilept
agent
time
start
advers
eff
ect
agent
method
administr
critic
care
volum
suppl
http
everi
minut
total
student
without
prior
cpr
train
recruit
upper
secondari
school
regular
class
hour
randomli
assign
tcpr
group
n
versu
vcpr
group
n
manikin
use
evalu
cpr
perform
data
transfer
manikin
computer
databas
use
laerdal
skillreport
system
softwar
analysi
base
audiorecord
videorecord
primari
outcom
measur
result
cardiff
evalu
test
secondari
measur
global
score
complet
period
cpr
result
mean
chest
compress
rate
increas
signifi
cantli
vcpr
group
compar
tcpr
vs
p
depth
remain
constant
mm
vs
mm
p
ns
hand
posit
correct
case
vcpr
tcpr
p
handsoff
period
almost
nonexist
vcpr
group
vs
second
p
median
nofl
ow
time
signifi
cantli
greater
vcpr
group
vs
second
p
consequ
global
evalu
cpr
perform
reveal
signifi
cant
improv
vcpr
group
score
compar
tcpr
group
vs
p
conclus
videoassist
cpr
use
origin
algorithm
allow
bystand
reach
compress
rate
depth
close
intern
guidelin
reduc
handsoff
event
cpr
initi
anticoagul
strategi
extracorpor
cardiopulmonari
resuscit
patient
iwashita
matsuduki
yukimitsu
k
yokoyama
nakata
yamamoto
k
ishikura
h
imai
mie
univers
hospit
tsu
mie
japan
critic
care
suppl
doi
introduct
extracorpor
cardiopulmonari
resuscit
ecpr
increasingli
use
emerg
critic
care
medicin
japan
although
major
complic
procedur
bleed
optim
heparin
dose
activ
coagul
time
act
remain
unknown
method
retrospect
evalu
initi
heparin
dose
act
valu
complic
patient
receiv
ecpr
februari
novemb
emerg
critic
care
center
mie
univers
hospit
japan
result
ecpr
perform
patient
act
evalu
patient
patient
administ
u
unfraction
heparin
time
prime
circuit
patient
cannul
took
longer
time
receiv
addit
u
unfraction
heparin
averag
heparin
dose
administ
ukg
bodi
weight
averag
act
second
patient
act
exceed
second
three
patient
experienc
fatal
bleed
chest
wall
could
stabil
conserv
treatment
one
patient
develop
cerebr
infarct
signifi
cant
diff
erenc
patient
fatal
bleed
without
fatal
bleed
regard
heparin
dose
act
durat
cpr
conclus
accord
extracorpor
life
support
organ
guidelin
target
act
around
time
normal
act
howev
diffi
cult
obtain
normal
act
emerg
situat
mani
patient
act
exceed
second
three
patient
experienc
fatal
bleed
possibl
due
chest
compress
postcardiac
arrest
patient
often
experi
coagulopathi
due
either
cardiac
arrest
hypothermia
therapi
therefor
anticoagul
protocol
pulmonari
extracorpor
membran
oxygen
protocol
requir
ecpr
patient
evalu
anticoagul
protocol
ecpr
observ
patient
act
frequent
exceed
target
valu
experienc
fatal
bleed
anticoagul
protocol
postcpr
patient
may
need
reconsid
introduct
outofhospit
cardiac
arrest
oohca
caus
uk
us
death
year
surviv
hospit
discharg
develop
world
histor
obviou
cognit
impair
survivor
primari
percutan
coronari
intervent
ppci
target
temperatur
manag
ttm
least
hyperthermia
avoid
shown
improv
surviv
comatos
patient
post
oohca
reliabl
method
predict
poor
outcom
present
aim
identifi
factor
associ
poor
outcom
singlecentr
region
referr
oohca
popul
method
perform
pragmat
singlecentr
retrospect
review
month
commenc
januari
patient
admit
region
oohca
centr
icu
follow
success
resuscit
oohca
keep
guidelin
patient
assess
suitabl
ppci
ttm
good
outcom
defi
ned
pittsburgh
cognit
perform
categori
cpc
score
independ
mild
impair
hospit
discharg
poor
outcom
defi
ned
death
cpc
moder
sever
impair
coma
hospit
discharg
cpc
score
determin
present
base
defi
cit
mmoll
present
lactat
mmoll
introduct
lack
standard
care
contribut
low
surviv
admit
outofhospit
cardiac
arrest
ohca
patient
object
studi
implement
post
arrest
consult
team
pact
improv
qualiti
care
admit
ohca
patient
conduct
prospect
cohort
studi
concurr
control
februari
februari
network
torontoarea
hospit
pact
implement
two
hospit
function
consult
servic
nurs
physician
oncal
patient
network
hospit
act
concurr
control
pact
focus
four
key
process
care
target
temperatur
manag
ttm
coronari
angiographi
avoid
prematur
withdraw
lifesustain
therapi
wlst
hour
basi
neuroprognost
electrophysiolog
assess
includ
nontraumat
ohca
patient
year
old
surviv
least
hour
comatos
exclud
patient
donotresuscit
order
intracrani
sever
bleed
use
gener
linear
mix
model
assess
whether
pact
implement
associ
higher
odd
achiev
four
target
process
care
adjust
secular
trend
unrel
intervent
primari
analysi
includ
patient
two
intervent
hospit
control
hospit
thirtytwo
percent
patient
femal
mean
age
year
almost
onehalf
patient
shockabl
initi
cardiac
arrest
rhythm
bystand
cpr
a
appli
pact
improv
use
ttm
ratio
or
ci
angiographi
patient
without
stelev
critic
care
volum
suppl
http
myocardi
infarct
ratio
or
ci
electrophysiolog
assess
ratio
or
ci
compar
concurr
control
hospit
patient
intervent
group
less
like
life
support
withdrawn
within
hour
basi
neuroprognosi
compar
patient
concurr
control
group
ratio
or
ci
conclus
pact
associ
reduc
wlst
basi
neuroprognost
improv
import
postcardiac
arrest
process
care
work
underway
identifi
factor
infl
uenc
implement
guid
futur
consider
pact
model
set
one
introduct
retrospect
audit
evalu
adult
patient
suff
ere
inhospit
cardiac
arrest
ihca
recent
nation
confi
dential
enquiri
patient
outcom
death
ncepod
report
look
specifi
calli
recognit
acut
unwel
intervent
made
decis
taken
admiss
postarrest
period
outcom
follow
cardiopulmonari
resuscit
cpr
audit
aim
guid
futur
improv
prevent
cardiac
arrest
enhanc
endoflif
care
decisionmak
method
medic
note
adult
patient
suff
ere
ihca
period
identifi
ed
data
collect
use
valid
ncepod
audit
tool
data
includ
patient
demograph
initi
clerk
consult
review
patient
care
hour
prior
cardiac
arrest
resuscit
statu
patient
resuscit
attempt
postcardiac
arrest
care
surviv
discharg
rate
result
medic
note
avail
assess
patient
identifi
ed
ihca
octob
septemb
frequenc
ihca
show
correl
day
week
month
initi
clerk
incomplet
historytak
vs
ncepod
examin
vs
ncepod
major
patient
appropri
escal
time
fashion
vs
ncepod
fi
rst
consult
review
delay
beyond
hour
case
ncepod
total
patient
suff
ere
cardiac
arrest
hour
admiss
ncepod
warn
sign
cardiac
arrest
consid
present
case
ncepod
signifi
cant
proport
go
unrecognis
despit
multipl
medic
review
outofhour
cpr
attempt
vs
ncepod
seem
associ
poorer
surviv
surviv
discharg
rate
inhospit
cardiac
arrest
compar
ncepod
data
larger
studi
nineti
per
cent
patient
document
resuscit
statu
ncepod
result
audit
highlight
persist
defi
cienci
care
pathway
acut
unwel
patient
improv
focus
earlier
consult
review
better
recognit
warn
sign
appropri
action
taken
furthermor
earlier
routin
senior
clinicianl
discuss
appropri
endoflif
care
vital
introduct
therapeut
hypothermia
th
improv
neurolog
outcom
patient
surviv
cardiac
arrest
suff
er
sever
secondari
neurolog
damag
use
th
cardiac
arrest
includ
erc
guidelin
purpos
studi
investig
knowledg
medic
nurs
staff
implement
th
patient
cardiac
arrest
method
data
collect
anonym
questionnair
design
purpos
research
address
medic
nurs
staff
greek
hospit
questionnair
consist
question
knowledg
behavior
relat
th
induct
target
temperatur
durat
cool
inform
potenti
barrier
implement
th
also
collect
obtain
questionnair
hospit
popul
studi
regist
nurs
rn
doctor
critic
care
volum
suppl
http
major
health
staff
never
implement
th
total
respond
state
main
reason
use
th
lack
inform
train
method
lack
nurs
staff
lack
avail
cool
method
requir
time
common
method
applic
cold
pack
intraven
fl
uid
doctor
nurs
p
actual
knowledg
implement
th
demonstr
correct
answer
respond
answer
know
method
answer
correctli
target
temperatur
mainten
rewarm
phase
total
doctor
despit
attend
advanc
cardiac
life
support
seminar
abl
answer
correctli
knowledg
question
continu
educ
health
profession
exist
protocol
propos
particip
best
way
increas
knowledg
adher
erc
guidelin
th
conclus
therapeut
hypothermia
rare
use
greek
hospit
level
knowledg
mainli
relat
lack
educ
lack
inform
new
techniqu
program
continu
educ
necessari
use
new
therapeut
techniqu
fi
eld
health
result
sixteen
patient
averag
age
includ
men
twelv
patient
cpc
hospit
discharg
sixteen
shiver
event
monitor
calorimetri
among
patient
averag
rate
energi
expenditur
without
shiver
lead
follow
paralyt
treatment
kcalhour
kcal
hour
kcalhour
kcalhour
signifi
cantli
greater
predict
basal
energi
expenditur
kcal
p
p
time
chang
baselin
energi
expenditur
recognit
treatment
clinic
shiver
minut
treatment
neuromuscular
blockad
baselin
energi
expenditur
minut
account
total
diff
erenc
kcal
kcal
treatment
kcal
kcal
treatment
shiver
episod
compar
baselin
p
p
conclus
energi
burden
shiver
underestim
standard
nutrit
formula
patient
undergo
ttm
cardiac
arrest
subclin
shiver
associ
increas
energi
expenditur
clinic
recognit
occur
long
increas
metabol
activ
persist
signifi
cant
period
time
treatment
fi
nding
infl
uenc
shiver
monitor
treat
ttm
temperatur
manag
follow
cardiac
arrest
introduc
protocol
improv
complianc
target
p
creber
g
tall
audit
achiev
therapeut
hypothermia
th
introduct
cool
protocol
institut
th
recommend
follow
return
spontan
circul
rosc
mani
patient
surviv
cardiac
arrest
key
intervent
may
avoid
hyperthermia
rather
cool
method
conduct
chart
review
patient
admit
depart
critic
care
dcc
hospit
follow
cardiac
arrest
year
group
record
complianc
key
recommend
produc
royal
colleg
anaesthetist
although
defi
ned
postrosc
hyperthermia
rather
th
protocol
design
personnel
emerg
depart
dcc
educ
use
recommend
practic
infus
cold
iv
normal
salin
l
follow
use
intravascular
cool
devic
alsiu
data
collect
undertaken
introduct
protocol
patient
admit
dcc
follow
cardiac
arrest
novemb
group
result
fortythre
patient
admit
group
group
group
follow
outofhospit
ooh
vf
arrest
cool
attempt
ooh
vf
patient
respect
patient
either
inhospit
nonvf
vt
cardiac
arrest
number
cool
cool
initi
within
hour
increas
achiev
target
temperatur
within
hour
rosc
respect
target
mainten
hour
rosc
increas
avoid
hypothermia
hour
rosc
improv
slow
rewarm
hour
achiev
avoid
temperatur
hour
rosc
increas
patient
cool
surviv
good
neurolog
outcom
achiev
group
group
conclus
institut
temperatur
manag
protocol
improv
complianc
recommend
goal
achiev
hypothermia
avoid
hyperthermia
occurr
snd
defi
ned
neurolog
disarrang
irrit
confus
delirium
within
hour
oper
result
durat
cpb
aortic
clamp
circulatori
arrest
minut
respect
nine
patient
underw
acp
minut
patient
underw
rcp
minut
concentr
alac
scvo
p
chang
hour
cpb
follow
alac
mmoll
scvo
p
mgdl
respect
serum
p
recov
hour
cpb
incid
hypophosphatemia
mgdl
snd
seri
respect
correl
minimum
p
time
confi
rm
gc
p
fisher
rtoz
transform
signifi
cant
correl
snd
mortal
rate
fi
rst
day
introduct
therapeut
temperatur
modul
ttm
wide
use
care
set
improv
outcom
patient
traumat
brain
injuri
tbi
fever
prevent
oxygen
util
calor
expenditur
reduc
metabol
effi
cienci
maxim
howev
patient
cool
without
consequ
shiver
experienc
patient
achiev
ttm
shiver
trigger
increas
metabol
demand
caus
addit
oxygen
consumpt
promot
catabol
prevent
ideal
set
review
data
surround
antishiv
compon
normothermia
protocol
surgic
icu
sicu
one
minnesota
hospit
method
retrospect
review
conduct
look
sicu
patient
manag
normothermia
protocol
particular
attent
paid
antishiv
portion
protocol
serum
magnesium
mg
level
assess
prior
initi
ttm
bedsid
shiver
assess
scale
bsa
score
collect
result
twenti
patient
receiv
ttm
tbi
evalu
march
octob
onehalf
patient
maintain
target
bsa
score
full
durat
ttm
n
serum
mg
level
initi
ttm
observ
neg
correl
level
shiver
indic
bsa
score
system
p
see
figur
conclus
literatur
suggest
posit
impact
ttm
patient
outcom
maxim
shiver
prevent
current
sicu
practic
provid
similar
mg
load
dose
patient
regardless
baselin
mg
level
observ
patient
achiev
baselin
serum
mg
level
associ
lower
shiver
score
throughout
ttm
cours
support
hypothesi
serum
mg
concentr
prior
ttm
import
predictor
shiver
reduct
suggest
load
dose
mg
tailor
individu
patient
achiev
level
